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1.1. XENOBIOTIC EXPOSURE 
Humans are exposed to a myriad of xenobiotics, such as pharmaceuticals, 
cosmetics, dietary, environmental or occupational chemicals. Moreover, an increasing 
number of chemicals are newly generated by isolation, purification or combinatorial 
chemistry techniques, causing a serious challenge when it comes to toxicological 
evaluation. This challenges became even more evident as result of the implementation of 
the EU chemical policy designated REACH in 2006 [1]. Toxicological testing protocols 
usually comprise both in vivo and in vitro assays, using laboratory animals, and organ-, 
tissue- and cell-systems, respectively, or in silico predictions. The in vivo (animal) studies 
have been increasingly been recognized to suffer from disadvantages such as high costs, 
time consuming, the need of many animals as well as the ethical aspect of the use of 
laboratory animals [2].  In vitro organ-, tissue- and cell-models are of particular interest 
due to their relative simplicity in manipulation, the collection of data in short term, being 
in line with the societal concern of laboratory animal use. In 2007, the US National 
Research Council (NRC) as proposed a new long-range vision for toxicity testing and risk 
assessment [3]. In this document, is proposed to increase the resource to in vitro toxicity 
pathway assays in detrimental of the usual qualitative in vivo systems, using high-
throughput screening with mechanistic quantitative parameters. As so, significant 
perturbations in these toxicity pathways would be the focus for risk assessment. It is also 
suggested that in silico methods should be implemented to determine the dose-response 
models of perturbations of pathway function [4]. 
In xenobiotic risk assessment or drug development, the preliminary analysis of 
compounds for carcinogenicity often relies on genotoxicity or mutagenicity testing. The 
currently used mutagenicity (in vitro) assays are considered to suffer from two main 
drawbacks, namely relatively tedious procedures and long duration and the lack of 
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(human) biotransformation, leading to limitations in efficiency and reliability. The 
currently standard in vitro approaches may fall short due to the inadequate representation 
of chemically reactive metabolites (CRMs) formed by (human) biotransformation [5]. 
Biotransformation and its inter-individual variability, play a major role in chemical 
genotoxicity, carcinogenicity and susceptibilities. 
 
1.2. GENERAL ASPECTS OF BIOTRANSFORMATION  
The elimination of xenobiotics habitually depends on their conversion to 
hydrophilic molecules by a process known as biotransformation (or metabolism), which 
is catalyzed by enzymes mainly in the liver but also in other tissues [6]. Absorption 
through the skin, lungs or gastrointestinal track of many xenobiotics is facilitated by 
lipophilicity, which is also an obstacle for their elimination, since they can be readily 
reabsorbed. In general, xenobiotic metabolizing enzymes catalyze the formation of 
products (metabolites) that are more water-soluble (hydrophilic) than the parent 
compound, thereby favoring excretion in urine, bile or feces [7]. Metabolism, in most of 
the cases, results in suppression of biological activity, as the metabolites, in contrast to 
the parent compounds, are often unable to reach their site of action and/or fail to interact 
with the correct targets [8]. Thus, biotransformation plays a major role in protecting the 
organism from possible toxic effects of xenobiotics.  
Recently, the concept ‘metabolic activation or bioactivation’ of drugs and other 
chemicals, is becoming better understood. Bioactivation of parent compounds into 
products with more biological activity, possibly being ‘pro-drug activation’ [9], the 
metabolite having the same or different pharmacological effects as the parent drug [10]. 
However, the metabolic activation or bioactivation of xenobiotics may also result in the 
formation of CRMs, which are known to play a role in multiple toxicities, and in 
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genotoxicity in particular [11, 12]. For about 75-80% of current drugs and other 
xenobiotics, metabolism is the major clearance pathway and is a key determinant in the 
performance and safety of drugs and other xenobiotics [13, 14].  The liver is the main site 
of xenobiotic biotransformation, although it also occurs in other organs and tissues.  For 
the majority of the 200 drugs often prescribed in the USA, the routes of elimination were 
found to be hepatic [15].  
Xenobiotic biotransformation processes are usually separated into three 
categories, namely phase I, phase II and phase III. Phase I reactions involve the 
introduction (or modification) of a functional group by hydrolysis, reduction and 
oxidation, normally resulting in a small increase of hydrophilicity of the compounds. 
Phase II reactions result in the conjugation with an endogenous polar cofactor, normally 
resulting in a greater increase in hydrophilicity. These conjugation reactions, include 
glucuronidation, sulfation, acetylation, methylation, glutathione- and amino acid- 
conjugation [6]. Finally, Phase III reactions/processes involve transporters, such as, P-
glycoprotein (P-gp), organic anion transporting polypeptides (OATPs) and multidrug 
resistance proteins (MRPs), which export the products formed by phase I and II reactions 
[16]. 
In phase I metabolism, cytochrome P450 (CYP) family is the major enzymatic 
system involved, being accountable for about three quarters of the total metabolism of 
marketed drugs (see Figure 1) [17]. The CYP enzymatic system is further described 
below, since will be object of study in the work presented in this thesis. The remaining 
phase I metabolism is carried out by a variety of other contributing enzymes, including 
Flavin-containing monooxygenases (FMOs), NADPH:quinone oxidoreductases (NQOs), 
and several others such as dehydrogenases, esterases and oxidases [17, 18].  
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In phase II metabolism the main contributors are UDP-glucuronosyl transferases 
(UGTs), complemented by sulfotransferases (SULTs), N-acetyltransferases (NATs) and 
glutathione S-transferases (GSTs) (see Figure 1) [19]. Phase II enzymes will not be 










Figure 1. Overview of the main phase I and phase II enzymes involved in xenobiotic metabolism in 
humans. ADH, alcohol dehydrogenase; ALDH, aldehyde dehydrogenase; CYP, cytochrome P450; DPD, 
dihydropyrimidine dehydrogenase; NQO1, NADPH:quinone oxidoreductase; COMT, catechol O-
methyltransferase; GST, glutathione-S-transferase; HMT, histamine methyltransferase; NAT, N-
acetyltransferase; ST, sulfotransferase; TPMT, thiopurine methyltransferase; UGT, uridine 5´-triphosphate 
glucuronosyltransferase. Adapted from [18]. 
 
1.2.1 Polymorphisms and interindividual differences  
Inter-individual variability in xenobiotic and drug metabolism is extensive. 
Plasma levels of a drug can vary more than 1000-fold between individuals upon the same 
drug dosage [20]. Moreover, it has been described that the proportion of patients which 
respond positively to the first drug prescribed in the treatment of a wide range of diseases 
is typically just 50–75% [21]. These variations may be due to differences in the expression 
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of genes responsible for drug metabolism, transport, and response and may be caused by 
genetic, epigenetic, physiological, patho-physiological, or environmental factors [22]. In 
fact, it is considered that genetic factors are responsible for 20-40% of the differences 
between individuals in drug response as well as susceptibility to the toxicity of drugs and 
xenobiotics [23]. Furthermore, it has been estimated that attrition during drug 
development for around 12% of the drug candidates is due to genetic safety concerns [24].  
Therefore, inter-individual variability in drug response and toxicity may lead to patient 
harm and ineffective use of limited healthcare resources [25]. 
Genetic polymorphism include mutations both in non-coding regions (promoter, 
intron) and protein-coding sequences. Mutations in non-coding regions may lead to 
altered expression levels, while mutations in protein-coding sequences may change the 
structure and catalytic properties of the enzyme [26]. Fortunately, the number of genetic 
biomarkers for the prediction of drug choice and correct dosage are increasing, allowing 
the personalization of treatment. Some recent genome-wide association studies showed 
that genetic polymorphism among the drug-metabolizing enzymes can disturb 
endogenous functions such as blood pressure, suicide risk, and bilirubin levels, as well as 
exogenous factors like coffee intake, cigarette consumption, drug efficacy and toxicity 
susceptibility [27]. Such polymorphisms and others, offer a resource of 
pharmacogenomic biomarkers that can help to optimize drug treatment, particularly in 
the areas of oncology, cardiovascular disease, infection, and psychiatry [22, 28]. 
CYP polymorphisms are strongly implicated in human susceptibility to cancers 
(see Table I) [29-32]. Moreover, CYP polymorphisms have been indicated as a major 
reason why substantial numbers of patients do not respond, respond partially, or suffer 
from adverse drug reactions (ADRs) [33, 34]. Therefore, it is fundamental to understand 
the consequences of CYP polymorphisms, to improve our comprehension of inter-
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individual differences in the outcome of drug treatments, as well as of chemical exposure 
in general [35]. 
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a According to the CYPallele nomenclature homepage (http://www.cypalleles.ki.se). 
b Genomic positions are given with corresponding rs numbers in parentheses. 
c gMAF, global allele frequency of the minor allele as reported in the 1000Genome phase 1 genotype data 
(released May 2011). Selected frequencies of individual ethnicities (AA, African American; Af African; 
As Asian; Ar, Arab; Ca Caucasian; Hs, Hispanic; In, Indian; Pc, Pacific; SA, South American) were 
compiled from dbSNP (build 137) at http://www.ncbi.nlm.nih.gov/projects/SNP/; from the Allele 
Frequency Database ALFRED at http://alfred.med.yale.edu/alfred/index.asp 
 
1.3. CYTOCHROME P450  
CYP enzymes are the major catalysts involved in the biotransformation of 
xenobiotics and are responsible for the metabolism of a wide variety of clinically, 
physiologically and toxicologically important compounds [36]. The name of CYP is 
derived from the characteristic presence of an absorption maximum at 450 nm in the 
differential spectra of reduced CO-bond complex [37]. The CYP superfamily consists of 
57 genes (and 58 pseudo-genes) and is divided into 18 families and 44 sub-families in 
humans, involved in the synthesis of endogenous compounds and the metabolism of drugs 
and other xenobiotics [38-40]. The CYP families 1, 2 and 3 are accountable for 70-80 % 
of all phase I metabolism of clinically used drugs and are involved in the 
biotransformation of a large number of drugs and other xenobiotics [29, 33]. In fact, five 
specific members namely, CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5, are 
responsible for about 95% of all CYP-catalyzed drug metabolism [17]. The majority of 
CYP-mediated metabolism is carried out by polymorphic enzymes [41]. All genes that 
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Figure 2. CYP isoforms contribution to drug metabolism and factors influencing variability. A total of 248 
known CYP-dependent drug metabolism pathways were analyzed. Variability factors are indicated in bold 
with possible directions of influence indicated (↑, increased activity; ↓, decreased activity; ↑↓, increased 
and decreased activity). Factors with controversial significance are shown between parentheses. Adapted 
from [29]. 
 
The primary reaction catalyzed by CYPs is mono-oxygenation, incorporating a 
single oxygen atom, from molecular oxygen, into a substrate (designated RH, Figure 3), 
while the other oxygen atom is reduced to water [6]. When CYPs act as a mono-
oxygenase, the products formed are not limited to alcohols and phenols, as a result of re-
arrangement reactions [43]. Thus, as a result of the main mono-oxygenase activity of 
CYP, in the presence of oxygen, drugs and other chemicals undergo different types of 
reactions, such as hydroxylations, epoxidations, heteroatom dealkylations, deaminations, 
dehydrogenations, oxygenations, esters cleavages, and others. On the contrary, under 
anaerobic conditions and in presence of reducible substrates, CYPs may act as a 
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reductase, e.g. resulting in azo-reduction, nitro-reduction and reductive dehalogenation 










Figure 3. Cytochrome P450 (CYP) general catalytic cycle. Individual steps in the cycle include: (1) 
substrate binding; (2) first one-electron reduction by CYPOR; (3) oxygen binding; (4) second one-electron 
reduction by CYPOR or b5; (5) protonation of the distal oxygen coordinating to iron; (6) water molecule 
abstraction, with formation of the reactive heme iron–oxygen species; (7) radical intermediate formation; 
(8) oxygen rebound with the radical intermediate; (9) product release. The cycle can be short-circuited in 
three different places without product formation, namely, autoxidation shunt, peroxide shunt and oxidase 
shunt. Adapted from [45] and [46] 
 
During the catalytic cycle, auto-oxidation may occur, whereby the cycle is shunted 
and molecular oxygen is reduced (released as a free radical) without product formation, 
known as uncoupling (autoxidation shunt) (see Figure 3). Furthermore, this uncoupling 
may occur in the presence of artificial oxygen delivery agents, such as peroxides 
(peroxide shunt) (see Figure 3) [36], or when the reactive heme iron–oxygen species 
intermediate is oxidized to water instead of oxygenation of the substrate (oxidase shunt) 
(see Figure 3) [46]. The accumulation of reactive oxygen species (ROS) can contribute 
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to free radical propagation [47] and ultimately leading to DNA adduct formation and to 
the development of cancer [48]. 
 
1.3.1 CYP1A2 and bioactivation 
The human CYP1A subfamily consists of CYP1A1 and CYP1A2. CYP1A1 is 
mainly expressed in extra-hepatic tissues while CYP1A2 is almost exclusively expressed 
in the liver, representing about 13-15% of its total CYP content [49]. These enzymes are 
important catalysts for the bioactivation of several precarcinogens, such as polycyclic 
aromatic hydrocarbonates (PAHs) as well as aromatic and heterocyclic amines (see 
Figures 4 and 5 for examples) [50]. Actually, the CYP1 family is strongly implicated in 











Figure 4. CYP1A2 mediated bioactivation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). 



















Figure 5. CYP1A2 mediated bioactivation of 2-amino-3-methylimidazo(4,5-f)quinoline (IQ). CYP1A2 
mediates the N-hydroxylation of IQ, which is followed by N-acetylation of the hydroxylamine and 
deacetylation forms an electrophilic aryl nitrenium ion. The aryl nitrenium ion alkylates guanine in DNA. 
This occurs either via the IQ amine nitrogen to form the C8-dG-IQ adduct, or alternatively, alkylates DNA 
via the C5 position of the IQ ring to form the N2-dG-IQ adduct. Adapted from [56]. 
 
The CYP1A2 crystal structure [57] (PDB file ID 2HI4) demonstrated a relatively 
planar and small binding cavity, with an estimated volume of about 375 Å [58], fitting 
closely with planar compounds, such as the typical CYP1A2 substrates, theophylline and 
caffeine, and the potent inhibitor α-naphthoflavone (see Figure 6) [59, 60]. CYP1A2 
mediates the metabolism of about 15% of clinical drugs [61], such as clozapine [62, 63],  
lidocaine [64], phenacetin [65, 66], propranolol [67] and tacrine [68].  




Figure 6. Overview of the structures of human CYP1A2 with co-crystallized ligand α-naphthoflavone        
(α-NF) (PDB file ID 2HI4) (a). Image zoomed in on the active center in complex with α-NF (b) or with 
caffeine (c). The metabolic site of caffeine is 4,34 Å apart from the heme. Adapted from [60]. 
 
CYP1A2 is a polymorphic enzyme and to date, 41 CYP1A2 haplotypes have been 
designated on the Human Cytochrome P450 Allele Nomenclature Committee home page 
(http://www.cypalleles.ki.se/cyp1a2.htm). The inter-individual differences in CYP1A2 
activity are well known: up to 60-fold variations have been reported [49, 69]. These 
differences are most likely to influence drug metabolism, and thus have clinical relevance 
in drug efficacy and safety; and alter susceptibility in exposure to (pre)carcinogens. 
Determinants such as diet [70], smoking [71] and intake of oral contraceptives [72] are 
well established modifiers of CYP1A2 activity. In turn, genetic factors were suggested to 
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represent about 35-75% of the inter-individual variability for CYP1A2 activity [73, 74]. 
CYP1A2 polymorphisms could also be related with observed toxicity of leflunomide in 
rheumatoid arthritis patients [75] and seem to play a role in efficacy of the treatment of 
patients with antipsychotics, such as clozapine and olanzepine [76]. Several recent studies 
indicated implications of CYP1A2 polymorphisms in cancer susceptibility, namely for 
pancreatic cancer [77, 78], and bladder cancer [79].  
 
1.3.2 Cytochrome b5 as CYP redox partner. 
To carry out catalysis microsomal CYP metabolism requires a coupled supply of  
2 electrons, which are normally provided by the auxiliary protein NADPH cytochrome 
P450 oxidoreductase (CYPOR) [80]. As CYP, CYPOR is a membrane-bound protein 
which contains two flavin moieties namely, FMN and FAD, essential for sequential one 
electron transfer to CYP, prevenient from NADPH [46]. For at least 4 decades, another 
heme protein, namely cytochrome b5 (b5), has been recognized to alter the rate of catalysis 
by selected CYPs [74, 81-83]. The discussion concerning b5 involvement in CYP 
reactions has been controversial, since it was first suggested by Hildebrandt and 
Estabrook in 1971 [84].  
The cytochrome protein b5 is a ubiquitous eukaryotic small protein, of 
approximately 17 kDa, which is present throughout the phyla and appears to be an 
essential component of a number of endoplasmic reticulum-linked redox enzyme systems 
[85, 86]. Physiologically, b5 can be reduced by both cytochrome b5 reductase (NADH 
dependent), and by CYPOR [87]. It has been reported, that b5 is able to enhance, inhibit, 
or not alter the catalysis of CYPs depending on the substrate, the specific CYP isoform 
and the experimental conditions [88-90]. This non-consistent influence of b5 is now better 
understood after the demonstration that b5 is able to catalyze product formation faster 
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than CYPOR, under single turnover conditions, which gives less time for side product 
formation, and also that b5 and CYPOR compete for a binding site on the proximal surface 
of CYP [91]. Several studies demonstrated that b5 could modulate specific activities of 
several CYPs. Effects of b5 are reported in the catalytic properties of human CYP1A1 
[92-94], CYP1A2 [92, 95], CYP3A5 [96], CYP3A4 [96-99], CYP2C9 [97, 99], CYP2B4 
[82], CYP2A6 [95, 97] and CYP2E1 [95, 97, 100, 101]. 
Although substantial studies have been reported on the function and effect of b5 
on CYP-mediated catalysis, during the last decades its mode of action is still not fully 
understood. Furthermore, analyzing the effects of apo-b5 on CYPs catalytic properties, it 
seems plausible that b5 also plays a conformational role in the human CYP enzymatic 
system [97, 102]. It is now generally accepted that b5 acts as an allosteric factor which 
facilitates the interaction between CYPOR and CYP, and may act as an alternative donor 
for the second, but not the first, electron in the CYP cycle (see Figure 3) [103]. However, 
recently it was demonstrated, using extreme in vitro conditions, that b5 is able to supply 
both electrons to CYP, prevenient from NADH [104]. 
 
1.4. CHEMICALLY REACTIVE METABOLITES: 
BIOACTIVATION AND BIOINACTIVATION 
Xenobiotics are body-foreign compounds (such as drugs, pollutants, cosmetics, 
food, etc.), which normally are not produced or expected to be present in the organism. 
Biotransformation of xenobiotics normally constitutes detoxification (bio-inactivation) 
and may involve a large number of proteins. In some cases, bio-activation of xenobiotics 
may occur, resulting in the formation of CRMs, that are of major importance in drug 
development and toxicology. CRMs can cause several unwanted effects, such as covalent 
binding to proteins and DNA, inducing multiple organ toxicities (the liver being the organ 
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most frequently affected) (see Figure 7). These alterations may induce mutagenesis which 
can result in tumour formation, immune mediated hypersensitivity reactions and CYP 
inhibition leading to drug-drug interactions [105].  
 
 
Figure 7.  Schematic view of possible causal relations between CRMs and toxicity outcomes. Genotoxicity, 
important to this thesis, is highlighted in red. Adapted from [11]  and [106]. 
 
The association between CRM formation and drug toxicity is complex [107]. Most 
toxicities are dose dependent, and can readily be replicated in various preclinical species 
including in human systems and are referred to as Type A toxicities. A classic example 
is hepatotoxicity caused by the formation of NAPQI, a quinone-imine derived from 
acetaminophen (paracetamol) metabolism (see Figure 8a) [108]. In other cases, toxicity 
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in man is an unpredictable and relatively rare event. In this so-called idiosyncratic toxicity 
(iADR), often referred to as Type B toxicity, dose dependence in a population is not clear 
and cannot be easily replicated in preclinical species. However, while they may not seem 
to be dose dependent in a broad human population, it does not mean there is no dose 
dependency in the adverse outcome [12]. An example of Type B idiosyncratic toxicity is 
agranulocytosis caused by the covalent binding to proteins of the diazatropylium ion, a 













Figure 8. a) Acetaminophen (paracetamol) is bioactivated by CYP to the reactive metabolite N-acetyl-p-
benzoquinone imine (NAPQI). b) Clozapine is bioactivated by CYP to form the reactive diazatropylium 
ion. Adapted from [12]. 
 
Testing for the propensity of compounds to form CRMs has increasingly become 
integral part of the absorption, distribution, metabolism, excretion, and toxicity 
(ADMET) guided lead-optimization in drug discovery and development. To avoid costly 
late stage failures predictive toxicology assays and models are being utilized as part of a 
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‘fail early’ or avoidance strategy [110]. Although in silico tools for identifying structural 
alerts is currently a standard practice at the lead optimization/candidate selection stage of 
drug development, it is imperative to demonstrate experimentally whether predicted 
structural alerts are actually are prone for CRMs formation [111]. In vitro data is 
additionally used in early metabolite profiling of CRM-positive candidates which can 
possibly assist in further prioritization and ranking of compounds during lead 
optimization/candidate selection of drug development [112].  
Traditionally the propensity of drug candidates and their bioactivated CRMs to 
irreversibly bind to cellular targets (such as: DNA, proteins, lipids, etc. See Figure 7), is 
performed by covalent binding assays (CB) [113]. LC-MS analysis of trapped CRMs 
using low molecular weight trapping agents, such as GSH or GSH-analogues, is a 
commonly used method [114, 115]. Though, it has been observed in in vitro studies [114] 
that even non-toxic drugs can occasionally produce significant amounts of GSH-
conjugates, indicating that GSH-conjugates formation per se is not predictive for toxicity 
[116]. Moreover, GSTs play an important role in bio-inactivation of several drugs, such 
as clozapine, since the spontaneous conjugation of CRMs with GSH is often limited 
[117].  
The theory of hard and soft, acid and bases (HSAB) has proven to be a useful tool 
to interconnect protein and DNA toxic processes [118]. Hard electrophiles will react more 
readily with hard nucleophilic centers in DNA, while soft electrophiles will preferably 
react with proteins (cysteines) (see Figure 9) [7, 106]. In contrast to DNA as the target, 
GSH has limited efficiency in trapping hard electrophilic molecules [119].  





Figure 9. Application of the theory of hard and soft, acid and bases (HSAB) to interconnect protein and 
DNA toxic processes. Adapted from [7, 106, 118]. 
 
1.5. BIOACTIVATION AND CHEMICAL CARCINOGENESIS 
1.5.1 Chemical carcinogenesis. 
Cancer development or carcinogenesis is a complex multistage process. 
Conceptually, it can be divided into four stages: initiation, promotion, malignant 
conversion and progression [120].  




Figure 10. Scheme of multistage carcinogenesis. Multistage carcinogenesis can be conceptually separated 
into four stages: tumor initiation, tumor promotion, malignant conversion, and tumor progression. The 
activation of proto-oncogenes and inactivation of tumor suppressor genes are mutational events that result 
from covalent damage to DNA caused by chemical exposures. The accumulation of mutations, and not 
necessarily the order in which they occur, constitutes multistage carcinogenesis. Adapted from [121]. 
 
It has been broadly accepted that carcinogenesis often results from chemical 
exposure, sometimes in complex chemical mixtures, encountering in the environment or 
through our diet and lifestyle, together with biological (virus) and physical (radiation) 
exposures [120]. The typical example is tobacco smoke, which is related to several 
cancers, including lung, bladder, head and neck cancers [122, 123]. Although the majority 
of chemical carcinogens do not react directly with cellular components, they are often 
bioactivated to mutagenic and carcinogenic metabolites by drug metabolizing enzymes, 
such as CYPs. Thus, enzymatic biotransformation plays a crucial role in the carcinogenic 
activity and organ specificity of chemical carcinogens, with the predominant involvement 
of CYPs [124, 125].  
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Recent advances in epigenetics, have shown that these mechanisms are critical for 
the stable propagation of gene activity states between generations of cells and therefore 
the epigenome governs the establishment and maintenance of cell identity [126]. The 
failure in correct preservation of heritable epigenetic marks may result in inappropriate 
activation/inhibition of various signaling pathways leading to disease states such as 
cancer [127, 128]. It has been shown that human cancer cells harbor epigenetic 
abnormalities, in addition to genetic alterations [127, 129]. However, the genetic origin 
of cancer is broadly accepted, some studies suggest that epigenetic modifications may be 
a key factor in some forms of cancer [130]. 
 
1.5.2 Bioactivation, DNA adduct formation, DNA repair and 
mutagenesis. 
Despite the fact that some compounds can act as direct mutagens, such as N-
methyl-N´-nitro-N-nitrosoguanidine (MNNG), a large proportion of mutagens are 





Figure 11. Chemical structure of MNNG, a direct acting DNA alkylating agent. MNNG reacts with DNA 
to form adducts at the O6 of guanine and O4 of thymine of DNA [133]. 
 
Chemical modifications of DNA, known as DNA adducts, e.g. induced by the 
exposure to genotoxins and/or their CRMs, have been widely investigated and play a key 
role in chemically induced carcinogenesis [134-136]. If not repaired, DNA adducts can 
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lead to mutations during cell division and thus ultimately disrupt the functioning of the 
systems regulating cell differentiation and proliferation [137]. However, there is a 
remarkable variety of DNA repair systems, which eliminate these alterations in DNA so 
that the ultimate mutation does not always occur. In fact, nearly all DNA adducts and 
DNA damage are repaired, with the rare exceptions leading to mutagenesis [131]. 
 
Figure 12. Competing metabolic activation and inactivation processes for DNA reactive carcinogens. 
Additionally, metabolic activation must occur in a pluripotential (tissue stem) cell, and the cell must 
replicate to fix the DNA alteration (DNA repair) produced by a DNA adduct as a permanent mutation. 
Adapted from [131]. 
 
 Bioactivation of xenobiotics has been a pillar of carcinogenesis ever since the 
publications by the Millers [138] in the 1970s.  These authors were able to demonstrate 
that an aromatic amide, 2-acetylaminofluorene (2-AAF), was metabolically activated to 
a reactive electrophile, N-hydroxy-2-acetylaminofluorene, which reacts with DNA to 
form DNA adducts, ultimately leading to mutations. Since then, a diversity of metabolic 
processes has been identified in the bioactivation of a variety of classes of chemical 
carcinogens, primarily involving CYP enzymes. Numerous other enzyme systems have 
Chapter 1                                                                                           General Introduction 
31 
 
also been identified in the specific activation of xenobiotics (see Figure 11) [132, 139]. 
Variability in metabolic capacity can modulate the levels of DNA adducts ultimately 
formed, depending on the route of exposure and the tissues involved. Amongst others, 
polymorphisms in drug metabolizing enzymes (such as CYPs) and DNA repair 
efficiency, have been shown to alter the potential for DNA damage [140].  
 
 
Figure 13. Enzyme contributions to bioactivation of procarcinogens. a) Fractions of bioactivation reactions 
ascribed to different groups of enzymes. A number of 713 reactions were accounted for this analysis. b) 
Fractions of CYP-mediated bioactivation reactions attributed to individual human CYPs (473 reactions 
were considered). Adapted from [132]. 
 
1.6. ADVERSE DRUG REACTIONS 
Adverse drug reactions (ADRs) are a major complication of drug development 
and therapy. It has been estimated that ADRs cost to the American society about 100 
billion US$ and cause more than 100,000 deaths per year [35]. Human adverse events, 
animal toxicity and clinical safety represent together about 56% of the attrition reasons 
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for withdrawal of drug candidates during drug development [141, 142]. Also because of 
the increasing of commercial consequences of drug withdrawals and/or black box 
warnings due to safety issues, the pharmaceutical industry faces an unprecedented 
challenge of providing patients with more effective and safer products [143]. 
The mechanisms underlying ADRs may be categorized into five types [9]: 1) on-
target or mechanism-related; 2) hypersensitivity and related immunological responses 3) 
bio-activation to toxic metabolites, 4) off-target and 5) idiosyncratic adverse drug 
reactions (IADRs). About 27% of the causes of attrition due to toxicity are related to 
biotransformation and about 28% are target-based (off- and on-) [142]. Moreover, drug 
accumulation, excessive dose and/or biotransformation to CRMs have been associated in 
several off-target and IADRs [113]. Although the exact mechanisms by which IADRs 
arise is not fully understood, retrospective studies of failed drugs indicate that drug 
metabolism and the generation of CRMs play an important role [110].  
 
1.7. IN VITRO ASSAYS FOR GENOTOXICITY STUDIES 
DNA reactivity is an unwanted property of a drug or drug metabolites, i.e. leading 
to increased risk of cancer and reproductive toxicity. The general strategy to minimize 
this property is to eliminate genotoxic risks as early as possible, normally in early stages 
of industrial chemicals production or in the hit-to-lead/lead optimization phase of drug 
development [144]. Simultaneously, there is a need for simple and rapid methods for 
evaluating the potential (geno)toxic effects of diverse environmental samples [145].  
Currently, genotoxicity testing guidelines for pharmaceutical industry incorporate 
a battery of in vitro and in vivo tests to identify hazards, measuring different types of 
genetic damage in a diversity of cell models to increase the probability of detecting DNA-
reactive compounds [146]. Unfortunately, the screening of thousands of compounds using 
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whole animal models is neither economically viable nor ethically acceptable, posing high-
throughput screening (HTS) assays as an alternative for handling larger flows of new 
chemicals or drug candidates in a systematic and time-efficient manner [147].  
In such in vitro tests, the usually examined end points include: i) induction of point 
mutations in bacteria; ii) induction of point mutations and chromosomal aberrations in 
mammalian cells; and iii) production of strand breaks and covalent modifications to DNA 
[146]. However, differences that may arise from biotransformation, due to the conditions 
of standard in vitro test systems (normally using induced rat liver extracts or other animal 
species), have a major influence when establishing the relevance for human risk 
assessment [5]. Moreover, inter-species differences in drug metabolism are consistently 
observed and often lead to complications in data extrapolation to the humans from animal 
safety data [13]. This is of particular importance when the critical toxic entity is not the 
chemical itself but a CRM, whether it applies to pharmaceuticals, pesticides or industrial 
chemicals [5]. 
In vitro cell-models for genotoxicity testing are of particular interest due to their 
relative simplicity in manipulation, the collection of data is in short term and are in line 
with the societal concern of laboratory animal use. Currently, the role of metabolism in 
drug and industrial chemical development, when using standardized mutagenicity in vitro 
assays, is achieved using induced rat liver extracts as exogenous metabolic system for 
detecting pro-mutagens [148, 149].  In fact, a major limitation in detecting genotoxicity 
of human CRMs by standard in vitro tests resides in the fact that most of these assays rely 
on non-human (usually rodent derived) metabolic systems, to mimic human metabolism 
[5]. Moreover, when using this approach, the metabolites (including CRMs) are often 
generated outside the target cells, with less probability to interact with the DNA target.  
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Therefore, there still is a collective need for sensitive and highly efficient cell-
systems for in vitro genotoxicity studies, incorporating (polymorphic) human 
biotransformation and allowing more efficient screening of increasing numbers of 
compounds with an increased reliability and predictability. Of special need in this context, 
are assays with the appropriate properties for high-throughput screening (HTS). 
Accordingly, several in vitro assays, using bacteria, yeast or human cell-lines were 
developed for HTS purposes, making use of reporters such as GFP and/or luciferase, 
which permit to obtain results in a timely manner. Amongst others, these include SOS-
lux [150], VITOTOX™ [151], GreenSreen® [152], BlueScreen™ [153] and  p53 
CALLUX [154] assays.  
 
1.7.1 Bacterial genotoxicity assays for high-throughput screening (HTS) 
Lately, the progress in chemical technologies has widely expanded the numbers 
of leads for new industrial chemicals and potential drug candidates. Furthermore, the 
requirement of thousands of toxicity profiles due to the implementation of the new EU 
chemical policy, designated REACH, reinforced the need for efficient and highly 
predictive HTS (geno-)toxicity models [1]. Hard electrophilic CRMs may react with 
DNA and might be detected in genotoxicity assays. In this context, bacterial assays (see 
Table II) are of special interest, presenting several characteristics that position them as 
highly attractive cellular systems, namely: fast to respond; easily obtained large and 
homogeneous population of live cells; low costs; conservation for longer periods of time; 
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Table II. Examples of bacterial genotoxicity assays. Adapted from [155]. 
Test method Bacterium SOS gene Index References 
Ames test S typhimurium mucAB his [156] 
WP2 test E. coli mucAB trp [157] 
Induct test E. coli Prophage λ phage [158] 
SOS chromotest E. coli sfiA::lacZ β-gal [159] 
umu test S typhimurium umuC::lacZ β-gal [160] 
SOS lux test E. coli luxCPABFE lux [150] 
VITOTOX® test  S typhimurium recN2-4::lux lux [151] 
Geno-Tox test S typhimurium Cda::lux lux [161] 
S. typhimurium, Salmonella typhimurium; E. coli, Escherichia coli; his, histidine; trp, tryptophane; β-gal, 
β-galactosidase; lux, luciferase. 
 
Apart from the standard, well-established Ames test, several other bacterial tests 
based on the induction DNA-repair (SOS)-response for detecting mutagenicity [162], 
namely the umu-test [160] and the SOS chromotest [159] were developed to rapidly assess 
the potential properties for carcinogenicity of drug candidates and other xenobiotics. Still, 
currently these assays can hardly be considered as HTS assays, since they are time 
consuming and/or demand many manipulation steps. More recently, several other 
bacterial test systems, also based on the induction DNA-repair (SOS)-response, were 
developed for HTS purposes and making use of reporters such as GFP and/or luciferase, 
which permit to obtain results faster. These include SOS-lux [150] and VITOTOX™ 
[151], assays. In all cases, rodent liver extracts are used has exogenous bioactivation 
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1.8. AIMS AND OUTLINE OF THIS THESIS 
1.8.1 Aims of this thesis 
When the studies described in this thesis started, there was still an ever increasing 
need for informative and highly efficient systems for in vitro studies of xenobiotics in 
toxicology, and in particular for cell-systems for genotoxicity studies. Moreover, in this 
context, assays with the appropriate properties for HTS applications are still needed. 
The primary aim of the research of this thesis was to develop improved and 
sensitive bacterial genotoxicity test systems, which were (i) metabolically competent in 
terms of human biotransformation and (ii) suitable for HTS testing applications, allowing 
efficient screening, both in terms of time and costs. For reasons of relevance and 
applicability in this context, the research was first focused on one of the major human 
biotransformation enzyme systems, namely CYP.  S. typhimurium and E. coli strains were 
used, since, bacterial assays present several advantages, such as: fast response; easy to 
obtain large and homogeneous populations of live cells; low costs; long conservation of 
strains; available at short notice; and lack of background in biotransformation. The newly 
developed bacterial test systems should also be applicable in genotoxicity and 
mechanistic studies using other, major human CYPs as well as allelic CYP-variants.  
 The secondary aim of the research was to investigate the significance of alleles of 
CYPs, representing non-synonymous polymorphic forms, and to characterize: (i) their 
activity with a diverse group of substrates and (ii) the role of the accessory redox partner 
cytochrome b5 in their activity. In this case, for mechanistic studies, E. coli strains were 
chosen, since they are easier to manipulate genetically and have been broadly been used 
to express CYPs. As for the genotoxicity assay S. typhimurium strains were preferred, 
because aromatic amines require CYP1A2-mediated oxidation and subsequent O-acetyl 
or O-sulfate conjugation to generate CRMs which react with DNA [163]. S. typhimurium 
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tester strains of the Ames test (namely, TA1535) are known to contain efficient bacterial 
O-acetyltransferases [164]. 
In this thesis, different bacterial backgrounds, namely TA1535 and TA100, two 
S. typhimurium strains used in the Ames test, and strains FP401 and PD301, two E. coli 
strains developed in our laboratory (Lisbon), were used for development of the 
genotoxicity system. Human CYP1A2 and several CYP1A2 polymorphic variants were 
chosen as model enzymes for proof of concept, since these CYP enzymes in particular 
constitute important enzymes in CRMs formation. Notably CYP1A2 catalyzes the 
bioactivation of approximately 17% of human pre-carcinogens [132], such as aromatic 
and heterocyclic amines [165] and mediates the metabolism of about 15% of clinical 
drugs [61]. 
 
1.8.2 Outline of this thesis 
Part I: Introduction 
In the present chapter, chapter 1, a general introduction to the work presented in 
this thesis is provided. Xenobiotic biotransformation and the role of CRMs in 
genotoxicity and ADRs are discussed. In this context, the CYP superfamily, including the 
electron donor accessory enzymes (b5 and CYPOR), is presented with special focus on 
CYP1A2 isoform. Chemical carcinogenesis and mutagenesis are introduced, and in vitro 
assays for genotoxicity detection are discussed, with emphasis on bacterial systems. 
 
Part II: Characterization of Human Cytochrome P450 1A2 Polymorphic Variants 
In chapter 2, the construction and characterization of 8 non-synonymous 
polymorphic forms of human CYP1A2, namely T83M, S212C, S298R, G299S, I314V, 
I386F, C406Y and R456H is described. The cDNAs of these variants plus WT form, are 
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co-expressed with human CYPOR in Escherichia coli BTC [166] strains. The activity of 
the CYP1A2 variants is screened using 8 different substrates: 3 fluorogenic probes, 2 
therapeutic drugs and 3 pro-mutagens. The resulting data set, from 16 different activity 
parameters measured, is thoroughly analyzed using multivariate analysis.  Results are 
then interpreted using the human CYP1A2 crystal structure. Chapter 3, describes the 
expression and characterization of the same 8 polymorphic forms of human CYP1A2 plus 
WT, but now co-expressed with b5 and CYPOR. Again, 16 activity parameters for the 8 
substrates are screened, and the results merged with the ones obtained in the previous 
chapter. This combined data set is then analyzed through multivariate analysis and the 
results rationalized using human CYP1A2 crystal structure. 
 
Part III: Development of Bacterial HTS-Systems for Detection of Genotoxic Electrophilic 
Reactive Metabolites 
In chapter 4, the engineering of bacterial genotoxicity systems suitable for HTS 
purposes is presented. Two different types of GFP plasmid reporters, specifically for 
genotoxicity and cytotoxicity, were constructed and expressed into Escherichia coli and 
Salmonella typhimurium strains. Initially, four different bacterial backgrounds are tested, 
namely, TA1535 and TA100 [167], two S. typhimurium strains used in the Ames test, and 
strains FP401[168] and PD301[166], two E. coli strains developed in our laboratory. All 
strains are tested with three direct-acting mutagens. Subsequently, the two most effective 
bacterial systems, based on strains TA1535 and PD301, are adapted to co-express human 
CYP1A2 and CYPOR, along with the GFP reporters. These strains are then tested with 
three known pro-mutagens that form DNA-reactive metabolites through CYP1A2-
mediated bioactivation.   
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Chapter 5, describes the co-expression of CYPOR with the same 8 polymorphic 
forms of human CYP1A2 plus WT, used in chapters 2 and 3. In this case, the system 
based on S. typhimurium TA1535 strains is applied and tested with the three CYP1A2-
dependent pro-mutagens. The resulting data set is analyzed using multivariate analysis 
and results compared with the results obtained in the previous chapters. 
 
Part IV: Conclusions    
In chapter 6, a summary and the conclusions regarding the research described in 
this thesis are given as well as future perspectives for further developments of the 
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Inter-individual variability in cytochrome P450 (CYP)-mediated xenobiotic 
metabolism is extensive. CYP1A2 is involved in the metabolism of drugs and in the 
bioactivation of carcinogens. The objective of this study was to functionally characterize 
functionally eight polymorphic forms of human CYP1A2, namely T83M, S212C, S298R, 
G299S, I314V, I386F, C406Y and R456H. The cDNAs of these variants were constructed 
and coexpressed in Escherichia coli with human NADPH cytochrome P450 
oxidoreductase (CYPOR). All variants showed similar levels of apoprotein and 
holoprotein expression, except for I386F and R456H, which showed only apoprotein, and 
both were functionally inactive. The activity of CYP1A2 variants was investigated using 
8 substrates, measuring 16 different activity parameters. The resulting heterogeneous 
activity data set was analyzed together with CYP1A2 wild-type (WT) form, applying 
multivariate analysis. This analysis indicated that variant G299S is substantially altered 
in catalytic properties in comparison to WT, whereas variant T83M is slightly but 
significantly different from the WT. Among the CYP1A2 variants, out of the 
heterogeneous set of eight substrates, carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK) was the most discriminative compound. In addition, R456 could be 












Inter-individual variability in xenobiotic and drug metabolism is extensive. 
Plasma levels of a drug can vary more than 1000-fold between individuals upon the same 
drug dosage [1]. These variations can be caused by induction or inhibition and genetic 
polymorphisms of metabolizing enzymes, or from physiological, pathophysiological or 
environmental factors [2]. In fact, genetic factors are considered to be responsible for 20-
40% of the differences between individuals in the response and susceptibility to drugs 
and xenobiotics [3]. Variability among individuals in drug metabolism can result in 
reduced drug efficacies or undesirable toxic side effects, which are phenomena that may 
compromise drug therapy and development. 
Cytochrome P450s (CYPs) are responsible for the metabolism of a wide variety 
of clinically, physiologically and toxicologically important compounds [4]. CYP families 
1, 2 and 3 are responsible for 70-80 % of all phase I metabolism of clinically used drugs 
[5] and are involved in the biotransformation of a large number of xenobiotics. 
Biotransformation can lead to bioactivation of pre-carcinogens and drugs, which can 
result in carcinogenic or other toxic effects. The majority of CYP-mediated xenobiotic 
metabolism is carried out by polymorphic enzymes [6]. Human CYP polymorphisms 
include mutations both in non-coding regions (promoter, intron) and protein-coding 
sequences. Mutations in non-coding regions may lead to altered expression levels, 
whereas those in protein-coding sequences may change the structure and catalytic 
properties of the enzyme [7]. Many drugs that can cause adverse reactions are 
metabolized in processes catalyzed by polymorphic CYP enzymes. Therefore, the 
understanding of the nature of CYP polymorphisms is fundamental for the 
comprehension of inter-individual differences in chemical exposure, adverse drug effects 
and toxicity in general [8].  
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The human CYP1A family consists of CYP1A1 and CYP1A2. Their genes are 
located on chromosome 15 and are oriented head-to-head, 23.3 kb apart [9]. The spacer 
sequence may contain distinct regulatory regions of each gene or, alternatively, the 
regulatory regions of both genes [10]. CYP1A1 is mainly expressed in extrahepatic 
tissues, whereas CYP1A2 is almost exclusively expressed in the liver, representing about 
~15 % of its total CYP content [11]. CYP1A enzymes catalyze the bioactivation of pre-
carcinogens, such as polycyclic aromatic hydrocarbons (CYP1A1) as well as aromatic 
and heterocyclic amines (CYP1A2) [12]. CYP1A2 is also responsible for the metabolism 
of drugs, such as phenacetin [13], clozapine [14, 15], naproxen [16], propranolol [17] and 
tizanidine [18].  
The CYP1A2 gene consists of seven exons, including non-coding exon 1 [19]. 
Inter-individual differences in CYP1A2 activity are well known: up to 60-fold variations 
have been reported [11, 20]. In addition, ~15- and 40-fold variations in mRNA and protein 
expression levels have been observed in the human liver [19, 21]. To date, 36 CYP1A2 
haplotypes have been published on the Human Cytochrome P450 Allele Nomenclature 
Committee home page (http://www.cypalleles.ki.se/cyp1a2.htm). Of these, 21 are in the 
non-coding region and 15 are in the coding region, all causing amino acid changes of the 
CYP1A2 protein. Apart from studies that characterized gene polymorphisms in the non-
coding region, few reports described non-synonymous protein polymorphisms. Mostly, 
these concern the identification of genetic polymorphisms and their frequencies, but not 
their effects on protein level and activities. Murayama et al [22], Saito et al [23] and Zhou 
et al [7] characterized most of the non-synonymous polymorphisms with a limited 
number of substrates. The primary objective of this study is to investigate polymorphic 
forms, representing the majority of alleles with the non-synonymous polymorphic 
CYP1A2 protein, and to characterize their activity with a diverse group of substrates. 
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On the basis of a crystal structure published by Sansen et al [24] of  CYP1A2 
wild-type (WT) [CYP1A2*1] we selected mutants that seem to be localized in the vicinity 
of the active center, heme, entrance/exit channel or the NADPH-cytochrome P450 
oxidoreductase (CYPOR) interaction zone. As such, these polymorphic forms concern 
T83M [CYP1A2*9], S212C [CYP1A2*12], S298R [no allele designation], G299S 
[CYP1A2*13], I314V [no allele designation], I386F [CYP1A2*4], C406Y [CYP1A2*5] 
and R456H [CYP1A2*8]. For this purpose, the cDNA of the WT allele, present in a 
bacterial expression vector [25], was adapted through genetic engineering to generate the 
eight different CYP1A2 forms. CYP1A2 alleles were coexpressed with human CYPOR 
in a bacterial cell model [26], and the activity of the eight allelic variants and WT was 
investigated. The enzyme activity of these variants was analyzed together with WT and 
scrutinized through multivariate analysis. Results of this analysis were interpreted using 
the CYP1A2 crystal structure [24]. 
 
2.2. MATERIALS AND METHODS 
2.2.1. Reagents 
L-arginine, ampicillin, kanamycin sulfate, chloramphenicol, cytochrome c, 
isopropyl β-D-thiogalactoside (dioxane-free) (IPTG), thiamine, 2-aminoanthracene 
(2AA), glucose-6-phosphate, NADPH, ethoxyresorufin (ER), methoxyresorufin (MR), 
resorufin, phenylmethanesulfonyl fluoride (PMSF) and α-naphthoflavone (α-NF) were 
obtained from Sigma Chemical Co. (St Louis, MO, USA). 2-Amino-3-
methylimidazo(4,5-f)quinoline (IQ) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK) were obtained from Toronto Research Chemicals Inc. (North York, 
Ontario, Canada). 3-cyano-7-ethoxycoumarin (CEC) and 3-cyano-7-hydroxycoumarin 
(CHC) were obtained from BD Biosciences (Bedford, MA, USA). Phenacetin was 
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obtained from Brocades-ACF (Maarssen, The Netherlands) and clozapine from Duchefa 
Farma bv. (Haarlem, The Netherlands). Bacto agar, bacto peptone, bacto tryptone and 
bacto yeast extract were obtained from Difco (Detroit, MI, USA). All other chemicals 
were of the highest quality.  
 
2.2.2. Site-directed mutagenesis 
Site directed mutagenesis was performed with the “Quickchange XL” (Cedar 
Creek, TX, USA) and applied according to the manufactures instructions. All variants, 
except I386F, were constructed using plasmid pCWh1A2 [26]  as DNA template, 
encoding human CYP1A2*1 (isoform 2) [NCBI NM_000761] with N-terminus modified 
as described by Fisher et al [25]. In the case of the variant I386F, the template was 
pUC18_h1A2. This plasmid was constructed by cloning the cDNA of CYP1A2 from 
pCWh1A2 as an NdeI-XbaI fragment in pUC18. Forward and reverse mutagenesis 
primers for the creation of the desired mutation for each variant are presented in 
Supplementary Information Table I.  
The introduced mutation for each variant was confirmed by sequencing the full 
extent of the CYP1A2 cDNA. The pCWh1A2 plasmid has a considerable size (6.9 Kb), 
and it is known that, for a site-directed mutagenesis procedure, large plasmids have a 
reduced but significant risk for incorporation of undesired mutations. Therefore, mutated 
cDNAs were re-cloned into the pCW vector to ensure that plasmid sequences remained 




Chapter 2                        Characterization of 8 Human Cytochrome P450 1A2 variants 
56 
 
2.2.3. Bacterial coexpression of CYP1A2 variants with CYPOR and 
membrane preparation 
The expression of the different variants of CYP1A2 with CYPOR was obtained 
as described previously, using the bi-plasmid coexpression system [26]. Briefly, each 
strain was cultured in the TB (Terrific Broth) medium supplemented with peptone (2 g l-
1), thiamine (1 g ml-1), ampicillin (50 g ml-1), kanamycin (15 g ml-1), chloramphenicol 
(10 g ml-1), trace elements solution [27] (4 l ml-1), and 0.2 mM isopropyl β-D-
thiogalactoside (dioxane-free) (final concentrations). Cultures were started with 250 L 
of –80 ºC glycerol stocks, and cells were grown for 16 h at 28 ºC with moderate agitation. 
Membrane preparations were isolated as follows. Cultures were harvested at 2772 
× g for 20 min at 4 °C. The pellet was resuspended in TS (Tris-sucrose) buffer (75 mM 
TrisHCl, 250 mM sucrose, pH 7.8). Lysozyme was added to a final concentration of 0.5 
mg/ml, and cells were incubated on a roller bench for 30 min at 4 °C. Subsequently, 
EDTA (0.5 mM) and the protease inhibitor phenylmethanesulfonyl fluoride (0.5 mM) 
were added. Cell lyses was performed by freezing (–80 ºC) and thawing (1 cycle) and by 
subsequent several short rounds (60 s) of low-intensity sonication, interspersed with 30 s 
of ice-bath submersion, such that the temperature of the preparation never exceeded 8 ºC. 
The suspension was centrifuged at 2772 × g, for 10 min at 4 °C to eliminate unbroken 
cells. Membranes were pelleted by ultracentrifugation of supernatant at 100 000 × g, at 4 
°C for 60 min. Membranes were resuspended in TGE buffer (75 mM TrisHCl. 10 % (v/v) 
glycerol, 25 mM EDTA, pH 7.5) using a Dounce homogenizer, Jencons PLS (East 
Sussex, UK) and stored at –80  °C. In the case of phenacetin and clozapine experiments, 
membranes were obtained from cells, which had been lysed by French Press (3 cycles at 
1000 psi on ice) and a subsequent sonication treatment (2 cycles of 2 min). Protein 
concentrations were determined using the method described by Bradford, following the 
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manufacturer’s protocol from Bio-Rad (San Francisco, CA, USA), using bovine serum 
albumin as the standard. 
The CYP content of whole cells and membrane preparations, was determined 
using the CO-difference spectra technique as described previously [28]. The CYPOR 
content of membrane preparations was determined using the NADPH-cytochrome c 
reduction assay as described previously [29].   
 
2.2.4. Western blot analysis 
Membrane proteins (10 µg) were separated by SDS-PAGE electrophoresis (10 %) 
and electrotransferred to nitrocellulose membranes Hybond-ECL from GE Healthcare 
(Uppsala, Sweden). Immunoblotting analyses were carried out with the enhanced 
chemiluminescent ECL western blotting detection kit from GE Healthcare, using as 
primary antibody a polyclonal antibody from rabbit serum raised against recombinant 
human CYP1A2 from CYPEX (Dundee, UK). 
 
2.2.5. 7-methoxy- and 7-ethoxy-resorufin O-dealkylation 
7-Methoxy- (MROD) and 7-ethoxy-resorufin (EROD) O-dealkylation activities 
was performed in a 96-well microplate format, as described by Kranendonk et al [29] 
using a Zenyth 3100 microplate reader from Anthos (Imola, Italy). All measurements 
were carried out in triplicate and were performed at least three times in separate 
experiments. Stock solutions of MR and ER were prepared in dimethyl sulfoxideand were 
varied over 8 concentrations (MR: ≤ 2 M;  ER: ≤  5 M), maintaining a constant final 
solvent concentration of 0.2% (v/v) throughout the experiment, thus preventing 
interference with CYP1A2 activity [30]. The reactions were followed for the first 15 min. 
Velocity data were plotted according to the Michaelis–Menten equation, and kinetic 
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parameters (Vmax and KM) were calculated using GraphPad Prism from GraphPad 
software (La Jolla, CA, USA) applying one binding site analysis (hyperbola). 
.  
2.2.6. 3-Cyano-7-ethoxycoumarin O-dealkylation 
The 3-cyano-7-ethoxycoumarin O-dealkylation (CECOD) activity was measured 
as the rate of the increase in CHC (excision: 409 nm; emission: 460 nm). All 
measurements were carried out in triplicate and were performed at least three times in 
separate experiments, in a 96-well microplate format using a Zenyth 3100 microplate 
reader. Rates (µM CHC formed per min) could be calculated using a fluorescence 
standard curve of the product CHC. The reaction was performed with membranes (1 pmol 
of CYP1A2 per well) under the same conditions as for EROD and MROD. Stock 
solutions of CEC were prepared in acetonitrile and were varied over eight concentrations 
(≤ 75 M), maintaining a constant final solvent concentration of 0.2% (v/v) throughout 
the experiment. The reactions were followed for the first 15 min. Velocity data were 
plotted according to the Michaelis–Menten equation, and kinetic parameters (Vmax and 
KM) were calculated using GraphPad prism software, applying one binding site analysis 
(hyperbola). 
 
2.2.7. Inhibition studies 
IC50 determinations for α-NF were performed for MROD, EROD and CECOD as 
described above. In all, 12 different α-NF concentrations (≤ 5 µM) were used for each 
substrate. Substrate concentrations were 1.0, 2.5, and 25.0 µM for MR, ER and CEC, 
respectively. 
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The activity for each inhibitor concentration was determined at least in triplicate. 
IC50 was calculated with GraphPad prism software using sigmoidal dose-response 
analysis.  
 
2.2.8. Clozapine N-demethylation 
Clozapine N-demethylation activity was measured as the rate of the increase in 
demethylated clozapine absorbance at 254 nm using high-performance liquid 
chromatography (HPLC) coupled with a Separations 759A absorbance detector from 
Applied Biosystems (Foster City, CA, USA). All measurements were performed in 
triplicate and at least three times in separate experiments. Rates (pmol demethylated 
clozapine formed per min) were estimated using a standard curve of the substrate 
(clozapine), assuming that the extinction coefficients of the substrate and metabolite 
(demethylated clozapine) are comparable [31].  
To verify Michaelis-Menten characteristics (that is, time, substrate and enzyme 
dependence) of the metabolism of clozapine by CYP1A2, a full kinetic analysis with WT 
was performed. For this purpose, 100 nM of CYP1A2 was used per incubation and a 
gradient of 7 clozapine concentrations (≤ 500 µM). Analysis of clozapine demethylation 
by the 8 polymorphic CYP1A2 forms was performed with 100 nM of enzyme and 50 and 
250 µM of clozapine. All incubations were performed in a final volume of 300 μL, and 
incubated for 60 min at 37 oC. Reactions were initiated by the addition of 3.3 mM 
NADPH and terminated with 30 µL of 10% (v/v) HClO4. The precipitated protein was 
removed by centrifugation (for 15 min at 4000 × g) and the supernatant was analyzed by 
HPLC. Metabolites were separated using a C18 Luna 5-U 100A column from 
Phenomenex (Torrance, CA, USA) at a flow-rate of 0.6 ml/min. A gradient program was 
applied, using two mobile-phase solutions: A contained 99% H2O, 1% acetonitrile and 
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0.02% formic acid and B contained 99% acetonitrile, 1% H2O and 0.02% formic acid. 
The separation was initiated with 100% A, and maintained for 5 min. Subsequently, 
solution B was increased linearly to reach 100 % after 30 min and the percentage of 
solution B was inversed to 0% in 5 min.  
 
2.2.9. Phenacetin O-deethylation  
Phenacetin O-deethylation activity was measured as the rate of the increase in 
acetaminophen absorbance at 254 nm by HPLC analysis using a Separations 759A 
absorbance detector. All measurements were performed in triplicate and at least three 
times in separate experiments. Rates (pmol acetaminophen formed per min) could be 
calculated by using a standard curve of the product acetaminophen. 
In order to verify Michaelis-Menten characteristics (time, substrate and enzyme 
dependence) of the metabolism of phenacetin by CYP1A2, a full kinetic analysis with 
WT was performed. For this purpose, 100 nM of CYP1A2 was used per incubation and 
a gradient of 7 phenacetin concentrations (≤ 400 µM). Analysis of phenacetin 
deethylation by the 8 polymorphic CYP1A2 forms was performed with 100 nM of 
enzyme and 20 and 200 µM phenacetin. Incubations and HPLC analysis were performed 
as for clozapine.  
 
2.2.10. Bioactivation assays 
The bioactivation/mutagenicity assays were performed using the liquid pre-
incubation assay technique, as described previously [32]. Experiments were performed in 
triplicate and at least three times in separate experiments. Revertant colonies were 
counted after 48h of incubation at 37 ºC. Plates were digitally photographed, and the 
number of L-arginine prototrophic revertant colonies per plate were determined using 
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Labworks Software (version 4.6) from UVP, Inc. (Upland, CA, USA). Mutagenic activities (in 
revertants per nmol or revertants per µmol) were determined from the slope of the linear 
portion of the dose-response curve.  
 
2.2.11. Multivariate statistical analysis 
The normalization procedure was based on the variance in the data set. Both 
column and row variances were applied. This type of double normalization is appropriate 
when different enzyme preparations are being compared (that is, using partially purified 
or subcellular fractions) and when different types of substrates and detection methods are 
used [33]. Data pre-processing was carried out by dividing the values of the initial data 
set by the row-column double variance: 
Xnorm= ( Xobs/ Varcol) / Varrow 
Differences between polymorphic variants and WT were analyzed globally by 
principal component analysis (PCA)[34] and by multidimensional scaling (MDS)[35]. 
 
2.3. RESULTS 
2.3.1. Site-directed mutagenesis, mutant enzyme expression and 
characterization 
The eight polymorphic variants of human CYP1A2 were constructed and 
expressed in Escherichia coli. A suitable E. coli host, the BTC strain, was applied for 
adequate coexpression of the CYP1A2 allelic variants with human CYPOR, using a bi-
plasmid system [26]. CYPOR expression levels were determined in the membrane protein 
fraction and were comparable among all strains (7.9-11.4 pmol/mg membrane protein). 
The CYPOR/CYP ratios for the different variants were found in the range of the normal 
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values as observed in human liver microsomes (0.08-0.5) [36] except for variants I386F 
and R456H, which had no detectable CYP holoenzyme. 
Immunoblot analysis of membrane preparations indicated that CYP-protein 
expression levels were similar for WT and all eight constructed variants (Supplementary 
Figure S1). The CO-difference spectra of all recombinant CYPs expressed in E. coli BTC 
were also determined to quantify the CYP1A2 holoenzyme content (Supplementary 
Figure S2). Holoprotein levels for most variants were comparable with or slightly lower 
than WT, except for variants I386F and R456H. I386F showed a strongly reduced 450-
nm peak and a large 420 nm peak in bacterial cells (Supplementary Figure S2), and a total 
absence of the 450-nm peak in membrane fractions (data not shown). This indicates 
instability of the I386F holoprotein, probably due to inefficient heme incorporation and/or 
anchoring as a stable apoprotein has been demonstrated by immunodetection 
(Supplementary Figure S1). For R456H, no 450-nm peak was detectable in either whole 
cells or membrane preparations, indicating the absence of holoprotein.  
 
2.3.2. WT and mutant CYP1A2 activities  
To determine enzyme activities, all allelic variants were studied using eight 
structural different substrates and were compared with WT (Figure 1). Three fluorogenic 
CYP1A2 substrates (ER, MR and CEC), and two therapeutic drugs (clozapine and 
phenacetin) were used. Furthermore, the bioactivation of three CYP1A2 dependent pre-



















Figure 1. Chemical structures of used substrates demonstrating the full structure space of CYP1A2 
compounds applied in this study. 
 
2.3.2.1. Kinetic studies with fluorogenic substrates 
The polymorphic variants and WT were tested with three typical CYP1A2 
fluorogenic substrates (ER, MR and CEC). The results of the Michaelis-Menten kinetic 
studies (yielding Vmax and KM values) and the inhibitory potency (IC50) of α-NF, a specific 
CYP1A inhibitor, are presented in Table 1. For I386F and R456H, lacking detectable CO-
difference spectra, no activity was detected for any of the three substrates, not even at a 
double membrane sample concentration and at the highest substrate concentration. 
Therefore, these two variants were excluded from the remaining analysis.   
Although, Kcat (Vmax/KM) is considered to be a valid kinetic descriptor, subtle but 
significant differences in KM or Vmax can be obscured. As such, KM and Vmax were brought 
forward separately. Variants T83M and I314V showed a small increase in Vmax compared 
with WT, for the three substrates. In addition, the affinity for these substrates was altered, 
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except for CEC, with KM values being slightly higher for MR and ER.  Variant S298R 
demonstrated a small decrease in Vmax both for MROD and EROD, whereas the CECOD 
activity was comparable with WT. Variants G299S and C406Y showed higher values for 
Vmax of MROD, but not for EROD and CECOD. Affinity of variants S298R and G299S 
for all substrates was found similar to WT, with KM values being comparable with WT. 
In the case of C406Y, the observed substrate affinities were comparable with WT for 
CECOD but not for MROD and EROD, with KM values being higher in both cases. 
Finally, variant S212C showed activities almost identical to WT, for the three fluorogenic 
substrates, all Vmax and KM values being comparable with WT. 
 
2.3.2.2. Kinetic studies with clozapine and phenacetin 
Both clozapine N-demethylation and phenacetin O-deethylation activity of the 
CYP1A2 variants were also determined. I386F and R456H showed no activity for any of 
the two substrates, even at the highest substrate and double membrane concentrations. 
Therefore, these two variants were excluded from the remainder of the analysis. On the 
basis of the kinetic analysis of WT, two substrate concentrations were chosen. The six 
remaining variants and WT were incubated with 50 and 250 µM of clozapine (Table 1 
and Supplementary Figure S3), and 20 and 200 µM of phenacetin (Table 1 and 
Supplementary Figure S4). Control assays were performed with the highest concentration 
of each substrate in the presence of 1mM of the CYP1A2 inhibitor α -NF. 
At 20 µM concentration of clozapine, a decreased N-demethylation activity for all 
variants was found when compared with WT, but this was not the case at a clozapine 
concentration of 200 µM. At a clozapine concentration of 20 µM, variants T83M, S212C, 
S298R, G299S, I314V and C406Y showed reaction velocities of 64, 74, 58, 72, 65 and 
44% of WT, respectively.  At a clozapine concentration of 200 µM, for T83M, S212C, 
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S298R, G299S and C406Y reaction velocities of 83, 89, 108, 112, and 80%, respectively, 
of the WT activity were obtained, and for the I314V variant 65%. 
At low substrate concentrations (50 µM), phenacetin O-deethylation activity was 
not significantly different for variants T83M, S212C and I314V, being 79, 85 and 97%, 
respectively, of the WT activity, but was significantly decreased for S298R, G299S and 
C406Y, being 57, 64 and 48%, respectively, of the WT activity.  At a phenacetin 
concentration of 250 µM, the lowest activity found was for variant S298R with 60% of 
the WT activity, whereas no significant differences in reaction velocities were observed 
for T83M, S212C, G299S, I314V and C406Y, being 117, 106, 88, 104 and 83%, 
respectively, of the WT activity. In the case of mutant C406Y, extra peaks on the HPLC 
chromatogram were observed, which increased along with phenacetin concentration, but 
disappeared when inhibited with α-NF, indicating a different metabolic profile for this 
variant (data not shown).  
 
2.3.2.3 Bioactivation of pre-mutagens 
Strain BTC1A2, coexpressing recombinant human CYP1A2 and human CYPOR, 
have previously been shown to correctly bioactivate several known CYP1A2-dependent 
mutagens [26]. The present polymorphic CYP1A2 variants were further characterized 
with this cell model. Three pre-mutagens (2AA, NNK and IQ) were used for this purpose 
(Table 1 and Supplementary Figures S5-S8). No mutagenic activity was observed with 
the CYP1A2 null strain for these three pre-mutagens.   
When compared with WT, variants S212C and I314V showed a slight increase in 
mutagenic activity for 2AA, whereas variants T83M, S298R, G299S and C406Y showed 
a decrease in mutagenicity. For I314V, the results were comparable with WT. In the case 
of IQ, variants T83M, S298R, G299S and I314V showed a small decrease in 
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mutagenicity, whereas variants S212C and C406Y were comparable with WT. For NNK, 
the differences were the most striking as, although variant S298R showed a similar 
mutagenic activity compared with WT, all other variants had a reduced capacity to 
bioactivate this mutagen. Remarkably, in the case of T83M and C406Y, no mutagenicity 
could be detected. 
I386F and R456H, two variants with perturbed expression of holoenzyme, showed 
no mutagenic activity for any of the three pre-mutagens, except for I386F with 2AA being 
significantly lower than WT. 
 
2.3.3. Multivariate analysis of data 
 To compare all obtained experimental data, a multivariate analysis was performed. 
The polymorphic CYP1A2 variants were numbered from 2 to 7, whereas variants I386F 
and R456H were not included in the analysis. The different parameters, such as Vmax, KM, 
relative reaction velocities, IC50 and mutagenic activities, were designated A to P (Table 
1). 
 
2.3.3.1. Principal component analysis (PCA) 
Principal component analysis (PCA), a procedure that transforms a high number 
of possibly correlated variables into a reduced number of uncorrelated variables 
denominated by principal components, was used to project present date from a 16-
dimensional (activity parameters) space into a 2-dimensional space for ease of 
visualization (Figure 2). After a two-variance normalization, the first analysis was by a 
Scree plot analysis (not shown). This analysis indicated that the first principal component 
retains 94.5 % of the initial variance; therefore this single principal component explains 
almost all significant variations in the data. The PCA analysis itself seems to indicate that 
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the trend of variation that governs our data set stems from the difference between all WT-
like enzymes [WT, no. 3 (S212C), no. 4 (S298R), no. 6 (I314V) and no. 7 (C406Y)], and 









Figure  2. Principal component analysis (PCA) plot of the CYP1A2 variants activity normalized data set 
for the first two principal components (first principal component retains 94.5 % of the initial variance). 
 
2.3.3.2. Multidimensional scaling (MDS) 
For our data set, two different multidimensional scaling (MDS) configuration 
plots were constructed. In the first MDS configuration plot, CYP1A2 variants were 
compared using all activity parameters (Figure 3a). This plot shows how the enzymes 
were similar/dissimilar for all assayed activities. Kruskal’s stress value was 0.002. The 
dendrogram depicted in Figure 3b deduced from MDS distances, showed that variants no. 
2 (T83M) and no. 4 (S298R) were very similar and both were found slightly different 
from WT and variants no. 3, no. 6 and no. 7 (S212C, I314V, C406Y). Variant no. 5 
(G299S) appears, again like in the PCA analysis, to constitute itself a particular enzyme, 
and different from all the others.  
 
 














Figure 3. (a) Multidimensional scaling (MDS) configuration plot of the CYP1A2 variants activity 
normalized data set for the different activities A to P.  (b) Dendrogram obtained from the distances between 
all CYP1A2 enzymes assayed in the MDS configuration plot. 
 
The second MDS configuration plot depicted in Figure 4 compares the different 
activity parameters for the assayed CYP1A2 enzymes. This plot shows the force of 
activities in scrutinizing between the different CYP1A2 enzymes.  Kruskal’s stress value 
was 0.207, slightly over the typical value of 0.15; however,we are confident that this plot is 
meaningful. Three clusters could be deduced from the MDS configuration plot, which 
shows the distances between the activities for all assayed enzymes. Two objects were 
located in very separate and opposite areas of the graph, namely parameter C (EROD 
Vmax) and parameter M (NNK mutagenic activity). All other parameters aggregated 
together in the central area of the two-dimensional plot.  
 
 












Figure 4. Multidimensional scaling (MDS) configuration plot of activities A to P for the different CYP1A2 
variants.  
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Table I. Data set of all obtained activity parameters.  
  MROD Vmax MROD KM EROD Vmax EROD KM CECOD Vmax CECOD KM Phenacetin 20 µM Phenacetin 200 µM 
  pmol R per min µM  pmol R per min µM  µM CHC per min µM  pmol paracetamol per min 
pmol paracetamol per 
min 
  A B C D E F G H 
  average std desv average std desv average std desv average std desv average std desv average std desv average 
std 
desv 
average std desv 
WT 1 2.55 0.10 0.59 0.06 0.75 0.04 1.16 0.16 3.37 0.04 5.00 0.23 31.47 3.45 84.28 5.87 
T83M 2 4.65 0.34 1.02 0.15 1.41 0.12 1.71 0.34 5.30 0.05 3.53 0.13 24.74 3.24 98.54 12.31 
S212C 3 2.78 0.15 0.58 0.08 0.84 0.04 1.14 0.14 2.99 0.07 4.48 0.40 26.67 1.53 89.63 5.89 
S298R 4 1.86 0.05 0.43 0.03 0.53 0.03 1.23 0.17 3.25 0.09 5.23 0.51 17.94 2.00 50.78 9.16 
G299S 5 3.38 0.20 0.88 0.11 0.72 0.02 1.53 0.13 4.13 0.08 4.04 0.29 20.03 1.80 74.26 5.13 
I314V 6 5.23 0.61 1.47 0.32 1.28 0.08 2.11 0.28 7.48 0.11 5.17 0.30 30.49 5.30 88.30 2.02 
C406Y 7 3.63 0.22 0.92 0.12 0.76 0.03 1.68 0.15 4.14 0.08 4.95 0.39 14.95 0.75 69.57 1.73 
Abbreviations: 2AA, 2-aminoanthracene; CEC, 3-cyano-7-ethoxycoumarin; CECOD, 3-cyano-7-ethoxycoumarin O-dealkylation; CHC, 3-cyano-7-hydroxycoumarin; 
EROD, 7-ethoxy-resorufin O-dealkylation; IQ, 2-Amino-3-methylimidazo(4,5-f)quinoline; MROD, 7-Methoxy- resorufin O-dealkylation; N-demeth, N-demethylation; 
NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; R, resorufin; rev, revertant colonies; WT, wild type.
  
 
Clozapine 50 µM 
 
Clozapine 250 µM 2AA IQ NNK IC50 MROD IC50 EROD IC50 CEC 
  
pmol N-demeth product per 
min 
pmol N-demeth product per min rev per nmol 2AA rev per nmol IQ rev per µmol NNK µM µM µM 
  I J K L M N O P 
  average std desv average std desv average std desv average 
std 
desv 
average std desv    
WT 1 64.8 5.3 140.3 6.6 10902 328 318 26 1098 95 0.0025 0.2388 0.1416 
T83M 2 41.4 2.2 117.1 5.9 8361 398 215 13 - - 0.0025 0.2043 0.0979 
S212C 3 48.3 0.2 124.1 4.1 12662 440 313 48 599 133 0.0024 0.1686 0.0599 
S298R 4 37.5 1.0 152.0 7.2 8274 227 232 39 1151 85 0.0025 0.1603 0.0676 
G299S 5 46.9 2.3 157.1 2.4 4657 447 244 16 575 65 0.0025 0.1577 0.0733 
I314V 6 42.4 1.1 91.2 9.7 11793 153 216 29 694 94 0.0027 0.2811 0.1265 
C406Y 7 28.6 1.4 112.0 2.8 9561 494 274 27 - - 0.0024 0.1260 0.0813 




Polymorphisms in xenobiotic-metabolizing enzymes have been recognized as a 
main factor in inter-individual variability in drug and xenobiotic responses and 
susceptibilities. In particular, CYP1A2 is involved in the metabolism of a large number 
of drugs and chemical carcinogens. A recent study found significant differences in 
CYP1A2 activity between ethnic groups (Swedes and Koreans), not related to 
environmental factors [37]. CYP1A2 polymorphisms could also be related to the toxicity 
of leflunomide in patients with rheumatoid arthritis [38] and seem to have a role in the 
efficacy of treatment of patients with antipsychotics, such as clozapine and olanzepine 
[39]. Several studies indicated implications of CYP1A2 polymorphisms in cancer 
susceptibility, namely for pancreatic cancer [40] and bladder cancer [41]. 
 To date, 39 single-nucleotide polymorphisms of human CYP1A2 have been 
reported (from which 36 haplotypes were determined), describing alterations on DNA 
sequence levels and in some cases their epidemiological frequencies. From the 17 known 
non-synonymous protein polymorphic alleles, 5 have not been characterized regarding 
their enzymatic activity (S212C, F21L, S298R, I314V and R431W; see Table 2). Two of 
these were included in this study. Formerly, other non-synonymous protein forms were 
probed with only two substrates, except for I386, D348W and C406, which were analyzed 
with more substrates (see Table 2).  In this report, we describe the thorough 
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Table 2. CYP1A2 non-synonymous protein polymorphic alleles: comparison between current and former 
studies. 
Non synonymous protein 
polymorphism 
Other studies This study 
Substrates References Substrates 
S18C _____ Solus, et al [42] _____ 
F21L _____ Huang, et al [43] _____ 
P42R ER and Phenacetin Saito, et al [23] _____ 
T83M ER and Phenacetin Murayama, et al [22] 8 a 
E168Q ER and Phenacetin Murayama, et al [22] _____ 
F186L ER and Phenacetin Murayama, et al [22] _____ 
S212C ER and Phenacetin Murayama, et al [22] 8 a 
S298R _____ Solus, et al [42] 8 a 
G299S ER and Phenacetin Murayama, et al [22] 8 a 
I314V _____ Solus, et al [42] 8 a 
D348N 
IQ, MeIQ, MeIQx, PhIP, 
Glu-1-P and Phenacetin 
Zhou, et al [7] _____ 
R377Q ER and Phenacetin Saito, et al [23] _____ 
I386F 
IQ, MeIQ, MeIQx, PhIP, 
Glu-1-P and Phenacetin 
Zhou, et al [7] 8 a 
C406Y 
IQ, MeIQ, MeIQx, PhIP, 
Glu-1-P and Phenacetin 
Zhou, et al [7] 8 a 
R431W _____ 
Zhou, et al [7] 
Chevalier, et al [44] 
_____ 
T438I ER and Phenacetin Murayama, et al [22] _____ 
R456H ER and Phenacetin Saito, et al [23] 8a 
Abbreviations: ER, ethoxyresorufin; IQ, 2-amino-3-methylimidazo(4,5-f)quinoline. Glu-1-P, 2-amino-6-
methyldlpyrido[1,2-a:30,20-d]imidazole; MelQ, 2-amino-2,4-dimethylimidazo[4,5-f]quinoline; MelQx, 2-
amino-3,8-dimethylimidazo[4,5-f]quinoxaline; PhlP, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. 
a This study, see Table 1 and Figure 1. 
  
The CYP content was similar to WT for all variants, except for I386F and R456H. 
These variants showed severely reduced or absent holoenzyme, respectively, in bacterial 
cells, and both were absent in membrane fractions, indicating highly unstable 
holoenzymes. The CYPOR expression levels in membrane preparations when co-
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expressed with the various CYP1A2 variants were similar to the WT strain. The 
CYPOR/CYP stoichiometry is recognized as a critical factor for the catalytic properties 
of CYP enzymatic system [26]. CYPOR/CYP ratios for the different variants were found 
to be in the range of those observed in human liver microsomes. These results first 
indicated that coexpression of these CYP1A2 variants with CYPOR represented an 
adequate approximation of the in vivo situation, and second that in principle the observed 
alterations in CYP1A2 activity could be solely ascribed to the CYP1A2 variant.  
CYP1A2 variants were subjected to several activity assays using eight 
substantially different substrates, in an attempt to discriminate between allelic variants as 
much as possible. Different substrate classes with different types of CYP1A2-mediated 
reactions were used, namely: O-dealkylation (MR, ER, CEC and phenacetin); N-
demethylation (clozapine); and N-hydroxylation (NNK, IQ and 2AA). 
As a result, a very heterogeneous activity data set could be generated for CYP1A2 allelic 
forms. To thoroughly analyse this diverse data set, multivariate statistical analysis, a very 
useful statistical tool, was performed on this data set. Variants I386F and R456H were 
excluded from this analysis because of the lack of detectable holoenzyme. Differences 
between polymorphic CYP1A2 variants and WT were analyzed globally by principal 
component analysis and multidimensional scaling, two statistical tools of complementary 
interest as was shown in several fields [45, 46], including the recent exploration of protein 
structure space [47, 48]. 
All applied statistical analyses indicated that variant S212C (no. 3) represents the 
most similar enzyme to WT. Murayama et al [22] found also similar relative activities to 
WT for this variant, using two substrates, namely ER and phenacetin. Both PCA and 
MDS analysis indicate that variants I314V (no. 6) and C406Y (no. 7) were similar to WT. 
In a previous report [7], no major differences were observed for variant C406Y activity, 
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corroborating our results. It is interesting to note that the lack of bioactivation of NNK of 
this variant described in this report coincides with observations from previously referred 
authors. This group described altered catalytic specificity of C406Y for three heterocyclic 
amine pre-mutagens, other than NNK. They proposed that possible changes in the 
regioselectivity and regiospecificity of the reactions might have lead to an altered 
metabolite profile. This theory seems to be reinforced by our observation of extra 
metabolites in phenacetin O-dealkylation for this variant. Variant S298R (no. 4) appears 
to be a slightly different enzyme from WT, both from MDS and PCA analysis. This 
variant is located on the surface of the heme domain, on the proximal side of the heme 
(see Figure 5). On the basis of alignment and superposition of the human CYP1A2 crystal 
structure [24], with the structure of the CYP BM3 heme and FMN-binding domains [49], 
S298 seems also to be located near the CYPOR interaction area. The S298R amino-acid 
change might influence the interaction of CYP1A2 with its redox partner, explaining the 
observed differences. Both MDS and PCA analysis indicated that variant T83M (no. 2) 
is a significantly different enzyme from WT.  On the basis of the human CYP1A2 
structure published by Sansen et al [24], and the description of substrate entrance and 
product exit channels of CYPs by Cojocaru et al [50], it seems likely that this residue is 
located in a substrate entrance/product exit channel. Finally, G299S (no. 5) is definitely 
indicated as the most distinguishable variant, of all studied variants in thisstudy. This is 
consistent with all performed statistical analyses, and it seems to indicate not only a 
significant different behaviour from WT but also from all other analyzed variants. G299 
is located beside S298, with the possibility of G299S disturbing the interaction of 
CYP1A2 with CYPOR (vide supra). From the MDS plot for substrates (Figure 4), it is 
interesting to note that NNK (mutagenic activity) represents the most discriminative 
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Figure 5. Localization of altered amino acids of the selected CYP1A2 polymorphic variants using the 
human CYP1A2 crystal structure published by Sansen, et al [24]. (This figure was generated using PDB 
file no. 2H14). 
 
Variants I386F and R456H showed to be two particular cases, both showing 
severe problems with holoprotein stability. In a previous study by Zhou et al [7], variant 
I386F showed a relative low expression level of holoenzyme when expressed in bacterial 
cells. The I386 residue is located in the substrate recognition site 5 and based on the 
CYP1A2 crystal structure published by Sansen et al [24], very close to the catalytic 
center, only 3.8 Å apart from the cocrystallized substrate α-NF and around 4 Å from the 
heme. In mammalian CYP structures, known up to now, the common structural features 
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of the heme surroundings is formed by the I-helix, the substrate recognition site 5 and the 
BC loop [51]. The I386F substitution represents the replacement of an aliphatic side chain 
with an aromatic side chain, which could distort the heme-anchoring structure, explaining 
the observed highly unstable I386F holoprotein. This is supported by the increase in the 
420- nm peak in the CO-difference spectrum of this variant, indicating dislocated heme 
positioning. In the case of R456H, there was no detectable holoenzyme, both in whole 
cells and membrane fractions, with a concomitant increase in the 420-nm peak in the CO-
difference spectrum, observations in accordance with previous study by Saito et al [23]. 
Previous studies with the rat orthologous of CYP1A2, suggested that the region 
containing this amino acid is crucial in heme binding and its interaction with CYPOR 
[52, 53]. The substitution of R456 in humans (corresponding to rat R454) showed 
markedly reduced activities. In addition, a positively charged residue, the position of 
which is variable in the C-terminal end of the substrate recognition site 5 region, has been 
identified by protein sequence alignments and is conserved in 97.7% of a total of 6379 
CYP sequences [51]. The location of this residue in all-known crystal CYP structures, 
including the CYP1A2 structure indicates that this residue interacts with the 7´-
propionate of the heme. A previous reported work, which compared four CYP crystal 
structures and 200 sequences, suggested a functional conserved heme interacting arginine 
that is also involved in the elimination of water from the active site [54]. 
 In summary, we successfully expressed eight allelic variants of CYP1A2 with 
human CYPOR and could measure multiple activities parameters of eight structural 
different substrates. Two of these variants, namely I386F and R456H, were enzymatically 
inactive. The collected heterogeneous data set from the remaining variants was analyzed 
using several multivariate analysis tools. This analysis indicated that variant G299S (no. 
5) seems to have substantial altered catalytic properties in comparison with WT, whereas 
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variant T83M (no. 2) is slightly but significantly different from the WT. Moreover, an 
important residue of the scaffold for proper heme binding and stabilization, R456, could 
be identified in CYP1A2. 
At present, it is acknowledged that polymorphisms in CYP1A2 do not profoundly 
penetrate into the phenotype level [55]. However, we have shown in this study that 
although the eight variants cause, seemingly on the whole, relative minor activity changes 
(besides I386F and R456H), some variants can have profound effects on particular 
CYP1A2 mediated biotransformation, as was demonstrated for the bioactivation of NNK. 
As such, the results indicated that several of the studied allelic forms can have 
pharmokinetic and/or toxicokinetic consequences. Moreover, our results seem to indicate 
and/or confirm structural characteristics and features of the CYP1A2 enzyme. As such, 
studying polymorphic CYP activity is also a driving tool for improving our knowledge 
on the molecular mechanism of the functioning of the human CYP1A2 and the CYP 
enzyme complex in general. 
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Supplementary Information Figure 1. Immunoblot analysis of CYP1A2 polymorphic variants and WT 
expressed in E. coli(Each lane contained 10 µg of membrane fraction; Mw: Molecular weight marker,values 














Supplementary Information Figure 2. CO-difference spectra of E. coli BTC whole cells expressing the 
different variants of CYP1A2. (Spectral data was normalized for cell density; spectra represents n=3. The 
standard deviation of [CYP] did not exceeded 2,5 % of mean)    













Supplementary Information Figure 3. Clozapine N-demethylation of CYP1A2 variants. (Relative 












Supplementary Information Figure 4.  Phenacetin O-dealkylation of CYP1A2 variants. (Relative 
activities determined with 20 µM [white bars] and 200 µM [grey bars] of phenacetin. Error bars represent 
standard deviations.) 











Supplementary Information Figure 5. Bioactivation capacity of CYP1A2 polymorphic variants. Dose-









Supplementary Information Figure 6. Bioactivation capacity of CYP1A2 polymorphic variants. Dose-









Supplementary Information Figure 7. Bioactivation capacity of CYP1A2 polymorphic variants. Dose-
response curves for NNK. 






















Supplementary Information Figure 8. Bioactivation capacity of CYP1A2 polymorphic variants of the 
premutagens a): 2AA; b): NKK and c): IQ (expressed in number of revertant colonies per nmol or µmol of 
compound; n=3, ** p< 0.01 and *** p<0.001) (). Error bars represent standard deviations.  
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Allele frequency Primers for site-directed mutagenesis (mutated nucleotide is designated underlined) 
Amino acid 
substitution 
CYP1A2*9 1 1 
Forward 5´ GATCCGCATTGGCTCCATGCCCGTGCTGGTGCTG 3´ 
T83M 
Reverse 3´ CTAGGCGTAACCGAGGTACGGGCACGACCACGAC 5´ 
CYP1A2*12 1 1 
Forward 5´ CAGCACTTCCCTGAGTGTAGCGATGAGATGCTC 3´ 
S212C 
Reverse 3´ GTCGTGAAGGGACTCACATCGCTACTCTACGAG 5´ 
No designation rs17861157 3 % 2 
Forward 5´ GAAGGGGCCTAGAGCCCGCGGCAACCTCATCCCAC 3´ 
S298R 
Reverse 3´ CTTCCCCGGATCTCGGGCGCCGTTGGAGTAGGGTG 5´ 
CYP1A2*13 rs35796837 1% 2 
Forward 5´ GGGCCTAGAGCCAGCAGCAACCTCATCCCACAG 3´ 
G299S 
Reverse 3´ CCCGGATCTCGGTCGTCGTTGGAGTAGGGTGTC 5´ 
No designation rs28399418 1 
Forward 5´ GTCAACCTTGTCAATGACGTCTTTGGAGCAGGATTTGAC 3´ 
I314V 
Reverse 3´ CAGTTGGAACAGTTACTGCAGAAACCTCGTCCTAAACTG 5´ 
CYP1A2*4 1 1 
Forward 5´ CCTTCTTGCCCTTCACCTTCCCCCACAGCACAACAAG 3´ 
I386F 
Reverse 3´ GGAAGAACGGGAAGTGGAAGGGGGTGTCGTGTTGTTC 5´ 
CYP1A2*5 rs55889066 1 
Forward 5´ CTACATCCCCAAGAAATGCTATGTCTTCGTAAACCAGTGG 3´ 
C406Y 
Reverse 3´ GATGTAGGGGTTCTTTACGATACAGAAGCATTTGGTCACC 5´ 
CYP1A2*8 1 1 
Forward 5´ GGCATGGGCAAGCACCGGTGTATCGGG 3´ 
R456H 
Reverse 3´ CCGTACCCGTTCGTGGCCACATAGCCC 5´ 
(1 not yet designated (SNP ID) or determined (allele frequency)) 









Functional characterization of eight human 
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Background Interindividual variability in cytochrome P450 (CYP)-mediated 
xenobiotic metabolism is extensive. CYP metabolism requires two electrons, which can 
be donated by NADPH cytochrome P450 oxidoreductase (CYPOR) and/or cytochrome 
b5 (b5). Although substantial number of studies have been reported on the function and 
effect of b5 in CYP-mediated catalysis, its mode of action is still not fully understood.  
Objective The aim of this work was to examine the effect of b5 on the activities of eight 
natural-occurring variants of human CYP1A2, namely: T83M, S212C, S298R, G299S, 
I314V, I386F, C406Y and R456H.  
Materials and Methods An approach, as used in our former study was applied, 
coexpressing these polymorphic CYP1A2 variants separately with CYPOR and b5 in the 
bacterial cell model BTC-CYP. For each variant, 16 different activity parameters were 
measured, using eight different substrates. This heterogeneous data set was merged with 
the one of our former study (i.e. without b5) and a multivariate analysis was carried out.  
Results This analysis indicated that b5 seems to have the ability to affect CYP1A2 
variants to behave more like the wild-type variant. This was especially the case for variant 
I386F, for which the presence of b5 was crucial to show activity. Variants T83M and 
C406Y showed considerably different activity-profiles when in the presence of b5. 
Furthermore, our data seem to implicate CYP1A2 residue G299 in its interaction with 
CYPOR and/or b5.  
Conclusion Results indicate the ability of b5 to affect CYP1A2 variants to behave more 
like the wild-type variant, attenuating detrimental effects of structural mutations of these 
variants, seemingly through extensive allosteric effects. 
 




Cytochrome P450 (CYP) is a large superfamily of enzymes that are responsible 
for the metabolism of a wide variety of clinically, physiologically, and toxicologically 
important compounds [1]. In this enzymatic system, CYPs from families 1-3 mediate 70-
80% of the phase I-dependent metabolism of clinical drugs [2] participating in the 
metabolism of a large number of structurally different xenobiotics. All genes that encode 
CYPs from families 1-3 are polymorphic [3]. Human CYP polymorphisms include not 
only mutations in noncoding regions (promoter, intron) but also in the protein-coding 
sequences. Mutations in noncoding sequences may lead to altered expression levels, 
whereas mutations in protein-coding sequences may change the structure and catalytic 
properties of the enzyme [4].Currently, it is generally accepted that genetic variations of 
genes encoding drug-metabolizing enzymes play a major role in the outcome of drug 
treatment. CYP polymorphism has been indicated as a major reason why substantial 
numbers of patients do not respond, respond partially, or present adverse drug reactions 
[5, 6]. Therefore, it is important to understand the effects of CYP polymorphism to 
improve our comprehension of interindividual differences in the outcome of drug 
treatments, as well as in chemical exposure in general [7]. 
Human CYP1A2 is almost exclusively expressed in the liver, representing ~15% 
of its total CYP content [8]. CYP1A2 catalyze the bioactivation of ~17% of human 
precarcinogens [9], such as aromatic and heterocyclic amines [10], and mediates the 
metabolism of about 15% of clinical drugs [11], such as clozapine [12], lidocaine [13], 
phenacetin [14], propranolol [15] and tacrine [16]. Differences between individuals in 
CYP1A2 activity are well known: up to 60-fold variations have been reported [8, 17]. To 
date, 36 CYP1A2 haplotypes have been catalogued by the Human Cytochrome P450 
Allele Nomenclature Committee (http://www.cypalleles.ki.se/cyp1a2.htm). Recently, our 
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group reported on a study on the functional characterization of eight CYP1A2 
polymorphic variants, relative to CYP1A2 wild-type (1A2*1) (WT) form, using a 
structurally diverse set of substrates, measuring 16 different activity parameters [18]. Our 
analysis indicated variants G299S [CYP1A2*13] and T83M [CYP1A2*9] to be 
significantly different from the WT variant, and could be interpreted structurally, on the 
basis of their location in the CYP1A2 protein. In addition, R456 could be identified as an 
important residue for proper heme binding and stabilization in the CYP1A2 protein [18].  
Microsomal CYP metabolism requires a coupled supply of electrons, which are 
donated by the auxiliary protein NADPH cytochrome P450 oxidoreductase (CYPOR) 
[19]. Similar to CYP, CYPOR is a membrane-bound protein. The reductase contains two 
flavin moieties, FMN and FAD, essential for the sequential one-electron transfer to CYP, 
originating from NADPH [20]. Another heme protein has been shown to be important for 
CYP-mediated reactions, namely, cytochrome b5 (b5). The discussion of b5 involvement 
in CYP reactions has been controversial since it was first suggested by Hildebrandt and 
Estabrook [21]. The heme protein b5 is a ubiquitous small protein of ~17 kDa that is 
present throughout the phyla. In all species and tissues, b5 is anchored in the membrane 
by a hydrophobic carboxyl-terminal end, except for erythrocytes, in which a soluble form 
is found [22]. Both these forms of b5 carry a prosthetic heme group and can exist in 
oxidized and reduced states [23]. Physiologically, b5 can be reduced both by cytochrome 
b5 reductase (NADH dependent) and by CYPOR [24]. Besides its involvement in CYP-
mediated biotransformation, b5 is also involved in lipid biosynthesis, serving as the 
electron donor to at least three separate microsomal desaturases involved in the fatty acid 
metabolism [25], and is known to be involved as an electron transfer partner in a large 
number of other oxidative (non-CYP) reactions in biological tissues [26]. 
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Several studies using different types of in-vitro systemshave reported that b5 could 
modulate specific activities of several CYPs. The role of b5 in modulating CYP17A1 
activity (17-hydroxylation and 17,20-lyase activity of C21-steroids) is now fairly 
established [27]. Other studies have reported the effects of b5 on the catalytic properties 
of xenobiotic metabolizing CYPs such as CYP3A5 [28], CYP3A4 [28-31], CYP2C9 [29, 
31], CYP2B4 [32], CYP2A6 [29, 33] and CYP2E1 [29, 33-35]. Depending on the 
xenobiotic CYP involved, substrate, and experimental (in-vitro) conditions, b5 has been 
shown to stimulate, inhibit or not to interfere with CYP reactions [36, 37]. Beside this 
CYP-dependent and/or substrate-dependent effect through mechanisms that are still not 
well understood, b5 might have differentiated effects on genetic variants of the same CYP 
isoforms, a factor that is important in the understanding of the variability in drug therapy 
and chemical exposure in general. 
Therefore, the primary aim of the present study was to examine the effect of b5 on 
the activities of eight natural occurring variants of human CYP1A2 to determine the role 
of b5 in the variability of CYP1A2-mediated biotransformation. For this purpose, we used 
the established Escherichia coli BTC cell model [38], which has been shown to 
functionally and correctly coexpress human CYP together with CYPOR and b5 in 
stoichiometries which reflect those found in the human liver [33]. CYP1A2-WT and its 
genetic variants T83M [CYP1A2*9], S212C [CYP1A2*12], S298R [no allele 
designation], G299S [CYP1A2*13], I314V [no allele designation], I386F [CYP1A2*4], 
C406Y [CYP1A2*5] and R456H [CYP1A2*8] were coexpressed separately, with 
CYPOR and b5 in this bacterial system. The same 16 different activity parameters were 
measured using the structural diverse set of eight substrates as in our former study [18]. 
This CYP1A2/b5 activity data set was combined with the one of our former study (activity 
data obtained in the absence of b5) [18], and subsequently examined together by 
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multivariate analysis. The result of this analysis were then interpreted using the CYP1A2 
crystal structure [39]. 
 
3.2. MATERIALS AND METHODS 
3.2.1. Reagents 
L-Arginine, ampicillin, kanamycin sulfate, chloramphenicol, cytochrome c, 
isopropyl β-D-thiogalactoside (dioxane-free) (IPTG), thiamine, 2-aminoanthracene 
(2AA), glucose-6-phosphate, NADPH, ethoxyresorufin (ER), methoxyresorufin (MR), 
resorufin, phenylmethanesulfonyl fluoride (PMSF) and α-naphthoflavone (α-NF) were 
obtained from Sigma Chemical Co. (St Louis, MO, USA). 2-Amino-3-
methylimidazo(4,5-f)quinoline (IQ) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK) were obtained from Toronto Research Chemicals Inc. (North York, 
Ontario, Canada). 3-Cyano-7-ethoxycoumarin (CEC) and 3-cyano-7-hydroxycoumarin 
(CHC) were obtained from BD Biosciences (Bedford, MA, USA). Phenacetin was 
obtained from Brocades-ACF (Maarssen, The Netherlands) and clozapine from Duchefa 
Farma bv. (Haarlem, The Netherlands). Bacto agar, bacto peptone, bacto tryptone and 
bacto yeast extract were obtained from Difco (Detroit, MI, USA). All other chemicals 
were of the highest quality.  
 
3.2.2. Construction of CYPOR/b5 expression plasmid pLCM_hB5_POR 
The expression of the different CYP1A2 variants with CYPOR and human b5 was 
achieved through the biplasmid coexpression system [33, 38], using the human CYP1A2 
expression vectors of all variants of our former study [18] and a newly constructed 
plasmid, pLCM_hb5_PORwt, encoding human b5 and CYPOR (see Figure, 
Supplemental digital content 1, http://links.lww.com/FPC/A539). The latter plasmid was 
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obtained through the PCR amplification of the pTAC_hB5 sequence of pLCM-b5-RED 
[33] using forward and reverse primers TACGTCTAGACACCAATGCTTCTGGCGTCA and 
TCAGGGATCCACTTCTGAGGAGGTGTTCAG. The PCR product was digested with BamHI and 
XbaI and subcloned in pUC18, and cDNA was verified by sequencing. Subsequently, 
pUC18_pTAC_hB5 was digested with BamHI and XbaI and the XbaI-BamHI fragment 
was isolated and ligated in pLCM_PORwt [40] previously opened by BamHI and XbaI 
digestion. The total pTAC_hB5_pTAC_PORwt DNA stretch of pLCM_hb5_PORwt was 
verified by sequencing.  
 
3.2.3. Bacterial coexpression of CYP1A2 variants with CYPOR and 
membrane preparation 
The pCWh1A2 expression vectors encoding each of the different nine CYP1A2 
variants [18] were combined separately with the plasmid pLCM_hb5_PORwt in BTC by 
electroporation. The control strain BTCb5Por was obtained by transfection with 
pLCM_hb5_PORwt and the empty pCW expression vector. Each strain was cultured in 
TB medium supplemented with peptone (2 g/l), thiamine (1 g/ml), ampicillin (50 
g/ml), kanamycin (15 g/mL), chloramphenicol (10 g/ml), trace elements solution [41] 
(4 l/ml), and 0.2 mmol/l isopropyl β-D-thiogalactoside (final concentrations). Cultures 
were started with 250 l of –80 ºC glycerol stocks and cells were grown for 16 h at 28 ºC 
with moderate agitation. 
All membrane preparations were obtained as described previously [18]. Briefly, 
cultures were harvested at 2772g, 20 min at 4 °C. The pellet was resuspended in TS buffer 
(75 mmol/l Tris-HCl, 250 mmol/l sucrose, pH 7.8). Lysozyme was added to a final 
concentration of 0.5 mg/ml and cells were incubated on a roller bench for 30 min at 4 °C. 
Subsequently, EDTA and protease inhibitor PMSF were added to a final concentration of 
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0.5 mmol/l each. Cell lyses was performed by freezing (–80 ºC) and thawing (1 cycle) 
and subsequent several short rounds (60 s) of low-intensity sonication, interspersed with 
30 s ice-bath submersion. The suspension was centrifuged at 2772g, for 10 min at 4 °C to 
eliminate unbroken cells. Membranes were pelleted by ultracentrifugation of supernatant 
at 100 000 g, at 4 °C, for 60 min. Membranes were resuspended in TGE buffer (75 mmol/l 
TrisHCl. 10 % (v/v) glycerol, 25 mmol/l EDTA, pH 7.5) using a Dounce homogenizer 
and stored at -80 °C. Protein concentrations were determined using the method described 
by Bradford, following the manufacturer’s protocol from BioRad (San Francisco, 
California, USA), using bovine serum albumin as standard. 
 
CYP and b5 concentrations in bacterial cultures and membrane preparations were 
determined using spectrophotometric techniques as described before [38, 42]. The 
CYPOR content of membrane preparations was determined using the NADPH-
cytochrome c reduction assay as described previously [40].  
 
Western blot analyses were carried out as described previously [18], except for 
the use of polyclonal (rabbit) antiserum for the detection of b5. Determination of the 
activity parameters of clozapine N-demethylation, phenacetin O-deethylation, 7-
methoxy-, 7-ethoxy-resorufin  and 3-cyano-7-ethoxycoumarin O-dealkylation, α-NF 
inhibition as well as the bioactivation (mutagenicity) assays and multivariate statistical 
analysis were performed as described previously [18]. 
 
3.3. RESULTS 
The E. coli cell model, BTC [38], was used for the separate coexpression of the 
human CYP1A2 variants together with both human CYPOR and b5 using a biplasmid 
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system [33, 38]. In addition, a CYP1A2 null strain expressing only human b5 with 
CYPOR was constructed (BTCb5Por) for use as control to verify that catalytic alterations 
are because of the combined effect of b5 with the CYP1A2 variants, and not related to 
independent b5 metabolism.  
CYP and b5 concentrations in bacterial cultures were determined (see Figures, 
Supplemental digital content 2 and 3, http://links.lww.com/FPC/A539, which shows the 
CYP and b5 contents in whole cells). The b5 holoprotein concentrations determined in 
whole bacterial cells were comparable among all strains. The CYP holoprotein levels of 
almost all the variants were similar to WT (ranging from 157 to 231 nmol/l) except for 
variants I386F and R456H. The CYP levels of mutant I386F were significantly lower 
than those of WT, and R456H did not show any detectable holoprotein when determined 
in whole bacterial cells.  
Immunoblot analysis of microsomal preparations indicated that both CYP and b5 
protein expression levels were similar between all strains (see Figures, Supplemental 
Digital Content 4 and 5, http://links.lww.com/FPC/A539, which shows CYP1A2 and b5 
immunoblot analysis of microsomal preparations). CYP, CYPOR, and b5 contents were 
determined in microsomal membrane fractions (Fig. 1). CYPOR and b5 contents ranged 
from 6 to 9 pmol/mg and 7 to 14 pmol /mg protein, respectively, being comparable among 
all strains. The CYP holoprotein amount was relatively similar to WT in membrane 
preparations for variants S212C, S298R, G299S, I314V and C406Y (ranging from 68 to 
105 pmol /mg protein) whereas variant T83M (55 pmol /mg protein) showed a slightly 
lower level. CYP1A2 variants I386F and R456H did not show any detectable CYP 
holoenzyme in their membrane preparations, as was the case in our former study [18], 
probably because of inefficient heme incorporation and/or anchoring as WT-like levels 
of apoprotein were determined by immunodetection for these two variants (see Figures, 
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Supplemental Digital Content 4 and 5, http://links.lww.com/FPC/A539, which shows 
CYP1A2 and b5 immunoblot analysis of microsomal preparations). 
 
Figure 1. CYP (white bars), b5 (solid bars) and CYPOR (grey bars) contents of microsomal membrane 
fractions (pmol/mg total protein). 
 
The CYPOR/CYP ratios (0.06-0.13) for the different strains were in the range of 
values observed in human liver microsomes (0.08-0.5) [43]. The b5/CYP ratios were 
calculated (0.09-0.23) and were a fraction lower when compared with those observed in 
human liver microsomes (0.27-2.70) [44]. Both CYP1A2 and CYPOR expression levels 
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3.3.1. Enzyme activities of CYP1A2 variants in the presence of 
cytochrome b5 
To determine enzyme activities of all CYP1A2 allelic variants, co-expressing both 
human b5 and CYPOR, eight structural different substrates were used and their activities 
were compared with the WT variant (see Figure, Supplemental Digital Content 6, 
http://links.lww.com/FPC/A539, which shows the chemical structures of the substrates 
used). Three fluorogenic CYP1A2 substrates (ER, MR and CEC), and two therapeutic 
drugs (clozapine and phenacetin) were used. Furthermore, the bioactivation of three 
CYP1A2 dependent premutagens (2AA, IQ and NNK) was measured. Results of all 
activity measurements are summarized in Table 1. 
 
3.3.1.1. Kinetic studies with fluorogenic substrates 
The polymorphic CYP1A2 variants and its WT form were tested with three typical 
CYP1A2 fluorogenic substrates (ER, MR and CEC). The results of the Michaelis-Menten 
kinetic studies (yielding Vmax and KM values) as well as the inhibitory potency (IC50) of 
α-NF, a specific CYP1A inhibitor, are presented in Table 1. Although Kcat (Vmax/KM) is 
considered to be a valid kinetic descriptor, subtle but significant differences in KM or Vmax 
can be obscured when only using Kcat values. As such, KM and Vmax were carried forward 
separately, as in our former study [18]. Surprisingly, variant I386F, which showed no 
(spectrophotometrically) detectable holoprotein in membrane fractions, showed activity 
for the three fluorogenic substrates. Membrane preparations of this variant were applied 
using the same total protein concentration as that for the WT variant, which showed equal 
apoprotein levels in the immunodetection (see Supplemental Figure 4, 
http://links.lww.com/FPC/A539). This activity was not because of any CYP1A2-
independent metabolism as membranes derived from the negative control strain 
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(BTCb5Por) did not show any activity with these three substrates. For variant R456H also 
lacking detectable holoprotein, no activity could be measured for any of these three 
substrates, not even at a double-membrane sample concentration and at increased 
substrate concentrations.  
Variants T83M, I314V and C406Y showed a small increase in Vmax compared 
with WT, for both MR and ER, but not for CEC. Only variant T83M showed the same 
pattern of increase in Vmax for CEC. However, the affinity for these three substrates was 
not significantly altered; only variants I314V and C406Y showed a small decrease in KM 
comparing with WT for CEC. Variants S212C, S298R and G299S showed activity 
parameters comparable with the WT variant for these three substrates, except for variant 
S212C [Vmax (MR) less than half of the one found for WT], variant G299S [KM (ER) 
slightly lower than the one found for WT] and S298R [Vmax (MR) and KM (MR) slightly 
lower than those of WT]. 
Finally, variant I386F, which, in our former study, did not show any activity for 
these substrates, not only showed activity in the presence of b5 as mentioned above but 
also showed different types of effects between substrates. The apparent affinity of this 
variant for these three substrates was decreased (higher KM values) when compared with 
those of the WT variant. This was also the case for the maximum reaction velocity (Vmax), 
which was about half (MR) or less (CEC) than the ones determined for the WT variant, 
except for the substrate ER. This substrate was metabolized at a doubled velocity by 
variant I386F compared with the WT variant.  
 
3.3.1.2. Kinetic studies with clozapine and phenacetin 
The clozapine N-demethylation and phenacetin O-deethylation activities of the 
CYP1A2 variants were determined, as in our previous study [18]. On the basis of the 
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kinetic analysis of WT, two substrate concentrations were chosen: one resembling the 
apparent affinity concentration (KM) and one well beyond the concentration point where 
Vmax was reached. Membranes of variant I386F showed no activity with clozapine and 
only (low) activity with the higher concentration of phenacetin. Again, R456H showed 
no activity for any of the two substrates, even at the highest substrate and double-
membrane concentrations. 
The seven remaining variants and WT were incubated with 50 and 250 µmol/l of 
clozapine (Table 1 and see Figure, Supplemental Digital Content 7, 
http://links.lww.com/FPC/A539, which shows the clozapine N-demethylation of CYP1A2 
variants), and 20 and 200 µmol/l of phenacetin (Table 1 and see Figure, Supplemental 
Digital Content 8, http://links.lww.com/FPC/A539, which shows the phenacetin O-
dealkylation of CYP1A2 variants). All control assays were carried out in the presence of 
1 mmol/l of the CYP1A2 inhibitor α-NF with the highest concentration of each substrate. 
In the case of clozapine N-demethylation using the lower substrate concentration, 
all variants showed an overall decreased activity when compared with WT, whereas this 
decrease was less apparent at the higher concentration. With 20 µmol/l clozapine, variants 
T83M, S212C, S298R, G299S, I314V and C406Y showed, respectively 38, 64, 77, 82, 
56 and 75% of the N-demethylation velocity found for the WT variant. In the case of 200 
µmol/l clozapine, these were 91, 67, 91, 75, 114 and 88%, respectively, of the WT 
activity. 
For both phenacetin substrate concentrations, the O-deethylation activity of all 
variants showed an overall decreased activity when compared with WT. When using 50 
µmol/l substrate, variants T83M, S212C, S298R, G299S, I314V and C406Y showed 
reaction velocities of 30, 62, 80, 111, 71 and 47% of WT, respectively. These velocities 
were, respectively 70, 60, 75, 71, 87 and 74% of the WT activity when measured with a 
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phenacetin concentration of 250 µmol/l . In the case of I386F, which only showed activity 
using the higher concentration of phenacetin, the reaction velocity represented ~6% of 
that found for the WT variant. The two negative control experiments (using 1 mmol/l of 
the CYP1A inhibitor α-NF with the WT variant or the null CYP1A2 strain BTCb5Por), 
did not show any activity for these two substrates, as expected.  
 
3.3.1.3. Bioactivation of premutagens 
The BTC strains, coexpressing recombinant human CYP1A2, CYPOR and b5, 
have previously been shown to be an efficient and appropriate system to study 
bioactivation of several known CYP1A2-dependent mutagens [38]. The role of b5 in the 
bioactivation activities of the eight polymorphic variants of CYP1A2 was evaluated with 
three known procarcinogens, namely, 2AA, NNK and IQ (Table 1 and see Figures, 
Supplemental Digital Content 9-11, http://links.lww.com/FPC/A539, which shows the 
mutagenic activities toward 2AA, IQ and NNK of the CYP1A2 variants). The three 
compounds were also assayed using the CYP1A2 null strain (BTCb5Por), which did not 
show any bioactivation capacity (mutagenicity) for the dose ranges applied for all 
CYP1A2 variant strains. 
Strains expressing variants T83M and C406Y showed a significant decrease in 
mutagenic activity when testing 2AA (52 and 64%, respectively) compared with the strain 
expressing the WT variant, whereas strains expressing all other variants were not 
significantly hampered in bioactivating 2AA. In the case of IQ, the strain expressing 
variant I386F could not bioactivate this carcinogen. Strains containing variants T83M and 
C314V showed a significant decrease in mutagenic activity, representing ~47 and 54% 
of the activity of the strain with CYP1A2-WT. Again, strains containing all other variants 
showed no significant differences compared with the CYP1A2-WT strain. The ability of 
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variants T83M and S212C to bioactivate NNK was markedly decreased, showing ~19 
and 50% of the activity of the WT variant. All other variants showed no significant 
differences compared with WT for this carcinogen. The strain expressing variant R456H, 
one of the two CYP1A2 variants with perturbed expression of holoenzyme, showed no 
mutagenic activity for any of the three premutagens.  
 
3.3.2. Multivariate analysis of activity data 
The experimental data set (Table 1) was combined with the experimental data set 
of our previous report on all CYP1A2 variants [18], that is the activity parameters of all 
CYP1A2 variants were obtained in the same way, but were expressed without b5. Multiple 
multivariate analyses were carried out to examine the effect of b5 objectively. The 
procedure for data normalization was based on the variance in the data set. Normalization 
by variance was applied both by column and by row. This type of double normalization 
is appropriate when different enzyme preparations are being compared, and different 
types of substrates and detection methods are used [45]. It is important to note that both 
data sets, the data from this present study and the one from our previous study [18], were 
combined and analysed as a single data set and not compared with each other as different 
data sets. Data of variants R456H and I386F were excluded from the multivariate analysis 
as R456H had no detectable activities for any of the assayed substrates, and I386F only 
showed activities in this presence of b5 (i.e. present study), both considered statistically 
perturbing for this type of analysis. 
The first analysis of comparison of the CYP1A2 variants involved the direct 
hierarchical classification of the data set on the basis of the Ward method with complete 
linking (Fig. 2). It seems clear that the tendency of the variation in the combined data set 
is mainly ruled by the presence or absence of b5. In the absence of b5, CYP1A2 variants 
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G299S and T83M behave most differently from the WT variant, corroborating the results 
of our previous analysis [18]. In the presence of b5, variant T83M is the clear outlier, with 
variants S212C and C406Y being slightly different from WT. Subsequently, a clustering 
by similarity was carried out using the Pearson correlation with average linkage, an 
analysis that determines which of the measured activity parameters was more powerful 
in showing altered biotransformation capacities among the CYP1A2 variants. A 
dendogram on the basis of the normalized data set was obtained (Fig. 3) and NNK 
bioactivation capacity was segregated from all other activity parameters, as was found in 















Figure 2. Dissimilarity tree for the different CYP1A2 variants. This classification was obtained directly 
from the data set based on the Ward method with complete linking. 
 
 
Chapter 3                                                                                    The role of cytochrome b5 
102 
 
Figure 3. Clustering performed by similarity using the Pearson correlation with average linkage, for all 
the different activities. 
 
3.3.2.1. Principal component analysis  
The principal component analysis (PCA) [46] was used to project the data set from 
a 16-dimensional (activity parameters) space into a two-dimensional space for ease of 
visualization (Fig. 4). The trend of variation that governs the merged activity data set 
stems from the difference between variantactivities in the presence or absence of b5, and 
this analysis retains 91% of the initial variance [principal component 1 (67%)  plus 2 
(24%)], which indicates a high significance in the distribution of the CYP1A2 variants 
over the b5(+) and b5(-) clusters. Variant G299S appears apart from the remaining WT-
like enzymes in the b5(-) cluster, with variant T83M slightly but significantly separated, 
corroborating the results of our previous study [18]. In the case of the b5(+) cluster, the 
T83M variant of CYP1A2 is now completely segregated, together with variant C406Y 
from all other variants that are more WT like. Furthermore, it seems that variants 
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Figure 4. PCA plot of the CYP1A2 variants’ (with and without b5) activity- normalized data set for the 
first two principal components (91% of the initial variance retained). 
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Table 1. Data set of all measured activity parameters of the CYP1A2 variants when coexpressed with CYPOR and cytchrome b5. 
 MROD Vmax MROD KM EROD Vmax EROD KM CECOD Vmax CECOD KM Phenacetin 20 µmol/l Phenacetin 200 µmol/l 
 (pmol R/min) (µmol/l) (pmol R/min) (µmol/l) (µmol/l CHC/min) (µmol/l) (pmol paracetamol/min) (pmol paracetamol/min) 
 Average SD Average SD Average SD Average SD Average SD Average SD Average SD Average SD 
WT 1.17 0.043 0.61 0.055 0.48 0.012 0.30 0.028 3.81 0.100 2.64 0.306 6.32 0.38 255.6 6.7 
T83M 1.94 0.031 0.68 0.025 0.87 0.020 0.38 0.031 5.52 0.099 2.40 0.195 1.87 0.33 178.9 1.4 
S212C 0.49 0.014 0.54 0.039 0.41 0.010 0.25 0.024 3.07 0.092 2.57 0.339 3.91 0.12 153.6 10.7 
S298R 0.88 0.020 0.43 0.026 0.44 0.013 0.25 0.029 3.63 0.128 3.48 0.511 5.04 0.35 191.8 2.2 
G299S 0.96 0.024 0.50 0.032 0.57 0.019 0.21 0.028 3.04 0.099 2.32 0.345 7.04 0.17 181.1 6.6 
I314V 1.75 0.052 0.59 0.043 0.84 0.023 0.30 0.031 4.50 0.112 1.95 0.229 4.47 0.18 222.3 9.3 
C406Y 1.61 0.083 0.74 0.087 0.74 0.031 0.40 0.059 3.35 0.096 1.94 0.263 3.00 0.12 189.1 8.5 




Clozapine  50 µmol/l 
 












(rev/nmol) (rev/nmol)  (rev/µmol)  (µmol/l) (µmol/l)M (µmol/l)M 
 Average SD Average SD Average SD Average SD Average SDv    
WT 51.4 0.0 83.9 1.4 7611 534 409 52 2707 393 0.020 0.063 0.199 
T83M 19.5 0.9 76.7 3.4 3958 192 192 12 522 12 0.033 0.053 0.160 
S212C 32.8 0.7 56.4 2.2 7199 623 358 37 1353 95 0.033 0.065 0.144 
S298R 39.4 0.3 76.3 4.4 6584 427 344 43 2334 372 0.018 0.035 0.202 
G299S 42.3 0.7 63.0 2.9 7499 386 304 45 3211 105 0.025 0.030 0.232 
I314V 28.8 0.2 96.0 2.8 7354 681 221 47 2304 316 0.018 0.037 0.313 
C406Y 38.5 0.4 74.1 0.5 4874 298 317 77 1963 113 0.018 0.025 0.162 
I386F - - - - 6759 325 - - 2253 28 0.036 0.073 1.399 
(-): no activity measurable. a:  IC50 values with a 95% confidence interval, calculated by a sigmoidal dose-response analysis using GraphPad Prism 5 software (GraphPad 
Software, San Diego, California, USA)




Genetic polymorphism in xenobiotic metabolizing enzymes is currently accepted 
as one of the main factors in the interindividual differences observed in drug and 
xenobiotic responses and susceptibilities. CYP enzymes are affected by various 
environmental, individual habits, and genetic factors, which make drug metabolism 
highly variable and even almost individualistic [47]. The CYP1A subfamily comprises 
two members, CYP1A1 and CYP1A2, with the latter being almost exclusively expressed 
in the liver. Genetic factors were suggested to represent 35-75% of the interindividual 
variability for CYP1A2 activity [48, 49]. Furthermore, the number of clinical drugs 
effecting CYP1A2 activity is increasing and the opportune identification of these drug 
interactions is important both in clinical practice and in drug discovery and development 
[50].  
To carry out catalysis, CYPs require two electrons, which are normally delivered 
by CYPOR. Another heme protein, b5, has been shown, at least for three decades, to alter 
the rate of catalysis by specific CYPs [32, 36, 51]. It has been reported to enhance, inhibit, 
or not to alter the catalysis of CYP, depending on the substrate, the CYP isoform, and the 
experimental conditions [37]. Despite the substantial work on the function and effect of 
b5 on CYP-mediated catalysis in the last decades, its mode of action is still not fully 
understood. Collectively, these studies, and in particular the work of Dr Lucy Waskel’s 
group (reviewed in Im and Waskell [52]), seem to indicated that (i) in principle, the first 
electron can only be donated by CYPOR, (ii) b5 can donate the second electron in 
competition with CYPOR, (iii) CYPOR and b5 donate the second electron at a similar 
speed in the formation of the reduced oxyferrous CYP, and (iv) the decay to the ferric 
ground state of CYP plus product release is accelerated when the second electron is 
delivered by b5 [52]. This acceleration of the actual oxygenation step of the substrate was 
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hypothesized to be caused by b5-mediated induction of conformational changes at CYP’s 
active site [52]. 
To our knowledge, so far, no study has been reported on the systematic evaluation 
of the effect of b5 on human CYP polymorphic variants. As such, the goal of this study 
was to examine the effect of human b5 on the activity of eight polymorphic variants and 
WT of human CYP1A2 using a set of eight structurally diverse substrates.  
For this purpose a bacterial E. coli cell model, which does not contain any 
endogenous (bacterial) CYP or b5, was applied for the coexpression of the CYP1A2 
variants with CYPOR and b5. The CYP contents were similar to WT for all variants, 
except for I386F and R456H. Although these two variants showed similar levels of 
CYP1A2 through immune detection (apoprotein), neither showed detectable holoenzyme 
in membrane fractions or in whole bacteria except for variant I386F (markedly reduced 
levels in whole cells). This indicated highly unstable holoenzymes of these variants (even 
in the presence of b5), corroborating our previous results [18]. Both CYPOR and b5 
expression levels in membrane preparations were similar in all strains. Comparing CYP 
levels with those of our former report [18], coexpression of the CYP1A2 did not seem to 
be influenced by the coexpression with b5 as no significant deviations could be observed. 
Both CYP1A2 and CYPOR expression levels were similar to those obtained in our former 
study [18] when coexpressed without b5. Furthermore, CYPOR/CYP ratios for the 
different variants were in the range of those observed in human liver microsomes, 
whereas the b5/CYP ratios were a fraction lower than the ones observed in human 
microsomes. Several in-vitro studies have been reported on the dose effect of b5, 
describing increasing effects when applying increased b5 levels (reviewed in Im and 
Waskell [52]). As such, the effects of b5 presented in this current study will be expected 
to be more pronounced in vivo. Still, with respect to the main goal of our study, the 
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variations observed in CYP1A2 activity can be uniquely attributed to the CYP1A2 variant 
itself and/or the presence/absence of b5.  
CYP1A2-WT and its variants were characterised for 16 different activities 
parameters using structurally different substrates, representing different types of 
CYP1A2-mediated reactions, specifically: N-demethylation (clozapine); O-dealkylation 
(MR, ER, CEC and phenacetin); and N-hydroxylation (NNK, IQ and 2AA). As this 
characterization was carried out in the same way as in our former report [18], the current 
data set could be combined with the one of our previous study [18]. This combined data 
set was examined using several multivariate analysis tools to analyse all activity data to 
objectively delineate the effect of b5 on the CYP1A2 variants. The combined data set was 
analysed by PCA [46], a very useful statistical tool of complementary importance as 
shown in several fields [53, 54] , plus the recent exploration of the protein structure space 
[55, 56].  
Both the Ward Method and the PCA (Figs 2 and 4) showed that all CYP1A2 
variants behaved quite distinguishably in their activity in presence of b5 compared with 
their activities in absence of b5, forming two separated clusters. Both the PCA and the 
Ward Method corroborate our previously published results [18], in which the nine 
CYP1A2 variants were analyzed for the same activity parameters in absence of b5. In this 
analysis, variant G299S was the most altered CYP1A2 enzyme relative to the WT variant, 
whereas T83M was slightly but significantly different from WT. Conversely, variant 
G299S was closely related with the WT form of CYP1A2 both in the PCA as well in the 
dissimilarity tree, when assayed in the presence of b5, whereas the more deviated forms 
were variants T83M and C406Y, consistently with both the PCA and Ward analysis 
method. 
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The PCA of the variants indicates which amino acid substitutions in the protein 
are related to activity profile alterations of CYP1A2 and can thus be informative of the 
functionalities of the protein structure. On the basis of the human CYP1A2 crystal 
structure (PDB #2HI4) published by Sansen et al. [39] (Fig. 5a and b) and from the 
description of substrate entrance and product exit channels of CYPs by Cojocaru et al. 
[57], residues T83 and C406 are located close to the substrate entrance/product exit 
channel. These two variants lacked detectable NNK bioactivation activity in absence of 
b5 as described in our former report [18]. However, both T83M and C406Y showed NNK 
bioactivation in the present study, that is in presence of b5, although less efficient 
compared with the WT variant. These results seem to suggest that b5 can influence the 
structure of the substrate entrance/product exit channel and thus the substrate positioning 
at the active centre. For NNK, this seems to be particularly important as the Pearson 
correlation analysis indicated bioactivation of this substrate as the most powerful among 
the 16 measured activities on examination of CYP1A2 variants (Fig. 3), as was the case 
in our former study [18].  
Variants I386F and R456H were found to be two particular variants with perturbed 
holoprotein stability, as was observed in our previous study. In the case of variant R456H, 
b5 showed no influence in holoprotein stabilization, reinforcing the importance of this 
residue in heme anchorage as was concluded in our previous report [18]. Residue R456 
is located adjacent to C457, which is the conserved cysteine (fifth ligand) involved in 
heme binding [58] (Fig. 5a and b). The presence of b5 was found to be crucial for the 
activity of variant I386F. In the absence of b5, among the 16 measured activities, only 
(residual) 2AA bioactivation activities could be measured [18]. In the presence of b5 
(present study), I386F showed activity in most of the assays, with the exception of 
clozapine N-demethylation and IQ bioactivation (Table 1). The I386 residue is located in 
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the substrate recognition site 5 (SRS-5), which, together with the I-helix and the BC loop, 
represent the common structural features of the heme surroundings in mammalian CYP 
structures known to date [59]. The I386F substitution represents the replacement of an 
aliphatic side chain with an aromatic side chain, distorting the heme anchoring structure, 
explaining the highly unstable I386F holoprotein. Apparently, b5 interacts with this 
variant, inducing a conformation that allows the (partial) stabilization of heme in the 



































Figure 5. Localization of altered amino acids of the selected CYP1A2 polymorphic variants using the 
human CYP1A2 crystal structure published by Sansen, et al [39]. (a) Overview of CYP1A2 structure with 
the locations of mutations indicated; (b) Image zoomed in on the active center and the most relevant 
polymorphisms of this study, namely, residues T83 and C406, located close to the substrate 
entrance/product exit channel; residue R456 located adjacent to the fifth ligand involved in heme binding; 
residue I386 located in SRS-5 in the I-helix; and residues G299 and S298 located at the proximal side near 
the CYPOR/b5 interaction zone. The prosthetic heme group as well as -NF substrate are indicated. Figures 
were generated with the Discovery Studio v3.1 software (Accelrys, San Diego, California, USA),using 
PDB file # 2HI4. 
 
The PCA showed striking results for variant G299S. This form is shown to be the 
most deviated variant in CYP1A2 activities in the absence of b5, but was found to act as 
a WT-like enzyme in the presence of this facultative, auxiliary heme protein (Fig. 4). On 
the basis of the superposition and alignment of the human CYP1A2 crystal structure [39] 
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with the structure of the CYP BM3 heme and FMN-binding domains [60], residue G299 
is located on the surface of the heme domain at the proximal side near the CYPOR/b5 
interaction zone (Fig. 5a and b). The secondary structural annotation of CYP1A2 (PDB 
#2HI4) also indicates that G299, along with S298, forms a β-hairpin structure. G299S 
replacement could be hypothesized to disrupt the local fold through steric hindrance of 
the β-hairpin. In contrast, S298R replacement could be hypothesized to be less disruptive 
to the β-hairpin, as evidenced by the similarity of S298R to WT in both the b5(-) and the 
b5(+) cluster of the PCA plot of catalytic data. Moreover, the G299 residue is located very 
close to the CYP1A2’s C-helix, which is indicated to play an important role in the 
interaction with b5 [52]. Previous reports of the group of Dr Lucy Waskel seem to indicate 
that both b5 and CYPOR interact with CYP on overlapping but nonidentical binding sites 
[32, 61]. On the basis of the “recovery” effect of b5 with variant G299S (vida supra), it is 
tempting to speculate that residue G299 is part of this binding site on CYP1A2, which 
interacts exclusively with CYPOR.  
This “recovery” effect of b5 seems not to be exclusive for variants I386F and 
G299S. In the PCA analysis, most variants seem to group closer to the WT variant in the 
b5(+) cluster (i.e. are more WT like) compared with the variants in the b5(-) cluster (Fig. 
4). CYP1A2 expression occurs almost exclusive in the liver, the organ where b5 is 
unambiguously present. The apparent general attenuation in CYP1A2 activities of the 
genetic variants by b5 might thus be an explanation for the lack of any clinical evidence 
to suggest that these particular genetic variants have phenotypic effects with respect to 
xenobiotic metabolism, and are as such considered to have low genetic penetrance of the 
CYP1A2 polymorphism to the phenotype level [62, 63]. Still, specific CYP1A2 alleles 
have been identified with altered drug clearance and response to drug therapy. However, 
these alleles showed genetic variation in the upstream, 5’-expression-regulating 
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sequences [50]. Variations in CYP1A2 activity can also be caused by the functional 
polymorphism of b5 or CYPOR. Recently, genetic variants of b5 have been described 
[64], although allelic variants are considered to be rare [65]. More than 50 different 
haplotypes of the human POR gene (encoding CYPOR) have been found so far 
(http://www.cypalleles.ki.se/por.htm). The effects of several CYPOR variants on human 
CYP1A2 have been reported by our group [40, 66]. 
Collectively, our data seem to indicate that b5 exerts a compensatory effect on the 
perturbed functional capacities of the polymorphic variants of this study, which may be 
interpreted by b5-induced allosteric attenuation of the conformational changes induced by 
their structural mutations. As such, b5 seems to be capable of altering the conformation 
of CYP1A2 in a quite extensive manner, much more than only the active site architecture, 
the hypothesis postulated to explain the accelerated decay to the ferric ground state of 
CYP plus product release, when the second electron is delivered by b5 relative to the case 
when this occurs by CYPOR [52] (see above). Indeed, our data on variant I386F (see 
above) seem to indicate the effect of b5at the heme/substrate-binding site. However, our 
data on variants T83M and C406Y (substrate entrance/product exit channel; see above) 
are in particular indicative for the more extensive structural influence of b5.  
In summary, we successfully coexpressed the WT form and eight allelic variants 
of human CYP1A2 separately, together with human CYPOR and human b5, and could 
measure 16 different activity parameters of the biotransformation of eight structurally 
different substrates. The heterogeneous data set generated from the current study was 
combined with the one of our previous study on these CYP1A2 variants [18], and 
analysed using several multivariate analysis tools. The general outcome of this analysis 
indicated the ability of b5 to affect CYP1A2 variants to behave more like the WT variant, 
attenuating the detrimental effects of structural mutations of these variants, seemingly 
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through allosteric effects. This was particularly apparent for variant I386F, for which the 
presence of b5 was crucial to show activity for the tested substrates. The results of this 
variant seem to corroborate the hypothesis that b5 can accelerate CYP-mediated reactions 
through conformational changes at CYP’s active site [52], as I386 is in close proximity 
to this center. However, the b5-mediated recovery of the activity of variants T83M and 
C406Y, located considerably further from the active site, seem to indicate that this 
allosteric effect is much more extensive. Furthermore, our data seem to implicate 
CYP1A2 residue G299 in its interaction with CYPOR and/or b5. 
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Supplemental Digital Content 1. Schematic representation of plasmid pLCM_hb5_PORwt, used for the 











Supplemental Digital Content 2. CYP content (nM) in whole cells. 














Supplemental Digital Content 4. Immunoblot analysis of CYP1A2 in E. coli stains co-expressing 
CYPOR, b5 and CY1A2 polymorphic variants and WT. Each lane contained 10 µg of membrane fraction. 
Polyclonal (rabbit) CYP1A2-antiserum was used, demonstrating several non-specific signals, which can be 
easily distinguished through a comparison with the signals of the corresponding CYP1A2-null strain 
(BTCb5Por) Mw: Molecular weight marker (values in kDa).  
 










Supplemental Digital Content 5. Immunoblot analysis of b5 in the BTC strains, co-expressing CYPOR, 
b5 and CY1A2 variants. Each lane contained 10 µg of membrane fraction. Polyclonal (rabbit) b5-antiserum 
was used, demonstrating several b5-non-specific signals, which can be easily distinguished through a 
comparison with the signals of the corresponding b5-null strain. Purified his(6)-tagged b5 was used as 













Supplemental Digital Content 6. Chemical structures of used substrates demonstrating the full structure-
space of CYP1A2-compounds applied in this study. 
 













Supplemental Digital Content 7. Clozapine N-demethylation of CYP1A2 variants. All variants were 
assayed with 100 nM CYP. Relative activities determined with 50 µM (white bars) and 250 µM (grey bars) 











Supplemental Digital Content 8. Phenacetin O-dealkylation of CYP1A2 variants, when expressed in 
presence of b5. All variants were assayed with 100 nM CYP. Relative activities determined with 20 µM 
(white bars) and 200 µM (grey bars) of phenacetin.  
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Supplemental Digital Content 9. Mutagenic activities (in revertants/nmol) of 2AA for CYP1A2 variants, 
when expressed in presence of b5.  
 
Supplemental Digital Content 10. Mutagenic activities (in revertants/nmol) of IQ for CYP1A2 variants, 
when expressed in presence of b5.  
 
 















Supplemental Digital Content 11. Mutagenic activities (in revertants/nmol) of NNK for CYP1A2 



















PART   III 
 
DEVELOPMENT OF BACTERIAL HTS-
SYSTEMS FOR DETECTION OF GENOTOXIC 



















Prototype systems containing human cytochrome P450 
for high-throughput real-time detection of DNA 






Adapted from:   Brito Palma, B.; Fisher, C.W.; Rueff, J.; Kranendonk, M.; “Prototype 
Systems Containing Human Cytochrome P450 for High-Throughput 
Real-Time Detection of DNA Damage by Compounds That Form DNA-
Reactive Metabolites” Chem Res Toxicol. 2016 May 16; 29(5):747-56. 
 
 




The formation of reactive metabolites through biotransformation is the suspected 
cause of many adverse drug reactions. Testing for the propensity of a drug to form 
reactive metabolites has increasingly become an integral part of the lead-optimization 
strategy in drug discovery. DNA reactivity is one undesirable facet of a drug or its 
metabolites and can lead to increased risk of cancer and reproductive toxicity. Many drugs 
are metabolized by cytochromes P450 in the liver and other tissues, and these reactions 
can generate hard electrophiles. These hard electrophilic reactive metabolites may react 
with DNA and may be detected in standard in vitro genotoxicity assays; however, the 
majority of these assays fall short due to the use of animal-derived organ extracts that 
inadequately represent human metabolism. The current study describes the development 
of bacterial systems that efficiently detect DNA-damaging electrophilic reactive 
metabolites generated by human P450 biotransformation. These assays use a GFP 
reporter system that detects DNA damage through induction of the SOS response and a 
GFP reporter to control for cytotoxicity. Two human CYP1A2-competent prototypes 
presented here have appropriate characteristics for the detection of DNA-damaging 
reactive metabolites in a high-throughput manner.  The advantages of this approach 
include a short assay time (120-180 min) with real-time measurement, sensitivity to small 
amounts of compound, and adaptability to a microplate format. These systems are suitable 










Testing for the propensity of a compound to form reactive metabolites has 
increasingly become an integral part of lead-optimization in drug development [1]. To 
avoid costly late stage failures, predictive toxicology assays and models are being utilized 
as part of a ‘fail early’ or avoidance strategy [2]. Early detection of chemical liabilities 
by the identification of structures prone to form electrophilic intermediates through 
metabolism (structural alerts) can be used to mitigate safety issues. This is of particular 
importance when the chemically labile structures (toxicophores) might coincide with the 
pharmacophore and an early decision is needed to determine whether the pharmacophore 
is a good candidate for further study. Although in silico tools for identifying structural 
alerts are currently standard practice at the lead-optimization/candidate selection stage of 
drug development, it is imperative to demonstrate experimentally whether these predicted 
structural alerts are actually indicative of reactive metabolite formation [3]. Sensitive and 
efficient methods for detecting reactive metabolites are needed for evaluating drug 
candidates, thereby assisting medicinal chemists in optimizing a large number of lead 
compounds [4]. 
Hard electrophilic compounds that react with DNA might be detected in 
genotoxicity assays. DNA reactivity is an unwanted property of a drug or its metabolites 
due to the increased risk of cancer and reproductive toxicity [5]. Several different assays 
for in vitro genotoxicity screening are currently employed in drug development. These 
assays include a miniaturized version of the Ames mutagenicity test, the SOS-lux assay, 
VITOTOX, GreenScreen or BlueScreen, in combination with one or two cytogenetic tests 
(e.g., in vitro micronuclei test) [6-10]. The current standard in vitro approaches may fall 
short due to inadequate representation of reactive metabolites formed by human drug 
metabolism [11]. The major limitation of these standard tests in detecting genotoxicity of 
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human reactive metabolites is their reliance on a non-human (usually rodent liver extract) 
metabolic system to mimic human metabolism. Predicting drug toxicity in humans from 
results obtained in animals and animal-derived tissues is seriously hampered due to many 
species-specific differences in drug metabolism [12]. In particular, cytochrome P450, one 
of the major enzyme families in drug metabolism, has substantially different activities 
among species [12]. 
Over the years several genetic engineering approaches have been used by different 
laboratories for the development of bacterial genotoxicity reporter systems [13]. These 
systems rely on promoter-reporter fusions that generate a quantifiable dose-dependent 
signal in the presence of DNA-damaging compounds and the induction of repair 
mechanisms. The promoter, acting as the sensing element, regulates transcription of the 
downstream reporter gene, which can be monitored quantitatively, reflecting the 
genotoxic potency. Bacteria such as Escherichia coli and Salmonella typhimurium 
respond to DNA damage via the SOS response [14]. This response leads to the 
coordinated induction of over 30 genes, which are under the control of the repressor 
LexA. This repressor binds specific sequence motifs (SOS boxes) present in the 
regulatory sequences of these genes. Genotoxic exposure leads to inactivation of LexA 
and consequently derepression of its regulon. The timing, as well as expression levels of 
the induced genes, is determined by the strength, number, and position of the SOS boxes 
in their promotor sequences. sulA (formerly sfiA), umuDC, recN and recA are among the 
most highly induced SOS genes [14]. The promoters of these genes/operons are of interest 
as these sequences could give the highest possible dynamic range in signal when fused to 
a reporter gene. These promoter sequences have been used in bacterial genotoxicity 
reporter assays such the SOS umu test (umu promoter), VITOTOX (recN) and the SOS 
Chromotest (sulA) [7, 8, 15, 16]. In particular, sulA, which in some studies was shown to 
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increase over 100-fold in its expression level when completely derepressed, was an 
obvious promoter to use in our reporter construct [17, 18]. While this work was in 
progress, Copp et al reported on a very effective application of a sulA::GFP reporter in 
E. coli [19]. This reporter was used to screen a library of nitroreductase variants generated 
by directed evolution techniques, to identify those most effective in bioactivating 
dinitrobenzamide prodrugs, by use of fluorescence activating cell sorting.  
An increasing number of genes have been used in transcriptional fusions to 
monitor gene expression. The majority of genotoxicity reporters are based on 
fluorescence or bioluminescence, using fluorescent protein (FP) or luciferase fusion 
constructions [13]. Both reporters have specific advantages; however, FPs are particularly 
robust and do not need substrates or cofactors [13, 20]. We chose to use the green 
fluorescent protein (GFP) GFPmut3.1 [21]. In bacteria, this FP can be expressed to very 
high levels, has one of the shortest maturation times among FPs (5-7 min, important for 
real-time measurement), and has demonstrated a high quantum yield (“brightness”) [22].  
Chemicals tested for their genotoxicity also exert different levels of cytotoxicity 
and may interfere with the synthesis of the genotoxic reporter protein and thus its signal. 
A suitable correction for this effect can prevent underestimation of genotoxicity or even 
a false negative outcome and should be included in the test method [13]. Some bacterial 
reporter assays include optical measurements of cell growth (A600) or the inclusion of an 
additional, constitutive expressing reporter strain or enzyme for this correction [13]. 
Optical density does not necessarily reflect cell viability. Moreover, bacterial cell division 
is halted upon genotoxic insult, inducing filamentation, which disrupts the correlation 
between optical density and bacterial cell number per volume [23]. Our approach includes 
an additional reporter strain for cytotoxicity testing using the same GFPmut3.1 reporter 
under the control of a synthetic constitutive promoter derived from the tetracycline 
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resistance gene of the transposon Tn10. Cytotoxicity measured by this approach will 
reflect the negative (cytotoxic) effects of the test compound and its dose on GFPmut3.1 
expression, synthesis, and maturation.  
Our laboratory has been involved in the development of bacterial cell systems that 
mimic human drug metabolism for in vitro genotoxicity assay applications. This work 
has sought to address the major limitations of in vitro mutagenicity tests by developing 
bacterial systems that contains human P450-mediated biotransformation capabilities and 
a genetic target for mutagenicity detection. These bacterial systems adequately reproduce 
the human P450 enzyme complex and have been used to study the role of P450-mediated 
pathways in chemical mutagenicity [24-29]. This article describes the development of 
several bacterial strains that include active human P450 biotransformation coupled with 
a genotoxicity and cytotoxicity reporter system for real-time measurements. Other 
laboratories have reported the use of human P450-containing genotoxicity reporter 
systems [30, 31]. However, these systems do not allow real-time measurements or 
effective high-throughput analysis due to the need for cell lysis and the addition of 
substrate for signal development. 
Our system, containing a combination of a genotoxicity- and a cytotoxicity-
reporter, was initially tested in four different bacterial backgrounds. Subsequently, the 
two systems that performed best were engineered to contain human P450 
biotransformation expression constructs. We have focused on the incorporation of human 
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4.2. MATERIALS AND METHODS 
4.2.1. Reagents 
Ampicillin, kanamycin sulfate, chloramphenicol, isopropyl β-D-thiogalactoside 
(dioxane-free) (IPTG), thiamine, glucose, cumene hydroperoxide (CHP), 1-aminopyrene 
(1AP), 4-nitroquinoline-1-oxide (4NQO), N-methyl-N´-nitro-N-nitrosoguanidine 
(MNNG), δ-aminolevulinic acid (δ-Ala), and 2-aminoanthracene (2AA) were obtained 
from Sigma Chemical Co. (St Louis, MO, USA). 2-amino-3-methylimidazo(4,5-
f)quinoline (IQ) was obtained from Toronto Research Chemicals Inc. (North York, 
Ontario, Canada). Bacto agar, bacto peptone, bacto tryptone, bacto yeast extract, NB 
medium, and casamino acids were obtained from Difco (Detroit, MI, USA). 
 
4.2.2. Cloning procedures  
The regulatory sequence of the E. coli sulA gene was obtained by PCR 
amplification (primers Fw_sulA and Rv_sulA; Table S1), using genomic DNA isolated 
from E. coli K12 (strain C600) as template. The PCR product was cloned in the 
multicloning site of plasmid pCR2.1 (Invitrogen/Life Technologies, Grand Island, NY). 
Subsequently, the fragment containing the sulA promoter sequence was excised with SphI 
and cloned into the SphI site of plasmid pGFPmut3.1 (Clontech/Life Technologies; 
Mountain View, CA). After verification of the in-frame fusion of the sulA ATG start 
codon with that of GFPmut3.1 by sequencing, the sulA::GFPmut3.1 fragment was 
excised by digestion with NotI and SphI and cloned into the human cytochrome P450 
oxidoreductase (CPR) expressing plasmid pLCMhOR, thus creating phORSAG (Figure 
S1) [27]. Subsequently, the cDNA of human CPR was deleted by digestion with BamHI 
and EcoO109I, the 3’ end was filled in with Klenow, and the DNA was ligated, resulting 
in plasmid pSAG (Figure S1). The 133 bp promoter-sequence of sulA including its SOS 
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box sequence matched NCBI Reference Sequence NC_000913.2, with the exception of 
two adjacent bases (CG) upstream of the translation start codon ATG due to the creation 
of the SphI site. The constitutive GFPmut3.1 expressing plasmids were constructed using 
the minimal (constitutive) promoter sequences of the Tet resistance gene of Tn10 [32]. 
This promotor sequence was obtained by PCR amplification (primers Fw_Tet_XbaI and 
Rv_Tet_SphI; Table S1) using genomic DNA of the E. coli K12 strain CA12184 
containing tolC::Tn10 (E. coli Genetic Stock Center, Yale University, New Haven, CT, 
USA). The PCR product was digested with SphI and cloned in the phORSAG plasmid, 
previously treated with NotI, with the 3´ end filled in with Klenow and subsequently 
digested with SphI, thereby substituting the promoter sulA sequence with that of the 
minimum TetR promoter sequence of Tn10, creating phORTc-gfp (Figure S1). Plasmid 
pTc-gfp was obtained by deletion of the CPR cDNA from phORTc-gfp by digestion with 
BamHI and EcoO109I, the 3´end was filled in with Klenow, and the DNA was ligated. 
The minimal TetR promoter sequence (94 bp) was verified by sequencing (using primer 
Rv_GFP; Table S1) and demonstrated the correct in-frame fusion of the ATG start codon 
with that of the GFPmut3.1 gene. The 5’sequences of the TetR gene from Tn10 matched 
NCBI GenBank J01830.1 sequence, with the exception of two adjacent bases (CG) 
upstream of the translation start codon ATG due to the creation of the SphI site. The mock 
plasmids pLCB and pLCBhOR (Figure S1) were obtained by BglI deletion or HpaI 
deletion of the mutator mucAB operon of plasmid pLCM or plasmid pLCMhOR, 
respectively [27, 29]. Recently we found the CPR cDNA sequence in plasmids 
pLCBhOR, phORSAG and phORTc gfp, derived from pLCMhOR, to contain two 
deviations (resulting in amino acid substitutions Gly109Glu and Glu403Gly) from the 
consensus POR sequence NM_000941 [33]. These deviations were corrected by 
substitution of the BamHI-EcoO109I fragment of plasmid pLCM_POR in these plasmids, 
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thus creating plasmids pLCB_POR, pSAG_POR, and pTc-gfp_POR, respectively [33]. 
Sequencing confirmed the consensus sequence of the CPR cDNA in these new plasmids. 
Cloning, propagation, and maintenance of plasmids were conducted using standard 
cloning E. coli strains. The heterologous expression of human CYP1A2 was obtained 
using the expression vector pCWh1A2 [34]. Its medium-high copy number parent 
plasmid pCW has a pMB1 replicon, which is compatible with the p15A replicon from the 
low copy number pLCM_POR derived plasmids (pLCB_POR, pSAG_POR and 
pTcGFP_POR) [35]. For transformation of the Ames tester strains TA1535 and TA100, 
plasmids were isolated and adapted to the restriction enzymes of S. typhimurium LT2 by 
passage through the restriction-deficient, methylation-proficient S. typhimurium strain 
LB5010 [36, 37]. Plasmids were transformed into tester strains using standard procedures.  
 
4.2.3. Bacterial cultures and CPR/CYP1A2 expression 
E. coli tester strains FP401 or PD301 and S. typhimurium strains TA1535 or 
TA100 containing either of the plasmids pSAG, pTcGFP or pLCB were cultured in LB 
medium (E. coli) or in NB medium (S. typhimurium), for 15 h at 37C [25, 37, 38]. Media 
were supplemented with kanamycin (15 µg/mL, all strains), chloramphenicol (10 µg/mL, 
strain PD301), or ampicillin (25 µg/mL, strain TA100). 
PD301 expressing CPR and CYP1A2 was cultured as described before [33]. 
Briefly, strains were cultured in Terrific Broth (TB) medium supplemented with peptone 
(2 g/L), thiamine (1 µg/mL), ampicillin (50 µg/mL), kanamycin (15 µg/mL), 
chloramphenicol (10 µg/mL), trace elements solution, (4 µL/mL), and 0.2 mM IPTG [39]. 
Cultures were started with 250 µL of –80C glycerol stocks and were grown for 16 h at 
28C with moderate agitation. 
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Bacterial cultures for coexpression of CYP1A2 with CPR in TA1535 derived 
tester strains were performed as previously described by Fujita et al. with minor 
modifications [40]. Precultures were grown for 16 h at 37C in Nutrient Broth medium 
supplemented with ampicillin (50 µg/mL) and kanamycin (15 µg/mL). Precultures were 
than diluted 1000-fold and grown for 8 h at 30C in TB medium (pH 6.4) supplemented 
with peptone (2 g/L), thiamine (1 µg/mL), ampicillin (50 µg/mL), kanamycin (15 µg/mL), 
trace elements solution (4 µL/mL), and 0.1 mM δ-Ala [39]. Cultures were cooled on ice 
for 15-20 min, induced with IPTG (0.2 mM), and grown for an additional 18 h at 25C 
with moderate agitation. 
CYP1A2 expression levels, membrane preparations, and protein and CPR 
contents were obtained or determined as reported previously [33]. 
 
4.2.4. High-throughput genotoxicity assay 
Bacterial cultures were concentrated by centrifugation, and the cell pellet was re-
suspended in an equal volume of Vogel-Bonner medium E (VB medium), and the cell 
density (A600) was determined [37]. Cultures were diluted in VB medium, containing 
glucose (0.5%) (w/v) and casamino acids (0.75 mg/mL), to a cell density of 0.050 A600. 
Test compounds were diluted in VB medium and/or DMSO. Preliminary experiments 
were performed using a log dose-gradient of test compounds to obtain an effective dose 
range. The final gradients concentrations for each agent tested are as follows: 4NQO (0, 
7.5, 15, 22.5, 30, 37.5, and 45 ng/well); MNNG (0, 60, 120, 180, 240, 300, 360, and 420 
ng/well, except for derivatives of TA1535 and TA100, which were tested with 0, 25, 50, 
75, 100, 125, 150, and 175 ng/well); CHP (0, 200, 400, 600, 800, 1000, 1200, and 1400 
ng/well); 2AA (0, 2, 4, 6, 8, 10, 12, and 14 ng/well); IQ (0, 2, 4, 6, 8, 10, 12, and 14 
ng/well) and 1AP (0, 100, 200, 300, 400, 500, 600, and 700 ng/well). When used, the 
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DMSO concentration was kept constant in all cases and was always ≤ 1 % (v/v). Test 
compound (10 µL) and diluted cultures (150 µL) were dispensed into the wells of flat 
bottom black 96-well microplates. Plates were covered with BREATHseal, placed in an 
orbital shaker, and incubated at 37C with shaking. Fluorescence readings (λex: 485 nm; 
λem: 510 nm) were performed at 90, 120, 150, 180, and 240 min in a microplate reader 
(Anthos Zenith 3100). Each assay contained two negative controls: one containing cell 
mixture and solvent and another containing solvent and diluted cells using VB medium 
without glucose or casamino acids supplementation. Positive controls using single dose 
of 4NQO (37.5 ng/well) were performed in all assays (with and without CYP1A2 
expression), whereas positive controls using a single dose of 2AA (10 ng/well) were 




For the development of prototypes of a bacterial high-throughput genotoxicity 
assay competent in human P450 biotransformation, we started by testing the principle of 
the assay by constructing strains for the detection of compounds that directly cause DNA 
damage. 
 
4.3.1. Bacterial strains 
The bacterial backgrounds used for development of our detection systems 
contained specific characteristics that enhance their sensitivity to detect potential 
mutagens (Table S2).  S. typhimurium strains TA1535 and TA100 were derived for use 
in the Ames assay [37]. Both strains carry mutations in the uvrB gene, which enhances 
the SOS response, and in rfa, which increases the permeability of the cell envelope. In 
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addition, TA100 carries a mutator plasmid, pKM101. E. coli tester strains FP401 and 
PD301 were developed in our laboratory. Both have mutations in rfa as well as in uvrA, 
which also enhance the SOS response. Furthermore, strain PD301 has mutations in the 
ada and ogt genes, which lead to reduced repair of DNA alkylation. Our previous work 
demonstrated these strains are suitable for the coexpresssion of human P450 and its 
reductase [25, 27, 41]. Each of the four bacterial systems was transformed with the SOS-
inducible GFP reporter plasmid, the constitutive GFP reporter plasmid, or a control 
plasmid lacking the gfp gene, enabling correction for any fluorescence generated by 
media/cell constituents or the test compound and/or metabolites (Table S2). Thus, for 
each of the four bacterial hosts, three tester strains were created: the inducible 
genotoxicity measuring strain (e.g. TA1535-I), the cytotoxicity measuring strain (e.g. 
TA1535-C), and the blank strain (e.g. TA1535-B). 
 
4.3.2. GFP fluorescence dose-response plots, induction factors, and SOS 
inducing potency 
For each dose level, the GFP fluorescence of the I-strains and their corresponding 
C-strains (for genotoxicity and cytotoxicity, respectively) was obtained and corrected for 
background fluorescence (obtained with the B-strains.. Subsequently, GFP fluorescence 
dose-response curves were plotted for the I-strains and their corresponding C-strains 
(Figure 1).  
The GFP fluorescence obtained for both the I-strains and C-strains were corrected 
for their GFP fluorescence at the start of incubation (t = 0 min) to correctly compare the 
test among the four different bacterial backgrounds at the start of the incubation. The ratio 
of GFP fluorescence of the I-strain divided by the fluorescence obtained for the C-strain 
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for dose level x appropriately reflects the induction of the sulA reporter for that particular 









in which   f , f , f , f   represent the GFP fluorescence measured at x and zero 
dose levels for the corresponding I- and C-strains, respectively. FI can be plotted against 
each of the tested dose levels. The SOS-Inducing Potency (SOSIP) can be derived from 
the linear part of this curve (using ANOVA with a 95% confidence interval) in the same 
manner as that calculated with the SOS Chromotest [16]. SOSIP represents the molar 
potency of each compound at inducing sulA-driven GFP expression. 
 
4.3.3. Assay condition optimization 
Assays were performed in a 96-well microplate format. Plates were incubated at 
37C, and several assay conditions were verified for optimal outcomes. These assay 
conditions included incubation volumes, cell density at starting point, aeration (shaking 
speed), and the top reading z-height (height of the reading sensor in the microplate reader) 
(data not shown). Optimal conditions were fixed, and assays were performed with an 
incubation volume of 160 µl (150 µL cells + 10 µL test compound), a starting cell density 
of A600=0.050, a shaking speed of 200 rpm, and a z-height of 0.3 mm. Fluorescence 
readings were performed at 0, 90, 120, 150, 180, and 240 min incubation times. The 96-
well format permitted the testing of a single compound in triplicate at eight different dose 
levels, for the I-, C-, and B- strains on one plate, including controls. Alternatively, this 
format permitted the testing of a compound at 12 different dose levels in duplicate for the 
I-, C-, and B-strains. This last format was used in all preliminary experiments using log-
dose gradients of test compounds. When a compound tested positive for one or more of 
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the log doses, then an appropriate linear dose gradient was determined for accurate SOSIP 
determinations. 
 
4.3.4. High-throughput genotoxicity/DNA damage assay using four 
tester bacterial strains with direct DNA damaging compounds 
E. coli and S. typhimurium prototype tester bacteria sets were tested with three 
well-known direct acting mutagens, 4NQO, MNNG, and CHP. The GFP fluorescence 
dose-response curves for 4NQO are depicted in Figure 1 (for GFP fluorescence dose-
response curves for MMNG and CHP, see Figures S3 and S4, respectively). FI plots of 













Figure 1. GFP fluorescence dose-responses curves of 4NQO for the I- and C-strains derived from S. 
typhimurium strains TA1535 and TA100 and E. coli strains FP401 and PD301 (for simplicity, only the 
curves for 90 and 120 min incubation times are presented; black lines: pSAG (I-strains); gray lines: pTcGFP 
(C-strains)).  



















Figure 2. Induction Factor (FI) plots of 4NQO, MNNG, and CHP obtained with the S. typhimurium systems 
derived from strains TA1535 and TA100 as well as with E. coli systems derived from strains FP401 and 
PD301 (for simplicity, only the plots for 90 and 120 min incubation times are presented). No dose-response 
was detected with the TA100-derived system for MNNG and CHP. No dose-response was detected with 
the TA1535-derived system for CHP (gray lines: 90 min; black lines: 120 min). 
 
4NQO tested positive with the four prototypes using the different bacterial 
backgrounds and the same dose gradient. In all cases, maximum responses were obtained 
at 120 min (Table 1). The S. typhimurium and E. coli derived set of strains demonstrated 
different sensitivities toward MNNG, resulting in the use of different dose gradients. The 
TA100-derived system did not show any activity for this DNA alkylating mutagen up to 
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a maximum dose level of 1 µg/well (data not shown). The other three prototypes were 
positive for MNNG, reaching maximum FI values after 120 min of incubation (Figure 2).  
CHP did not demonstrate a positive response in the TA1535- or the TA100-
derived systems with doses up to 10 µg/well (data not shown). However, this oxidative 
mutagen demonstrated a positive response in E. coli backgrounds FP401 and PD301, 
reaching a maximum FI after 120 min of incubation.  
The SOS induction potency of 4NQO, MNNG, and CHP were calculated for each 
of the four prototype systems and are summarized in Table 1.  
 
Table 1. SOSIP values of 4NQO, MNNG and CHP Using Four Different Bacterial Backgrounds 
aValues are per nanomole of test compound and represent mean ± SD; N ≥ 3. ---: no SOSIP could be 
derived. 
 
4.3.5. Human P450 competent high-throughput genotoxicity assay 
prototypes 
On the basis of the results of the assay with direct acting DNA-damaging agents, 
the two most effective strains, TA1535 and PD301, were used in the development of 
human P450-competent systems for genotoxicity assays. As a proof of concept, we 
created heterologous systems containing human CYP1A2 with CPR using our previously 
developed biplasmid system for their coexpression in bacteria [25, 35]. This system 
allows for the efficient expression of these human proteins and their correct insertion into 
the bacterial cell membrane, with physiologically relevant CPR/P450 stoichiometries and 
 SOSIP(a) 
bacterial 4NQO MNNG CHP 
background 90 min 120 min 90 min 120 min 90 min 120 min 
TA1535 76 ± 8 118 ± 10 18 ± 1 22 ± 1 --- --- 
TA100 43 ± 6 58 ± 4 --- --- --- --- 
FP401 113 ± 5 128 ± 3 6 ± 1 7 ± 1 0.9 ± 0.1 1.7 ± 0.3 
PD301 113 ± 16 164 ± 24 15 ± 2 22 ± 2 1.2 ± 0.1 1.7 ± 0.1 
Chapter 4                     Prototype CYP Expression Systems for Detection of Genotoxicity 
141 
 
with enzyme activities that replicate the enzymatic activity found in vivo [42]. This 
approach has been in use for over a decade in our laboratory and has given consistent 
CPR/P450 stoichiometries in bacterial cell models [25, 26, 33, 41, 43].  
 
4.3.5.1. CYP1A2 and CPR expression 
Before use in the assay, cultures were always characterized for their P450 
expression levels. The I-, C- and B-strains all produced similar levels of the P450 
holoenzyme when grown under the same conditions on the same day. Daily values ranged 
between from 214 to 251 nmol/L (Figure S2). To verify if the consistency in CPR/P450 
ratio was maintained, the CPR and P450 expression levels were determined in membrane 
preparations of the different strains. Contents ranged from 8.5 to 12.1 pmol/mg for CPR 
and 79.9 to 90.1 pmol/mg for CYP1A2, confirming the consistency of CPR/P450 ratio 
(see Table S3). 
 
4.3.5.2. Human CYP1A2-competent genotoxicity prototype test systems for the 
detection of DNA-reactive metabolites  
Three carcinogens, IQ, 2AA, and 1AP, were assayed with the two human 
CYP1A2-expressing systems. All three compounds generated robust positive responses 
with the two CYP1A2-expressing systems (Figure 3 and Table 2; for GFP fluorescence 
plots of the I- and C-strains, see Figures S5 and S6). No response was obtained when 
testing the same dose gradient of these three compounds with the two bacterial systems 
devoid of human CYP1A2 enzyme (data not shown).  
 




Figure 3. Induction factor  (FI) plots of 2AA, IQ, and 1-AP using human CYP1A2-competent TA1535- 
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Table 2. SOSIP values of 2AA, IQ, and 1AP using two human CYP1A2-Competent Bacterial 
Backgrounds.  
aValues are per nanomole of test compound and represent mean ± SD; N ≥ 3. 
 
Both TA1535- and PD301-based bacterial systems competent in CYP1A2 
demonstrated maximum SOSIP values at 120 minutes for IQ and 180 min for 1AP. In the 
case of 2AA, the maximum SOSIP was reached at 120 min when using the CYP1A2-
competent TA1535 bacterial background, versus 150 min when using the CYP1A2-
competent PD301 background. 
 
4.4. DISCUSSION 
Reactive metabolites are known to be involved in adverse drug reactions. For 50% 
of current drugs, metabolism by P450 is the major clearance pathway and is a key 
determinant in performance and safety [12, 44]. Experimental in vitro data is important 
to confirm in silico analysis and to minimize the likelihood that important structural (in 
silico) alerts will be overlooked during the chemical design phase. This is of increasing 
importance as newer and more complex drug structures are introduced that take full 
advantage of the breadth of chemical space available for pharmacological targets. 
Identification of competing pathways, and catalysis by polymorphic enzymes, including 
individual differences in human biotransformation, add complexity to the identification 
of potential metabolite formation as well as ranking of compounds [44, 45]. 
  SOSIP
(a) 
bacterial  2AA IQ 1AP 
background  90 min 120 min 150 min 90 min 120 min 120 min 180 min 
TA1535_1A2 54 ± 8 82 ± 6 47 ± 9 90 ± 9 130 ± 14 0.9 ± 0.1 1.1 ± 0.1 
PD301_1A2 28 ± 12 110 ± 15 189 ± 17 65 ± 5 404 ± 17 2.1 ± 0.1 5.1 ± 0.3 
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The current in vitro high-throughput genotoxicity testing methods are limited in 
detecting relevant reactive metabolites due to inadequate representation and/or failure to 
incorporate a human biotransformation system. This issue is a general limitation of in 
vitro toxicity test systems for in vitro to in vivo extrapolations [46].  
In this article, we described the development of bacterial real-time detection 
systems to detect DNA damage that are highly sensitive, require short assay times, and 
are competent in human cytochromes P450. These systems maximize the dynamic range 
of the signal by using one of the most highly inducible genes that reacts to DNA damage, 
namely, sulA. The reporter GFPmut3.1, a GFP variant with one of the shortest maturation 
times and with a high quantum yield, was chosen to minimize assay duration and enable 
effective real-time measurements. The assay also includes a reporter to correct for 
possible cytotoxic effects of the test compound, making use of the same GFP as the 
genotoxicity reporter. A different FP could have been used for this purpose (with different 
excitation/emission properties to distinguish between the two signals), which would 
enable the use of a single bacterial strain for both the genotoxicity and cytotoxicity 
reporters; however, FPs differ considerably in maturation times [22]. These differences 
would interfere with the interpretation of the genotoxicity signal. 
Initially, we tested four different bacterial backgrounds, namely, TA1535 and 
TA100, two S. typhimurium strains used in the Ames test, and strains FP401 and PD301, 
two E. coli strains developed in our laboratory, that were used for the construction of 
human P450-competent mutagenicity tester bacteria. The prototypes were tested with 
three direct-acting mutagens. When responding, all four prototypes demonstrated a 
maximum response (SOSIP) after 120 min of exposure. The usefulness of including a 
cytotoxicity reporter strain (C-strains) in the assay is best demonstrated by the results 
obtained with CHP, a compound with a high level of toxicity (Figure S4). 
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The TA1535-based assay was unable to detect the oxidative mutagen CHP, as was 
the case of the TA100-based system. These two S. typhimurum strains, part of the original 
set of tester strains developed by the Ames laboratory, are less appropriate for the 
detection of oxidative mutagens, which triggered the development of tester strain TA102 
for this purpose [47]. Interestingly, strain TA100 (the bacterial system of the VITOTOX 
test, containing a DNA damage (recN)- inducible reporter) is equivalent to TA1535 but 
also contains the mutator plasmid pKM101 [37]. These types of plasmids are used in 
bacterial mutagenicity tests to increase mutation frequencies after genotoxic exposure 
which results from mutagenic translesion DNA transcription (mediated by the plasmid-
borne mucAB genes); however, this causes a concomitant downregulation of the SOS 
response [35, 48]. Although it is favorable for bacterial mutagenicity assays, this type of 
mutator plasmid might not be adequate for use in SOS-based reporter assays, and our 
preliminary results indicated this is the case. When comparing the two E. coli derived 
systems, the PD301 background demonstrated increased sensitivity for detecting the 
genotoxicity of 4NQO, MNNG, and CHP relative to that of the FP401-derived system. 
This finding corroborates our previous study in which strain PD301 was demonstrated to 
be more sensitive in the detection of chemical mutagenicity when compared to strain 
FP401 due to the inactivation of the ada and ogt genes present in PD301 [25]. The 
functionality of our reporter assay was demonstrated from the results obtained with 
4NQO and MNNG. These direct-acting mutagens gave SOSIP values of 71 and 0.9 per 
nmol, respectively, in the SOS Chromotest, a test also based on a sulA reporter fusion 
[49]. When tested with the TA1535- and the PD301- derived systems, 4NQO gave 
SOSIPs of 118 and 163 per nmol, respectively, whereas MNNG an SOSIP of 22 per nmol 
for both strains. Although it was tested with only a low number of direct-acting DNA-
damaging compounds, the principle of the assay was demonstrated by using the TA1535- 
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and the PD301-derived systems. Responses were found in very short assay times (120 
min), with relatively low (nanogram range) dose levels.  
Subsequently, the two most effective bacterial systems, based on strains TA1535 
and PD301, were adapted to contain human P450 biotransformation capabilities using the 
biplasmid system for coexpression of CYP1A2 and its redox partner CPR, along with the 
GFP reporters [25, 28]. The low level of inducer (0.2 mM IPTG) that we use for 
coexpression of P450 and CPR with the biplasmid expression system leads to very 
reproducible expression levels of both of these human proteins [25, 41, 43]. Moreover, 
we have demonstrated that this approach leads to CYP1A2 activities that are comparable 
with those in human liver, in alkoxyresorufin dealkylation reactions, and in the 
metabolism of two therapeutic drugs (clozapine and phenacetine) [27, 41]. Within 
individual experiments, the I-, C-, and B-strains demonstrated equivalent expression 
levels of CYP1A2 and CPR in each of the two systems (Table S3). These results imply 
equivalent CYP1A2 biotransformation capabilities among the genotoxicity and 
cytotoxicity reporter strains as well as the mock strains used. Differences in CYP1A2 
biotransformation capabilities between the tester strains of the same bacterial background 
(TA1535- or PD301 –derived) would have caused incorrect FI and SOSIP results. 
Furthermore, the similar CYP1A2 and CPR expression levels in both the E. coli and S. 
typhimurium derived systems allowed for a direct comparison of these two types of 
reporter assays to the bacterial background used and not to differences in P450 
biotransformation capacities. The CPR/P450 ratios for the different strains were very 
similar (between 0.10 and 0.13), which are well within in the range observed in human 
liver microsomes (0.08–0.5) (see Table S3) [50, 51]. 
2AA, IQ and 1AP are well-known to form DNA-reactive metabolites through 
CYP1A2-mediated metabolism [52]. Genotoxicity of these three compounds was readily 
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detected using dose levels in the nanogram range. Remarkably, maximum SOSIP values 
were obtained at different incubation times. Both systems gave maximum SOSIP values 
after 120 min for IQ and 180 min for 1AP. However, 2AA reached maximum SOSIP 
values at 120 min when using the TA1535-derived system and 180 min for the PD301 
system. This may be explained by differences in bacterial N- and O-acetyl-transferase 
capacities between the PD301- and TA1535- derived systems. In addition to CYP1A2-
mediated oxidation, heterocyclic and aromatic amines require a subsequent N-acetyl or 
O-acetyl conjugation to generate DNA-damaging metabolites [53]. S. typhimurum tester 
strains of the Ames assay have been shown to contain very efficient bacterial N- and O-
acetyl transferases [54]. Since both bacterial systems contain equivalent CYP1A2 
activities, the more efficient acetylation capability of the TA1535-derived system of 
CYP1A2-generated 2AA metabolites may be responsible for reaching earlier maximum 
SOSIP levels.  
Although it was tested with a very limited number of compounds, the two bacterial 
CYP1A2 systems presented here have the appropriate characteristics for the detection of 
DNA-reactive metabolites in a high-throughput manner. These characteristics include a 
short assay time (120-180 min), real-time measurement, the use of small amounts of test 
compound (less than a few micrograms), and adaptability to a microplate format. To our 
knowledge, the only genotoxicity test using human P450 containing bacterial strains is 
based on the umu test, an end-point assay requiring cell lysis and the addition of substrate. 
This procedure is incompatible with real-time measurements and, unlike the assay 
presented here, is unsuitable for true high-throughput screening [30, 31].  
The systems described here will require further validation for specificity and 
reproducibility and for confirmation of their high-throughput characteristics. This 
validation can be performed using additional known CYP1A2 substrates that produce 
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genotoxic and nongenotoxic metabolites. These bacterial systems may be further 
optimized using bacterial backgrounds other than the four presented here. Additional 
improvements could be made through the use of different reporter fusions, both in the 
promoter sequence used (i.e., the SOS promoter) or in the reporter gene. the specific 
characteristics of these assays should be maintained in future developments of enhanced 
versions, in particular the dynamic range (promoter induction levels) and very short signal 
development time (for real time measurements). Further refinements could include the 
integration of reporter genes or cDNAs encoding human biotransformation enzymes into 
the bacterial chromosome, creating more stable and robust systems and allowing the 
creation of a battery of specific human biotransformation competent high-throughput 
genotoxicity test assays.  
Human CYP1A2 has been used here to provide a proof of concept, but it can be 
exchanged for other human P450 isoforms, as the major human drug metabolizing P450s 
are readily expressed in bacteria [35]. Detoxification of reactive metabolites by other 
human metabolic systems is not represented in our prototype assays and thus they may 
be prone to overestimate reactive metabolite formation. However, it is important to 
characterize the capacity of human P450 in generating DNA-damaging metabolites of a 
compound, especially in the case of saturated or diminished capacity of detoxifying 
routes, i.e., by drug-drug interactions or genetic polymorphism of conjugating enzymes.  
Concerns are often raised regarding the relevance of models based on bacterial 
cells versus models based on mammalian or human cell lines. However, the Ames assay, 
developed more than 3 decades ago, is still part of standard in vitro genotoxicity assays 
and continues to demonstrate the usefulness of bacterial-based assays. Our bacterial 
systems were developed to provide a method that would more accurately predict which 
compounds could produce DNA-reactive metabolites in humans. Moreover, the short cell 
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cycle of bacteria (relative to those of mammalian cells) allows a fast turnaround in data 
output. In addition, bacterial systems have low costs and ease of use in these applications. 
Both of these properties are important for screening a large number of drug candidates to 
detect their chemical liabilities. Recently, the application of a multistrain (bacterial) 
bioreporter bioassay for drug screening was reported, including reporters for DNA 
damage, heat shock, and oxidative stress [55]. However, no human drug metabolism 
capability was incorporated into this system; thus, it provides only information regarding 
the parent compounds, not their metabolites. 
In summary, we describe here the development of bacterial test systems for real-
time detection of DNA-reactive metabolites. The systems are based on bacterial strains 
that produce active human P450, namely, CYP1A2, and lend themselves to adaptation to 
a high-throughput assay format. These attributes include the ability to be run in microplate 
format, requiring only a small amount of test chemical, having a short turnaround time 
for data output, and producing real-time measurements. These systems are prototypes that 
can be expanded to include additional human biotransformation capabilities.  
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4.5. SUPPORTING INFORMATION  
Table S1. PCR primers 
Fw_sulA AAGATTAATTTATGTTTTCCCGTCACCA 
Rv_sulA TAAGCATGCTCAATCCAGCCCCTGTGAGTTACTGTA (SphI) 
Rv_GFP CCATTAACATCACCATC 
Fw_Tet_XbaI CTAATCTAGACATCATTAATTCCT (XbaI) 
Rv_Tet_SphI GAACTATGCATGCCACTTTCTCTAC (SphI) 
 
Table S2. Strains 
Strains  Description Reference 
S. typhimurium   
TA1535  hisG46, gal, Δ(chl, uvrB, bio), rfa [1] 
TA100 TA1535, pKM101 [1] 
E. coli   
FP400 AB1157, uvrA6, galE, his+, pro+, leu+, thr+ [2] 
FP401 FP400, rfa [2] 
PD300 FP400, ada- [Tets], Δ ogt::cmr [3] 
PD301 PD300, rfa [3] 
 
Table S3. P450 and CPR contents of membrane preparation 
  CYP  
(pmol/mg protein) * 
CPR  




B 79.9 ± 0.1 9.2 ± 0.2 0.12 
C 83.2 ± 0.1 8.8 ± 0.2 0.11 
I 81.0 ± 0.1 8.5 ± 0.2 0.10 
E. coli PD301 
B 85.2 ± 0.1 10.9 ± 0.3 0.13 
C 90.1 ± 0.1 12.1 ± 0.4 0.13 
I 87.1 ± 0.1 11.4 ± 0.4 0.13 
Human liver 
microssomes 
   0.2 [0.08-0.5] a 
* Values represent mean ± Standard Deviation, N=3. 
a CPR content in human liver microsomes from Venkatakrishnan et al. [4], and total P450 content in human 






























Figure S2: P450 contents determined in whole cells of the different strains cultured on three different days 








































Figure S3. A) and B) GFP fluorescence dose-response curves of MNNG after 90 and 120 min incubation, 
respectively (black lines: pSAG (I-strains); gray lines: pTcGFP (C-strains); C) FI plots of MNNG. 
(diamonds: 90 min; circles: 120 min incubation). 
 
 
























Figure S4. A) and B) GFP fluorescence dose-response curves of CHP after 90 and 120 min incubation, 
respectively (black lines: pSAG (I-strains); gray lines: pTcGFP (C-strains); C) FI plots of CHP (diamonds: 
90 min; circles: 120 min incubation). 
 
 
























Figure S5.  A) and B) GFP fluorescence dose-response curves of 2AA after 90 and 120 min incubation 
(black lines: pSAG (I-strains); gray lines: pTcGFP (C-strains); C) FI plots of 2AA (diamonds: 90 min; 
circles: 120 min; squares 150 min incubation). 
 
 























Figure S6. A) and B) GFP fluorescence dose-response curves of IQ and 1AP after 90 and 120 min 
incubation, respectively (black lines: pSAG (I-strains); gray lines: pTcGFP (C-strains); C) FI plots of IQ 
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Cytochrome P450 expression system for high-
throughput real-time detection of genotoxicity: 








Adapted from:   Palma, B.B.; Moutinho, M.; Urban, P.; Rueff, J.; Kranendonk, M.; 
“Cytochrome P450 expression system for high-throughput real-time 
detection of genotoxicity: Application to the study of human CYP1A2 
variants” Mutat Res Genet Toxicol Environ Mutagen. 2016 Aug; 
806:24-33.  
 




Individual variations in cytochrome P450-mediated metabolism are believed to 
contribute to individual susceptibility to chemical carcinogenesis. CYP1A2 is one of the 
major forms of cytochrome P450 involved in drug metabolism and bioactivation of 
carcinogens. We have applied a recently developed high-throughput Salmonella 
typhimurium TA1535 system for detection of DNA damaging agents to the study of 
CYP1A2 polymorphisms. Non-synonymous variants T83M [CYP1A2*9], S212C 
[CYP1A2*12], S298R [part of CYP1A2*21], G299S [CYP1A2*13], I314V [no allele 
designation], I386F [CYP1A2*4], C406Y [CYP1A2*5] and R456H [CYP1A2*8] were 
examined. The cDNAs for each of these variants and the wild-type were co-expressed 
with human NADPH cytochrome P450 oxidoreductase in the TA1535-based system. The 
bioactivation capacity of these CYP1A2 variants was investigated using three CYP1A2-
dependent pro-mutagens, 1-aminopyrene (1AP), 2-aminoanthracene (2AA), and 2-
amino-3-methylimidazo(4,5-f)quinoline (IQ). All CYP1A2 variants except R456H, 
T83M, and I386F gave positive responses with all three compounds. Variant R456H 
generated no detectable holoenzyme and no detectable response for any of the 
compounds; I386F did not bioactivate IQ; T83M did not bioactivate 1AP. Multivariate 
analysis indicated variant T83M to be substantially altered in catalytic properties when 
compared with wild-type CYP1A2; variants G299S and I386F are slightly but 
significantly different. These results corroborate our previous studies, indicating the 
effectiveness of this new high-throughput system, not only for examining the effect of 
CYP1A2 polymorphisms on pro-mutagen bioactivation, but also for obtaining insights 
on CYP1A2 function at the mechanistic level. 
 
 




The time and cost required to perform in vivo testing hamper the early stages in 
drug development [1]. Moreover, animal toxicity testing has shown poor concordance 
between predicted and actual adverse drug reactions (ADRs) in humans [2]. Sensitive and 
efficient methods for evaluation of the propensity of drug candidates to form reactive 
metabolites (RMs) are needed. High-throughput (HT) screening assays are appropriate 
for handling the flow of new drug candidates in a systematic and time-efficient manner 
[3]. However, ADMET profiling does not address the influence of human genetic 
polymorphisms [4]. The extensive inter-individual variability in xenobiotic and drug 
metabolism presents a major clinical problem [5]. Even at the same dose, drug plasma 
levels can vary more than 1000-fold between individuals [6]. Such variations can arise 
from genetic polymorphisms of drug-metabolizing enzymes (DMEs) and also from 
physiological, patho-physiological, and environmental factors [7]. Genetic factors are 
considered to account for 20-40% of the differences between individuals, in both the 
therapeutic response and the toxic effects of drugs and xenobiotics [8]. 
Polymorphisms of DMEs are strongly implicated in inter-individual differences 
in overall exposures to both the parent drug and RMs, affecting drug response and the 
risk of ADRs [9]. Cytochrome P450s (CYPs) are responsible for the metabolism of a wide 
variety of clinically, physiologically, and toxicologically important compounds [10]. 
CYP is the enzyme system most frequently involved in drug metabolism, along with two 
additional major enzyme classes, esterases and UDP-glucuronosyl transferases [11, 12]. 
The majority of CYP-mediated xenobiotic metabolism is carried out by highly 
polymorphic forms [13] and represent a key factor in inter-individual differences in drug 
response [14]. Furthermore, several ADRs and/or lack of efficacy of therapeutic drugs 
can be explained by the presence of CYP polymorphisms [15, 16]. Approximately 40% 
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of the 157 different pharmacogenomic drug labels listed by FDA are associated with 
variations in CYP genes [17]. Two recent studies identified over 6000 single nucleotide 
variations scattered across the 57 human CYP genes, 50% being novel and more than 
90% being rare [14, 18]. Verification of the phenotypic consequences of these large 
numbers of CYP variants will require highly efficient screening systems for in vitro 
toxicology and genotoxicology studies. 
CYP families 1- 3 are responsible for 70-80% of the metabolism of clinically used 
drugs [19] and are involved in the biotransformation of a large number of xenobiotics. 
The human CYP1A family consists of CYP1A1 and CYP1A2.  CYP1A1 is expressed 
primarily in extra-hepatic tissues, while CYP1A2 is almost exclusively expressed in the 
liver, representing about 4-16% of total CYP content of that organ [20]. Inter-individual 
differences in CYP1A2 activity are well known; variations of up to 60-fold have been 
reported [21, 22]. In addition, CYP1A2 expression is highly inducible: variations of 
approximately 15-fold in mRNA content and 40-fold in protein levels have been observed 
in human liver [23, 24]. To date, 41 CYP1A2 haplotypes have been designated by the 
Human Cytochrome P450 Allele Nomenclature Committee [25]. 
Over the past two decades, our group has established several bacterial cell systems 
competent in recombinant human CYP biotransformation [26-28]. This work has sought 
to address the major limitations of in vitro mutagenicity tests by developing bacterial 
systems that express human CYP-mediated biotransformation capabilities and a genetic 
target for mutagenicity detection. These systems have been used for the study of eight 
non-synonymous polymorphic variants of human CYP1A2 [29, 30]. We have recently 
reported on the development of bacterial HT-test systems containing active human 
CYP1A2, for the rapid, real-time detection of DNA reactive metabolites [31]. 
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The primary objective of this study was to evaluate the effectiveness of these new 
HT systems for the study of polymorphic genetic variants of CYP1A2, using the wild 
type (WT) and eight CYP1A2 variants: T83M [CYP1A2*9], S212C [CYP1A2*12], 
S298R [part of CYP1A2*21], G299S [CYP1A2*13], I314V [no allele designation], 
I386F [CYP1A2*4], C406Y [CYP1A2*5] and R456H [CYP1A2*8] (Supplemental Fig. 
1). As a proof of concept, three pro-mutagens, 2-amino-3-methylimidazo(4,5-f)quinoline 
(IQ); 2-aminoanthracene (2AA), and 1-aminopyrene (1AP) (Fig. 1), were tested to detect 
the presence of CYP1A2-dependent genotoxicity. The data was evaluated through 
multivariate statistical analysis and interpreted using the CYP1A2 crystal structure [32]. 
 
Figure 1. Chemical structures of the three CYP1A2 dependent pre-mutagens used in this study. 
 
5.2. MATERIALS AND METHODS 
5.2.1. Reagents 
Ampicillin, kanamycin sulfate, chloramphenicol, isopropyl β-D-
thiogalactopyranoside (dioxane-free) (IPTG), thiamine, glucose, 1-aminopyrene (1AP), 
and 2-aminoanthracene (2AA) were obtained from Sigma Chemical Co. (St Louis, MO, 
USA). 2-amino-3-methylimidazo(4,5-f)quinoline (IQ) was obtained from Toronto 
Research Chemicals Inc. (North York, Ontario, Canada). Bacto agar, bacto peptone, bacto 
tryptone, bacto yeast extract, NB-medium, and casamino acids were obtained from Difco 
(Detroit, MI, USA).  
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5.2.2. Bacterial tester strains 
The recently developed bacterial HT-test systems expressing active recombinant 
human CYP1A2, for the rapid detection of DNA reactive metabolites [31], are based on 
the bacterial strains S. typhimurium TA1535 [33] or E. coli PD301 [26]. The detection 
method relies on a fusion between the promoter sequence of sulA (one of the most highly 
inducible genes that responds to DNA damage) with a reporter, GFPmut3.1, GFP variant 
with one of the shortest maturation times and high quantum yield. This allows a short 
assay duration and effective real-time measurements. The assay includes a general 
cytotoxicity measurement by which possible effects on formation of the genotoxicity 
reporter signal can be corrected [31]. Due to its real-time measurement capability, the 
DNA damage potency (SOS inducing potency or SOSIP) can be derived at different 
incubation times during one single assay.  
Strain TA1535 was transfected with the expression vector encoding WT human 
CYP1A2 wildtype (WT) or one of eight CYP1A2 variants (Supplemental Fig. 1) [29]. 
Each of these was combined with one of the three human cytochrome P450 
oxidoreductase (CPR) expression/reporter vectors (pLCB_POR, pTcGFP_POR, or 




Table 1. Strains used in this study. 
Strains  Description Reference 
TA1535  hisG46, gal, Δ(chl, uvrB, bio), rfa [33] 
TA15235/CYP1A2_I TA1535/pCWh1A2/pSAG_POR [31] 
TA15235/CYP1A2_C TA1535/pCWh1A2/pTc-gfp_POR [31] 
TA15235/CYP1A2_B TA1535/pCWh1A2/pLCB_POR [31] 
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Plasmids Description Reference 
pCWh1A2 E. coli exp. vector, pCWori+ derived, Ampr, 
ptac.ptac/LacIq, containing modified cDNA of 
human CYP1A2 WT or CYP1A2 variant; 
[29, 51] 
pSAG_POR derivative of pLCMhOR, ΔmucAB, Kanr, 
containing cDNA of human CPR under tac 
promotor, containing cDNA of GFPmut 3.1 under 
sulA promotor. 
[31] 
pTc-gfp_POR derivative of pLCMhOR, ΔmucAB, Kanr, 
containing cDNA of human CPR under tac 
promotor, containing cDNA of GFPmut 3.1 under 
synthetic TetR promotor. 
[31] 
pLCB_POR derivative of pLCMhOR, ΔmucAB, Kanr, 
containing cDNA of human CPR under tac 
promotor. 
[31] 
   
 
5.2.3. Bacterial cultures and CYP1A2/CPR expression 
Bacterial growth with co-expression of the CYP1A2 WT and variants with human 
CPR, membrane preparations, and determinations of protein content (Bradford assay) 
were performed as reported previously [27, 30, 31, 34]. The CYP contents of whole cells 
and membrane preparations were determined using CO-difference spectrophotometry, 
while the CPR content of membrane preparations was determined using the NADPH-
cytochrome c reduction assay, as described previously [27, 30, 31, 34]. 
 
5.2.4. High-throughput genotoxicity assay 
The assay was performed as described previously [31]. Briefly, bacterial cultures 
of the TA1535 derived I-, C-, and B-strains (Table 1) were diluted with VB medium [33] 
containing glucose (0.5%, w/v) and casamino acids (0.75 mg/mL) to A600 = 0.05. Test 
compounds were diluted in VB medium and/or in DMSO. The volume of DMSO used 
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was kept constant in all assay wells and was ≤1% of the total assay volume. Final pre-
mutagen doses were as follows: 2AA and IQ: 0, 2, 4, 6, 8, 10, 12, and 14 ng/well; 1AP: 
0, 100, 200, 300, 400, 500, 600, and 700 ng/well. Test compound (10 µL) and diluted 
cultures (150 µL) were dispensed into the wells and the microplates were covered with 
BREATHseal™. Each assay contained two negative controls: cell mixture plus solvent; 
and solvent plus diluted cells, using VB medium without glucose/ casamino acids 
supplementation. The covered microplates were placed in an orbital shaker and incubated 
at 37 C with 200 rpm shaking. Fluorescence readings (λex: 485 nm; λem: 510 nm) were 
performed at 90, 120, 150, and 180 min using a microplate reader (Anthos Zenith 3100). 
All doses were tested at least in triplicate. GFP-specific fluorescence was obtained by 
subtracting background fluorescence obtained with the B-strain. Subsequent calculations 
of the Induction Factors (FI) and SOS Inducing Potencies (SOSIP) were performed as 











in which   f , f , f , f   represent the GFP fluorescence measured at x and zero dose level, 
for the corresponding I- and C-strains, respectively. The Induction Factors can be plotted 
against each of the tested doses. The SOSIP was derived from the linear part of this curve 
(using ANOVA with 95% confidence interval). SOSIP represents the molar potency of 








The data set used for multivariate statistical analysis consisted of the SOSIP values 
for the four measured time points, for each of the three tested compounds. The 
normalization procedure was based on the variance in the dataset. Both the column and 
row variances were applied as described previously [35]. The CYP1A2 activities of the 
three different pre-mutagens were analyzed using principal component analysis (PCA) 
and multidimensional scaling (MDS). PCA visualizes systematic patterns or trends of 
variation in large data sets. The trends of variation hidden in the initial multidimensional 
space are made evident by constructing new orthogonal axes in the projected space (the 
two first principal components), derived from the directions of greatest variability [36]. 
MDS is a nonlinear projection of the distances separating each object from the others in 
the original multidimensional space into a 2- or 3-dimensional diagram designated as the 
MDS configuration plot [37]. MDS enables the visualization and evaluation of the 
distances between two variants, considering the influence of all other variants at the same 
time. Kruskal’s stress, a diagnostic index which varies from 0 (a perfect fitting) up to 1, 
(no fitting) was used as to evaluate the quality of MDS analysis; it measures the closeness 
of the distance mapping in the 2D MDS plot compared to the “real” distances in the 
original space. The multivariate statistics and dendogram constructions (Pearson 




5.3.1. CYP1A2 and CPR expression 
Before use in the assay, cultures were characterized for their CYP expression 
levels, determined in whole cells. The set of the I-, C- and B-strains (Table 1) containing 
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one of the nine forms of CYP1A2 (Supplemental Fig. 1) produced the same level of P450 
holoenzyme, when grown under the same conditions on the same day (Fig. 2). Daily 
expression levels of CYP in whole cells ranged from 117 to 251 nmol/l for all forms, with 
the exception of the I386F and R456H variants. The CYP holoenzyme level for the I386F 
variant was significantly lower (approximately one-fifth) than that found with the 
CYP1A2 WT, while the R456H variant did not show any detectable holoprotein. To 
verify consistency of CPR/CYP stoichiometries, CPR and CYP levels were determined 
in membrane preparations for each CYP1A2-containing strain (see Table 2). Contents 
ranged from 8.3-13.4 pmol/mg for CPR and 72.5-85.2 pmol/mg for CYP, except for 
membranes of the I386F and R456H variants, which did not contain detectable CYP 
holoenzyme. CPR/CYP ratios ranged from 0.10-0.13.  
 
 
Figure 2. Expression levels (nmol/L) of CYP1A2 wildtype and its variants expressed in the B- (white bars), 
C- (gray bars) and I- strains (black bars), determined in whole cells.  
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Table 2. CYP and CPR contents in membrane preparations and respective ratios. 
CYP1A2 variant a 
CYP  
(pmol/mg protein) b 
CPR  
(pmol/mg protein) b 
CPR/CYP 
WT 79.9 ± 0.1 9.2 ± 0.2 0.12 
T83M 76.7 ± 0.1 9.6 ± 0.2 0.13 
S212C 85.2 ± 0.1 8.3 ± 0.2 0.10 
S298R 76.8 ± 0.1 10.3 ± 0.4 0.13 
G299S 87.0 ± 0.1 11.4 ± 0.3 0.13 
I314V 72.5 ± 0.1 9.7 ± 0.3 0.13 
I386F -- 12.5 ± 0.3  
C406Y 82.4± 0.1 10.5 ± 0.3 0.13 
R456H -- 13.4 ± 0.4  
Human liver microsomes   
0.2 [0.08-0.5] 
c 
a Values for each CYP1A2 variant are representative when expressed either in the blanc (B), cytotoxicity 
measuring (C) or inducible genotoxicity measuring (I) strains. 
b Values represent mean ± standard deviation, N=3; --: undetectable. 
c CPR content in human liver microsomes from Venkatakrishnan et al. [52], and total CYP content in 
human liver microsomes from Paine et al. [53]. 
 
5.3.2. HT genotoxicity testing with CYP1A2 variants 
Three CYP1A2 dependent promutagens, 1AP, 2AA, and IQ, (Fig.1) were assayed 
for genotoxicity with the TA1535-derived system, expressing human CYP1A2 WT and 
the eight CYP1A2 variants (see Fig. 3A and 3B for FI plots). The SOSIP values are 
presented in Fig. 4A-C, and Supplemental Table 1A-C. The three compounds showed no 
genotoxicity in the HT assay in reporter strains that did not express the CYP1A2 system 
(data not shown). Variant R456H did not generate a positive response with any of the 
compounds (see Fig. 3B). 
 
 




Figure 3. FI plots for the TA1535 derived HT system, containing the different CYP1A2 variants and WT 
for 2AA, IQ and 1AP at different incubation times (light gray/dotted lines/diamonds: 90 min; medium 
gray/trace lines/squares: 120 min; dark gray/dote-trace lines/triangles: 150 min; black/continuous 
lines/circles: 180 min). 




























Figure 3. (Continued). 
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When compared to CYP1A2 WT, most of the CYP1A2 variants demonstrated a 
slight decrease in the maximum SOSIP for 2AA, except for variants I314V and S298R, 
which demonstrated CYP1A2 WT-like values (see Fig. 4A and Supplemental Table 1A). 
Maximum SOSIP values were reached after 150 and 180 min incubation time for variants 
T83M and G299S, respectively, while the S298R and I386F variants reached their 
maximum values at 90 min. The remaining variants reached their maximum response at 
120 min, as was found for CYP1A2 WT. 
All variants demonstrated similar maximum SOSIP values for IQ when compared 
to CYP1A2 WT, except for variants I386F and R456H. The I386F and R456H variants 
showed no genotoxicity (see Fig. 4B and Supplemental Table 1B), even up to 240 min 
incubation (data not shown). Variants S298R, G299S, and I314V reached their maximum 
FI’s and consequently maximum SOSIP values after 180 min incubation, whereas variants 
S212C and C406Y behaved as the CYP1A2 WT, reaching maximum SOSIP values at 
120 min. Variant T83M showed maximum SOSIP after 150 min. 
The responses for 1AP were the most discriminating among variants (see Fig. 4C 
and Supplemental Table 1C). Variants S212C and C406Y showed similar SOSIP 
maximums compared to the CYP1A2 WT. However, all other variants demonstrated 
reduced capacity to bioactivate this promutagen. Interestingly, no response could be 
detected for variant T83M, while G299S began to show activity only after 120 min of 
incubation, indicating less efficient 1AP bioactivation capacity. All other variants reached 































Figure 4. Histogram representing SOSIP values obtained with the TA1535 derived HT system, containing 
the different CYP1A2 variants and WT for 2AA (A), IQ (B) and 1AP (C) (column shading represents 
incubation times: white: 90 min; light gray: 120 min; dark gray: 150 min; black: 180 min).  
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5.3.3. Multivariate analysis of data 
 As in previous studies, the experimental data set (Supplemental Tables 1AC) was 
examined using several methods of multivariate analysis [29, 30]. (As variant R456H 
demonstrated no bioactivation activity, it was not included in the analysis.) Using the 
Pearson correlation with average linkage, a “clustering by similarity”-dendogram was 
obtained, based on the normalized data set (Fig. 5). Three classes of similarity were 
identified: one encompasses the T83M variant, the second one includes variants G299S 
and I386F, and the third CYP1A2 WT and the remaining variants. Variant T83M clearly 
has the least similar bioactivation activity when compared with the CYP1A2 WT, while 










Figure 5. Clustering performed by similarity using the Pearson correlation with average linkage, for seven 
different CYP1A2 variants and CYP1A2 WT. 
 
 Principal component analysis (PCA) [38] is a multivariate analysis procedure 
which transforms a high number of possibly correlated variables into a reduced number 
of variables denominated by principal components. PCA was used to project the data set 
from a 12-dimensional space (SOSIP values at four different incubation times for the 
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three compounds) into a 2-dimensional space, for ease of visualization (Fig. 6). The PCA 
analysis retained 96% of the initial variance [principal component 1 (89%) plus 
component 2 (7%)]. Therefore, this analysis accounts for >95% of the variation in the 
data set. The PCA results clearly demonstrated variant T83M to be the most different 
variant when compared to CYP1A2 WT. The PCA analysis itself indicates that the 
variation stems primarily from the difference between variant T83M and the WT-like 
isoforms (WT, S212C, S298R, I314V, and C406Y), while variants G299S and I386F are 










Figure 6.  Gabriel plot of the PCA analysis for seven different CYP1A2 variants and WT. Normalized data-
set for the first two principal components (96% of the initial variance retained). 
 
Multidimensional scaling (MDS) [39] is a nonlinear multivariate analysis 
procedure which permits the visualization of the level of similarity between individual 
parameters in a data set. In the MDS configuration plot (Fig. 7), CYP1A2 variants were 
compared to their SOSIP values for the three pre-mutagens obtained at the four different 
incubation times. This plot shows the similarity/dissimilarity of the CYP1A2 variants in 
their bioactivation capacity of the three compounds. The correlation matrix was deduced 
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from the data set and a MDS was derived from this correlation matrix.  The objects 
represent the variants scattered throughout the diagram, depending on their behaviour 
toward the three tested chemicals when taken globally. Two enzymes will be found close 
to each other in this MDS plot if and only if their behaviours toward the considered 
chemicals are similar. The Kruskal’s stress is a diagnostic index that measures the 
closeness of the distance mapping in the MDS plot compared to the real distances in the 
multidimensional original space. The stress derived from the MDS plot (Fig. 7) is 0.032, 
indicating this analysis to be highly significant. When observing the MDS plot (Fig. 7), 
it is evident that the T83M variant is by far the least similar variant compared to the 
CYP1A2 WT and the separation of G299S and I386F from the rest of the variants is less 










Figure 7.  MDS configuration plot of seven different CYP1A2 variants and CYP1A2 WT. 
 
5.4. DISCUSSION 
Recently, we reported on the development of bacterial prototype systems for real-
time detection of DNA reactive metabolites [31]. The systems are based on S. 
typhimurium or E. coli strains that express active recombinant human CYP1A2 and lend 
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themselves to adaptation to a HT assay format. The S. typhimurium TA1535-based system 
was selected for this current study versus the E. coli PD301-based system. Aromatic 
amines, such as 2AA, IQ, and 1AP, require CYP1A2-mediated oxidation and subsequent 
O-acetyl or O-sulfo conjugation to generate DNA-damaging metabolites [40]. The S. 
typhimurium tester strains of the Ames test, such as TA1535 [33], are known to express 
efficient bacterial O-acetyltransferases [41]. 
All CYP1A2 variants and the CYP1A2 WT expressed in the TA1535-derived 
system demonstrated similar CYP content, except for I386F and R456H. The I386F and 
R456H variants showed severely reduced or absent holoenzyme, respectively, in whole 
bacterial cells. Non-synonymous mutations in CYP polymorphic variants frequently lead 
to altered protein turnover. Although this cannot be determined accurately in bacterial 
cells, we found no changes in (apo)protein stability of the R456H and I386F variants, as 
described in our previous reports [29, 30]. Moreover, when expressed in the simian cell 
model COS-7, these variants demonstrated no significant alteration in protein stability 
[42]. The low or absent holoenzyme expression of R456H and I386F may be related to 
inefficient incorporation and/or anchoring of the prosthetic heme group, as indicated 
previously [29, 30]. The CPR- and CYP-expression levels in the new strains used in this 
study were comparable to those found in our previous studies [29, 31]. The CPR/CYP 
stoichiometry is recognized as an important factor for the catalytic properties of CYP 
enzymatic system [26]. The CPR/CYP ratio was constant in individual experiments, and 
daily values ranged (0.10-0.13) well within those observed for in human liver microsomes 
(0.08-0.5) [31]. These results indicate that co-expression of these CYP1A2 variants with 
CPR represents an adequate approximation of the in vivo situation, and that observed 
differences in CYP1A2 bioactivation activity could be solely ascribed to the structural 
deviations of the CYP1A2 variants [29].  
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Three CYP1A2 dependent promutagens, 2AA, IQ, and 1AP, were tested and their 
genotoxicity was detected using doses in the ng range. Variant R456H gave no detectable 
bioactivation activity for any of the compounds, as expected. Residue R456 is located 
adjacent to C457, the conserved cysteine (fifth ligand) involved in heme binding [43], as 
described in our former studies [29, 30]. In the case of variant I386F, which showed 
severely reduced levels of holoenzyme, no response to IQ was detected, but bioactivation 
of 2AA and 1AP was observed, albeit with decreased levels when compared to the 
CYP1A2 WT. The I386F substitution represents the replacement of an aliphatic side-
chain with an aromatic side-chain in the substrate recognition site 5 (SRS-5) that could 
distort the heme-anchoring structure. We have previously shown the destabilization of 
the I386F holoprotein [29, 30].  
The real-time measurement capacity of our HT-system allowed the consistent 
detection of differences in the time at which maximum SOSIP was reached among 
variants, for the three compounds (Figures 3A-C and Supplemental Table 1A-C). This 
indicates differences in the reaction velocity by which the genotoxic metabolites are 
formed by the different CYP1A2 variants. These differences represent additional 
information on the biotransformation/bioactivation efficacy of the CYP1A2 variants. As 
such, the data set used for multivariate analysis [38, 39] included the SOSIP values of all 
measured time points. The two applied statistical multivariate tools are of interest in 
several fields [44, 45] including the exploration of the protein structure space [46, 47]. 
All applied multivariate analyses had similar outcomes. Variant T83M was found 
to be the most divergent variant, when compared to CYP1A2 WT. The G299S and I386F 
variants also appeared significantly different from the CYP1A2 WT. All remaining 
variants (S212C, S298R, I314V and C406Y) could not be distinguished from the 
CYP1A2 WT. These results are in concordance with the recent report of Ito et al. [42] 
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describing the kinetic characterization of 20 allelic forms of CYP1A2, expressed in COS-
7 cells, using de-ethylation of ethoxyresorufin and of phenacetin as probe reactions. For 
the six coinciding variants with our report, equivalent results were obtained, i.e., variant 
R465H, no activity; variants T83M, G299S and I386F significantly different when 
compared with CYP1A2 wild type form; variants S212C and C406Y not significantly 
different from CYP1A2 WT. Of note, the Ito et al. study was based on a detailed kinetic 
characterization (Vmax, KM, CLint) of the variants. Still, the determined efficacy parameter 
(CLint: Vmax/KM) for the variants has a direct relation with the SOSIP values obtained for 
the three tested aromatic amines of this study, which reflects the efficacy of the variants 
to generate the DNA damaging metabolites. This is further confirmed, as activity 
evaluations coincide with those obtained in our previous study [29], investigating the 
same CYP1A2 variants but using eight diverse substrates, measuring 16 activity 
parameters (including Vmax and KM) for each variant. Although the initial objective of this 
current study was not to substitute characterization of polymorphic CYPs through 
determination of detailed kinetic parameters, the HT-assay and multivariate analysis seem 
to constitute a simplified method for the initial evaluation of CYP1A2 polymorphic 
variants. 
Based on the human CYP1A2 structure published by Sansen and coworkers [32] 
(Supplemental Fig. 1), and the description of substrate entrance and product exit channels 
of CYPs by Cojocaru and coworkers [48] T83 is located in a substrate entrance/product 
exit channel. The T83M variant has demonstrated very different enzymatic activity from 
the WT in both our previous studies [29, 30]. It is interesting to note that, in the present 
work, the T83M variant did not bioactivate 1AP.  
In the superposition and alignment of the human CYP1A2 crystal structure [32] 
with the structures of the CYP BM3 heme and FMN-binding domains [49], G299 is 
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located near the site of the CYPOR/cytochrome b5 interaction. The secondary structural 
annotation of CYP1A2 (PDB #2HI4) also indicates that G299, along with S298, forms a 
beta hairpin structure. The G299S replacement could potentially disrupt the local fold 
through steric hindrance of the beta hairpin. The G299S variant was found to have very 
different enzymatic activity compared with CYP1A2 WT in our previous study of 
CYP1A2 variants [29]. Further investigation showed that in the presence of human 
cytochrome b5 the G299S variant behaved like the CYP1A2 WT [30]. 
 
5.4.1. Conclusions 
We expressed either CYP1A2 WT or one of eight variants with human CPR in the 
TA1535-derived prototype HT system and determined the effect of these variants on 
biotransformation activity for three well-known promutagens. Multivariate analysis 
indicated variant T83M as the most divergent from the CYP1A2 WT, while variants 
G299S and I386F are significantly different from the CYP1A2 WT, corroborating our 
previous studies. We demonstrated an application of our prototype HT system for the 
detection of genotoxic metabolites produced by CYP1A2 polymorphic variants, leading 
to the same conclusions reached in our previous studies [29, 30]. Moreover, these 
conclusions were reached with a substantially smaller data set. In this report we only used 
three CYP1A2 substrates versus eight CYP1A2 substrates (measuring 16 different 
activity parameters) in our previous studies [29, 30]. The current results indicate the 
effectiveness of the prototype HT system, not only for obtaining valuable information on 
the role of genetic CYP1A2 polymorphism on pre-mutagen bioactivation, but also for 
obtaining insights on the molecular mechanism underlying the functioning of this CYP 
isoform. This prototype HT system appears suitable for the study of structural 
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polymorphic variants of other human xenobiotic metabolizing CYPs, as these are readily 
expressed in E. coli [26-28] and S. typhimurium [50].  
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5.5. SUPPLEMENTARY DATA 
Table 1. SOSIP values obtained with the TA1535 derived HT system, containing the different CYP1A2 
variants and WT for 2AA (A), IQ (B) and for 1AP (C) 
   SOSIPa 
(A) 
1A2 Variant 90 min 120 min 150 min 180 min 
WT 54 ± 8 82 ± 6 47 ± 9 45 ± 8 
T83M 24 ± 3 32 ± 4 39 ± 3 37 ± 5 
S212C 27 ± 2 45 ± 2 34 ± 1 34 ± 1 
S298R 61 ± 8 51 ± 9 50 ± 8 49 ± 8 
G299S 37 ± 4 53 ± 2 54 ± 3 58 ± 3 
I314V 51 ± 9 70 ± 8 48 ± 8 47 ± 8 
I386F 35 ± 3 11 ± 1 14 ± 1 11 ± 1 
C406Y 33 ± 3 47 ± 2 33 ± 2 26 ± 2 















1A2 Variant 90 min 120 min 150 min 180 min 
WT 521 ± 103 864 ± 87 850 ± 48 1106 ± 59 
T83M --- --- --- --- 
S212C 301 ± 57 466 ± 94 620 ± 94 1055 ± 126 
S298R 164 ± 19 245 ± 19 392 ± 29 498 ± 35 
G299S 0 195 ± 29 477 ± 84 722 ± 65 
I314V 220 ± 27 320 ± 22 456 ± 22 718 ± 45 
I386F 117 ± 33 536 ± 58 622 ± 93 648 ± 83 
C406Y 563 ± 49 852 ± 101 974 ± 94 1229 ± 52 
R456H --- --- --- --- 
 
a Values are per nanomole (2AA and IQ) or per micromole (1AP) test compound and represent the mean ± 
SD; N ≥ 3. ---: no response detected; values shaded in grey represent maximum SOSIP values. 
   SOSIPa 
(B) 
1A2 Variant 90 min 120 min 150 min 180 min 
WT 90 ± 9 130 ± 14 97 ± 14 72 ± 17 
T83M 73 ± 14 108 ± 14 120 ± 16 110 ± 6 
S212C 70 ± 9 121 ± 10 81 ± 13 87 ± 12 
S298R 67 ± 14 73 ± 15 92 ± 18 98 ± 22 
G299S 78 ± 5 83 ± 6 85 ± 7 103 ± 6 
I314V 53 ± 12 56 ± 13 69 ± 16 98 ± 16 
I386F --- --- --- --- 
C406Y 101 ± 6 135 ± 8 118 ± 8 84 ± 3 
R456H --- --- --- --- 




Figure 1. Localization of altered amino acids of the selected CYP1A2 polymorphic variants using the 
human CYP1A2 crystal structure published by Sansen et al. [1] (figure was generated using PDB file # 
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Humans are continuously exposed to a variety of xenobiotics, such as dietary, 
pharmaceuticals, cosmetics, occupational or environmental chemicals.  Most genotoxic 
carcinogens are chemically inert, requiring metabolic bioactivation by biotransformation 
enzymes to form chemically reactive metabolites (CRMs), which may covalently bind to 
DNA, RNA and proteins. A diversity of metabolic pathways have been recognized in the 
bioactivation of a variety of classes of carcinogens, with a key role of cytochrome P540 
(CYP) enzymes [1]. In this context, the CYP1A family is of special interest, in 
bioactivating specific classes of chemical carcinogens and the development of cancer [2]. 
In fact, a single member of this family, namely CYP1A2, is responsible for the 
bioactivation of nearly 17% of known human pro-carcinogens [3], such as aromatic and 
heterocyclic amines [4]. Beside, CYP1A2 is involved in approximately 15% of the 
metabolism of clinical drugs [5]. 
Ever since the introduction of the revolutionary S. typhimurium mutagenicity 
assay, the “Ames test” over four decades ago, continuous efforts have been made on the 
engineering, improvement and application of additional bacterial-based genotoxicity 
assays [6]. However, the majority of the bacterial cell systems used for genotoxicity 
assessment lack xenobiotic biotransformation since they do not contain appropriate 
metabolic competences [7]. Moreover, at moment most of these assays are time 
consuming and/or demand many manipulation steps, thus not satisfying the current 
necessity of efficient high through-put screening (HTS). A possible approach to overcome 
these limitation is the engineering of new HTS-suitable bacterial systems with the stable 
introduction of expression vectors (cDNAs), encoding human biotransformation 
enzymes.   
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The primary aim of the research described in this thesis was to develop new 
bacterial genotoxicity test systems, being: i) competent in terms of human 
biotransformation and ii) suitable for HTS applications. The newly developed bacterial 
test systems should be suitable for genotoxicity and mechanistic studies, and for co-
expression of different biotransformation enzymes and related polymorphic variants.  The 
secondary aim of the research was to investigate the relevance of different CYP alleles 
of non-synonymous polymorphic forms. For these purposes, the characterization of their 
activity towards a diverse group of substrates should be studied, including the role of the 
accessory redox partner cytochrome b5 (b5). Human CYP1A2 and several CYP1A2 
polymorphic variants were chosen as model enzymes for proof of concept.  
 
Part I. Introduction 
In Part I of this thesis, a general introduction to the work presented in this thesis 
is provided. At the end of Chapter 1 the aims, in brief also described above, and an 
outline of this thesis are presented, 
In Chapter 1, the pathways of xenobiotic biotransformation and the role of CRMs 
in genotoxicity and adverse drug reactions (ADRs) are discussed. An overview of the 
biotransformation enzymes involved in the bioactivation/bioinactivation of foreign 
compounds and the association between CRMs and toxicity in general, and genotoxicity 
in particular, is provided. Inter-individual differences in drug metabolism resulting from 
genetic polymorphisms of drug metabolizing enzymes, and their implications in the 
occurrence of ADRs and susceptibility to cancer is highlighted. The importance of the 
CYP superfamily, including the electron donor accessory enzymes b5 and NADPH 
cytochrome P450 oxidoreductase (CYPOR), is explained with a special focus on the 
CYP1A2 isoform. Chemical carcinogenesis and mutagenesis, and the role of 
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bioactivation of xenobiotics is introduced. In this context, HTS-suitable in vitro assays 
for genotoxicity detection are discussed as well, with emphasis on bacterial systems.  
In the early days, all HTS-suitable (yeast and bacterial) assays described at that 
time, applied external bioactivation systems (in majority rodent liver extracts) for the 
detecting of pro-mutagens. The primary aim of this PhD research was the development 
of bacterial genotoxicity test systems for HTS applications, competent in human 
biotransformation. Human CYP1A2, one of the major biotransformation enzymes 
involved in the metabolism of chemical carcinogens (vide supra) was selected as model 
for proof of concept. 
 
Part II. Characterization of Human Cytochrome P450 1A2 Polymorphic 
Variants 
Part II of this thesis deals with a comprehensive characterization of WT plus 8 
non-synonymous polymorphic forms of human CYP1A2, namely T83M, S212C, S298R, 
G299S, I314V, I386F, C406Y and R456H. These 8 naturally occurring variants were 
selected from a total of 15 (variants known in 2006, currently 24) non-synonymous 
polymorphisms (http://www.cypalleles.ki.se/cyp1a2.htm). This selection was based on 
the crystal structure published by Sansen et al. [8] of human CYP1A2 WT. Selection 
criteria for CYP1A2 variants concerned the localization of their structural deviations in 
the proximity of the active center, heme-moiety anchoring, substrate/product 
entrance/exit channel or the CYPOR interaction interface. The selection was performed 
with the assistance of MSc Eva Stjernschantz† and Dr. Chris Oostenbrink of the Division 
of Molecular Toxicology at the Vrije Universiteit Amsterdam. 
At the start of this research, most of the work published about CYP1A2 
polymorphisms was related to the characterization of gene polymorphisms in the non-
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coding region. Few reports described non-synonymous variants, concerning the 
identification of polymorphisms in the population and their frequencies, but not the 
effects on protein level and activity. When activity was investigated, it was performed 
with a very limited number of substrates.  In Chapter 2, a thorough characterization of 
the WT plus 8 non-synonymous polymorphic forms (variants indicated above) of human 
CYP1A2 is described for their metabolizing capacities. Each of the nine CYP1A2 
variants was co-expressed with human CYPOR in E. coli BTC strains [9], using a bi-
plasmid co-expression system. The CYP1A2 contents of variants were similar to WT, 
except for variants I386F and R456H. These two variants showed severely reduced or 
absent holoenzyme in whole cells, respectively. Neither of the two could be detected as 
holoenzymes in membrane (microsomal) fractions, however, immunoblot analysis 
indicated that CYP1A2 (apo-)-protein expression levels were similar among all variants. 
The CYPOR/CYP ratios for the different variants were found to be in the range of those 
observed in human liver microsomes, except for I386F and R456H, due to lack of 
CYP1A2 holoenzyme (vide supra). Activities of the CYP1A2 variants were determined, 
using 8 different substrates, using a large part of the known chemical space of CYP1A2’s. 
These concerned 3 fluorogenic probes (MR, ER and CEC), 2 drugs (phenacetine and 
clozapine) and 3 pro-mutagens (NNK, IQ and 2AA). The resulting data set, consisting of 
16 different activity parameters for each variant, was extensively analyzed using 
multivariate analysis methods. Variants R456H and I386F were not included in this 
analysis. These results were subsequently interpreted using the human CYP1A2 crystal 
structure. It was concluded that among all analyzed human CYP1A2 variants, variant 
G299S is the most deviated enzyme in comparison to WT, whereas variant T83M is only 
slightly but significantly different from the WT. Furthermore, bioactivation of NNK 
(mutagenicity) was shown to be the most discriminative activity among the CYP1A2 
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variants. In addition, R456 could be identified as a critical residue for proper heme 
anchoring and stabilization. 
The investigation of the effect of the b5 protein on the activities of WT plus the 
same 8 non-synonymous polymorphic forms of human CYP1A2 is described in Chapter 
3. In this chapter, a similar approach, as reported in Chapter 2 was applied, i.e. co-
expressing separately the CYP1A2 variants with human CYPOR and human b5, using the 
bi-plasmid system in the E. coli BTC strains [9, 10]. CYPOR contents and b5 (holo- and 
apo-protein) expression levels were determined and were comparable among the strains. 
CYP1A2 variant contents, were comparable amongst variants (except for I386F and 
R456H) and similar to the ones described in Chapter 2, indicating that b5 co-expression 
had minor effects on CYP expression.  The CYP1A2 variants were screened using the 
same methods and substrates as described in Chapter 2 determining the same 16 activity 
parameters. The results obtained were merged with the ones reported in Chapter 2. This 
combined data set was then analyzed through multivariate analysis and the structural 
knowledge derived from the human CYP1A2 crystal structure. Again, variants I386F and 
R456H were excluded from this analysis. Nevertheless, in the presence of b5 variant 
I386F showed activity with all substrates, except with clozapine and IQ. Multivariate 
analysis indicated that among all human CYP1A2 variants analyzed, variants T83M and 
C406Y are the most divergent enzymes in catalytic properties in comparison with WT in 
b5’s presence. Collectively, data indicate that b5 likely exerts a compensatory effect on 
the perturbed functional capacities of each of the polymorphic variants, leading to a more 
WT-like behavior. This is especially the case for the I386F variant, for which b5 presence 
was essential for activity. Furthermore, the data seems to implicate CYP1A2 residue 
G299 in the interaction with CYPOR and/or b5. It is concluded that b5 can affect CYP1A2 
polymorphic variants to behave more like the WT variant, seemingly through extensive 
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allosteric effects. These effects probably influence the active center (I386F), close to the 
CYPOR/CYP1A2 interface, but also more distal zones such as the substrate 
entrance/product exit channel (T83M and C406Y). 
 
Part III. Development of Bacterial HTS-Systems for Detection of 
Genotoxic Electrophilic Reactive Metabolites 
Part III of this thesis describes the engineering of bacterial systems that 
efficiently detect DNA-damaging electrophilic reactive metabolites generated by human 
CYP1A2 biotransformation.    
In Chapter 4, the development of genotoxicity test systems, metabolically 
competent in human CYP1A2 and suitable for HTS purposes is presented. The principle 
of the detection method was based on a reporter fusion with the promotor sequence of 
sulA, one of the highest inducible bacterial genes upon DNA damage [11]. A specific 
GFP variant was selected as reporter, namely GFPmut3.1 [12]. This GFP was 
demonstrated to have one of the shortest maturation times and a high quantum yield, thus 
minimizing assay duration and enabling effective real-time measurements. An additional 
strain containing a constitutive promoter to correct for possible cytotoxic effects of test 
compounds was included, using the same GFP reporter. The reporter systems were 
initially used in four different bacterial backgrounds. These concerned TA1535 and 
TA100 [13], two S. typhimurium strains of the Ames test, and FP401[14] and PD301[9], 
two E. coli strains developed in our laboratory in Lisbon. After optimization of assay 
conditions, all reporter strains were tested with three direct-acting mutagens (4NQO, 
MNNG and CHP), to determine the sensitivity in genotoxicity detection of each of the 4 
bacterial strains used. Results were compared with the ones of the SOS-chromotest [15]. 
Subsequently, the two most effective bacterial systems, namely the ones based on strains 
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TA1535 and PD301, were adapted to co-express human CYP1A2 and CYPOR, using the 
bi-plasmid system described previously, along with the GFP reporters. All strains 
demonstrated equivalent CYP and CYPOR levels and CYPOR/CYP ratios were within 
the range observed in human liver microsomes. The two systems were tested with three 
pro-mutagens, namely, 2AA, IQ and 1AP, well-known to form DNA-reactive metabolites 
through CYP1A2-mediated metabolism [16].  In Chapter 4, it is concluded that the two 
human CYP1A2 competent prototype systems, have the appropriate characteristics for 
HTS-detection of DNA-damaging reactive metabolites.  
The application of the newly developed bacterial genotoxicity assay (described in 
Chapter 4) is reported in Chapter 5. This concerns the study of WT plus the same 8 
polymorphic forms of human CYP1A2, studied in Chapters 2 and 3, using the HTS S. 
typhimurium TA1535 based system. CYP and CYPOR levels were comparable among 
all strains and CYPOR/CYP ratios within the range observed in human liver microsomes, 
except for the strains containing variants I386F and R456H, with expression issues as 
described in Chapter 2 and 3. Still, the bioactivation of two pro-mutagens by the I386F 
variant could be detected. The CYP1A2 dependent genotoxicity of the pro-mutagens 
2AA, IQ and 1AP could be detected and results were analyzed through multivariate 
analysis. Variant T83M demonstrated again to be the most divergent isoform among all 
variants, while variants G299S and I386F were slightly but significantly different from 
WT. These results were comparable with those obtained in in Chapter 2, in which for 
each variant 8 different substrates (namely NNK, IQ, 2AA MR, ER, CEC, phenacetine 
and clozapine) were used and 16 different activity parameters were measured. This 
particular result indicated the effectiveness of the newly developed bacterial HTS system 
for genotoxicity, not only for investigation of the effect of CYP1A2 polymorphisms on 
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pro-mutagens bioactivation, but also to obtain insights on the molecular mechanism of 
CYP1A2 functioning. 
 
FINAL CONSIDERATIONS, CONCLUSIONS AND PERSPECTIVES 
Some Final Considerations 
It is important to mention that the CYPOR/CYP ratios of all strains investigated 
in this thesis were always comparable with those found in human liver microsomes.  This 
characteristic was considered important for in vivo significance. Moreover, the 
equivalence in CYP1A2 biotransformation capability of each variant, independent of the 
different E. coli and S. typhimurium strains used, permitted the conclusion that differences 
in detection of pro-mutagen genotoxicity is due to the bacterial background and not to 
differences in CYP biotransformation capacities (for Chapter 4); Conversely, when 
using the same bacterial background the differences in CYP1A2 biotransformation 
observed between the polymorphic CYP forms can be ascribed to differences between 
the variants (for Chapters 2, 3 and 5). 
In Part III of this thesis, the engineering of several novel E. coli and S. 
typhimurium tester strains, suitable for in vitro HTS-testing for xenobiotic genotoxicity, 
as well as for the study of 9 variants of human CYP1A2 is described. Two different types 
of plasmid-based GFP reporters were constructed, for the detection of genotoxicity and 
cytotoxicity, respectively. The usefulness of a cytotoxicity reporter strain (C-strains) was 
most apparent when testing CHP, a highly cytotoxic compound. The inclusion of the C-
strains in HTS-testing is important to be highlighted, as is the very short time in data 
collection. The effectiveness of the HTS genotoxicity assay was successfully 
demonstrated as was the adaptation to a HTS-assay format, including microplate format, 
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requirement for small amount of test chemical, short turnaround time for data output, and 
real-time measurements. 
All together, results of this thesis allow several important conclusions on specific 
aspects of the molecular functioning of the CYP1A2 enzyme complex, and the role of the 
accessory redox partner b5 in their activity. In Part II, E. coli BTC [9] strains, developed 
in our lab in Lisbon, were chosen for mechanistic studies, because they were easily 
obtained through standard genetic manipulation of PD301, the mother strain of BTC. In 
Part III, when applying WT plus the 8 CYP1A2 variants in the novel genotoxicity 
















Figure 1. Localization of altered amino acids of the selected CYP1A2 polymorphic variants using the 
crystal structure of human CYP1A2, published by Sansen et al [8] (PDB file ID 2HI4). In pale yellow the 
substrate-entrance/product-exit and CYPOR/b5 interaction zones are highlighted. Highlighted are also the 
most altered variants used in this thesis, namely: T83M and C406Y, which residues are suggested to be 
part of the architecture of the exit/entrance substrate/product channel(s). Substitutions of these residues may 
change substrate sampling and substrate orientation/positioning, leading to ineffective and/or alternative 
metabolism; G299S, located at the CYPOR/b5 interaction zone, is forming a β-hairpin along with S298 
(secondary structural annotation based on PBD file 2HI4); I386F, located in the SRS5, results in the 
replacement of an aliphatic side chain to an aromatic side chain, which may distort the heme anchoring 
architecture; R456H, residue R456 is adjacent to C457, the conserved cysteine (fifth ligand) involved in 
heme binding [17]. 
 
Variants I386F and R456H were demonstrated to be two particular forms with 
perturbed holoprotein stability. This observation was consistent in all studies in this 
thesis. The R456H substitution showed to be the most detrimental, since activity nor 
holoprotein levels could be detected. For variant I386F, when using whole bacterial cells, 
holoprotein and some activities were detected, while in membrane (microsomal) 
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preparations this was only the case when co-expressed with b5. In fact, b5 seems to 
improve protein stability and thus activity of this variant, seemingly through allosteric 
interactions.  
Variant G299S is of special interest. In the absence of b5, variant G299S was 
always the most divergent in catalytic properties, when compared to WT. However, in 
the presence of b5, its activity profile was very much like the WT. The results obtained 
clearly implicate G299 in CYP1A2’s interaction with the overlapping CYPOR/b5 binding 
site. Interestingly, the G299S substitution seems to be more disruptive to the local 
structure than the adjacent S298R substitution, which showed WT like activities 
throughout the different studies. 
Variants T83M and C406Y demonstrated the most surprising results, i.e. 
substantially altered catalytic properties of both these polymorphic forms when compared 
to the WT variant. Moreover, the altered activity profiles of both T83M and C406Y in 
the presence of b5 (Chapter 3) seem the emphasize their divergence, as all other variants 
behaved in a more WT-like manner. The only exception, was in Chapter 2, where variant 
C406Y was considered as a WT-like enzyme. However, the same work also showed a 
lack of NNK bioactivation, while in phenacetine metabolism, beside the dealkylation 
product extra metabolites were observed. Interestingly, Zhou et al. (2004) postulated a 
possibly altered metabolic profile for variant C406Y [18].  
 
Conclusions and Perspectives 
Biotransformation and related inter-individual differences, play a major role in 
chemical genotoxicity, carcinogenicity and individual susceptibilities. CYP metabolism 
is usually the main clearance pathway for drugs and other xenobiotics. [19, 20]. Metabolic 
activation, i.e. bioactivation of xenobiotics sometimes results in the formation of CRMs, 
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known to be a crucial determinant in multiple toxicities (such as ADRs) in general, and 
in genotoxicity in particular [21, 22]. Although the generation of CRMs is not an absolute 
indicator that exposure to a compound will result in toxicity, the ultimate action of CRMs 
is also dependent on the efficiency of various metabolic detoxification routes and the 
presence of toxicological targets at the site of CRM formation [23]. Absorption, 
distribution, metabolism, excretion and toxicity (ADME-Tox) guided lead-optimization 
is often based on a strategy of avoiding compounds having a potential to produce CRMs 
[24].  
The initial tests of chemicals for their potential to induce carcinogenesis, usually 
depends on genotoxicity or mutagenicity testing. This is currently particularly relevant 
due to the implementation of the EU chemical policy REACH, with a requirement for 
thousands of toxicity profiles of non-characterized or poorly characterized chemicals 
[25]. The screening of thousands of compounds using whole animal models is neither 
economically viable nor ethically acceptable, thus reinforcing the need for new, highly 
effective HTS (geno)toxicity screening methods [26]. In this context, bacterial in vitro 
cell-models are of interest due to their simplicity in manipulation, short term in data 
collection and the fact that they are in line with the societal concern on laboratory animal 
use. However, the inadequate representation and/or absence of human biotransformation 
in such in vitro assays is still a major handicap of in vitro genotoxicity test systems when 
relevant CRMs occur and for in vitro to in vivo extrapolations [27].  
The need for improved in vitro genotoxicity HTS-testing has been addressed by 
several laboratories with the development of new test systems. However, some can only 
be considered as “semi” HTS, while appropriate human biotransformation incorporation 
is still the general handicap in all cases. The work described in this thesis, addressed these 
particular issues.  
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We designed and engineered the novel SOS-CYPtest system. This system is using 
several E. coli and S. typhimurium tester strains, which are metabolically competent in 
human CYP biotransformation and are appropriate for in vitro HTS genotoxicity testing 
of chemicals, which was the primary aim of this study. The SOS-CYPtest system strains 
were engineered to include a GFP reporter, and to express an active human CYP 
(CYP1A2) and several of its polymorphic forms. In the first phase, the ability to detect 
DNA-damaging agents was demonstrated. Subsequently, the genotoxicity of CYP1A2-
dependent pro-mutagens was successfully detected. Although only applied for a restricted 
number of compounds, the newly developed SOS-CYPtest system seems to have the 
appropriate characteristics for the detection of DNA damaging CRMs in a HTS manner. 
HTS characteristics include a short assay time (max 120-180 min), the need of only small 
amounts of test compound (less than a few micrograms), the adaptability to a microplate 
format and real-time measurement. Besides the sensitive and efficient screening of a large 
number of chemicals, obtaining relevant data on the role of particular human CYP 
isoforms in the genotoxicity of chemicals, as another example of its applicability, the 
SOS-CYPtest system was also tested to study genetically polymorphic variants of human 
CYPs.. It was demonstrated not only to generate successfully genotoxicity data, relevant 
for risk assessment and individual susceptibility in the exposure to chemical carcinogens, 
but also to yield new insights in the molecular mechanisms of function of human CYP1A2 
variants. In Figure 2, a graphical illustration is given to visualize the different test systems 
developed, the expressed proteins involved, the probe substrates used, the pro-mutagens 
used as well as the flow schemes used to the ultimate applications in terms of risk 
assessment and mechanistic information. 
 
 



























Figure 2. Graphical summary of the research described in this thesis. For the development of the novel 
SOS-CYPtest system, two bacterial backgrounds were used, namely E. coli PD301 strains [14] and S. 
typhimurium TA1535 strains [13]. Both backgrounds were used for the detection of 3 direct DNA-reactive 
mutagens, namely: CHP, cumene hydroperoxide; 4NQO, 4-nitroquinoline-1-oxide; MNNG, N-methyl-N´-
nitro-N-nitrosoguanidine. In the SOS-CYPtest system, CYPOR and WT CYP1A2 were co-expressed in 
both bacterial backgrounds, while the CYP1A2 variants were only co-expressed in S. typhimurium TA1535 
strains. Three CYP1A2-mediated DNA-reactive pro-mutagens were tested, namely: 1AP, 1-aminopyrene; 
2AA, 2-aminoanthracene; and IQ, 2-amino-3-methylimidazo(4,5-f)quinoline. For mechanistic studies of 
CYP1A2 variants, the E. coli BTC system [9] was used. Several techniques were applied, namely 
Michaelis-Menten kinetics and inhibition assays, endpoint HPLC kinetics and mutagenicity plate reversion 
assays. In total 9 different compounds representing different classes of CYP1A2 substrates were used, 
namely: 3 fluorogenic probes (ER, ethoxyresorufin; MR, methoxyresorufin; and CEC, 3-cyano-7-
ethoxycoumarin), 2 therapeutic drugs (phenacetine and clozapine) and 4 pro-mutagens [1AP; 2AA; IQ; and 
NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone]. To scrutinize appropriately all results, 
multivariate analysis methods were applied.   
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The novel bacterial system, the SOS-CYPtest system, was designed and 
engineered to offer a HTS test system that would accurately detect which compounds can 
produce DNA-reactive CRMs in humans. Systems for detection of DNA damaging CRMs 
do not per se require the complexity of the eukaryotic or mammalian nucleus. The use of 
such complex systems might even diminish or impair effective detection of some CRMs. 
Moreover, the short cell cycle of bacteria allows a fast turnaround in data output (2-3 hrs), 
as demonstrated in this thesis. Comparable HTS assays using yeast or mammalian cells, 
require more than 16 hrs. Our systems are effective in detecting hard genotoxic 
electrophilic CRMs generated by biotransformation enzymes, such as the CYPs. 
However, detoxification of CRMs by other metabolic enzymes, such as e.g. GSTs, is not 
present in the current systems and consequently the test systems may overestimate CRM 
exposure. Thus, the use of the standard Ames plate assays combined with human liver 
S9, representing bioactivation and bioinactivation, might be more adequate for risk 
assessment, however, not for identifying CYP-isoenzyme selective metabolic pathways 
and related variability. Therefore, the identification and capability in generating 
genotoxic metabolites by CYP-isoenzymes of chemicals remains of great relevance. This 
is also the case when detoxification pathways would become saturated (e.g. at high levels 
of exposure or in the case of drug-drug interactions) or in cases where the detoxification 
capacity is limited (e.g. due to genetic polymorphisms of genes encoding detoxifying 
enzymes). 
The secondary aim of this thesis was to investigate specific CYP alleles, focusing 
on non-synonymous polymorphic forms, and the role of the accessory enzyme b5.  
CYP1A2 was chosen as a model enzyme. Due to the huge amount of data produced, and 
to be able to scrutinize appropriately all results, multivariate analysis methods were 
applied and appeared to be a powerful and very useful tool regarding data analysis. 
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Collectively, it is concluded that 5 of the 8 different CYP1A2 variants analyzed were of 
relevance, namely variants T83M, G299S, I386F, C406Y and R456H. Consistently, 
R456H was an inactive enzyme. T83M and C406Y are the most divergent enzymes 
comparing to WT CYP1A2, while variant I386F is a very unstable enzyme in which b5 
plays a key role in its stability/activity. The results obtained clearly implicate G299 in 
CYP1A2 to interact with CYPOR/b5. Collectively, b5 seems to compensate for structural 
deviations of the CYP1A2 variants, most likely through extensive allosteric effects.  Not 
only the proximal zones of the active center and the b5/CYPOR/CYP1A2 interface are 
affected, but also more distal zones such as the substrate entrance/product exit channel. 
 
In conclusion, this thesis describes the design and the engineering of a new SOS-
CYPtest system, a bacterial assay for the real-time detection of in situ generated DNA 
reactive metabolites, and competent for human CYPs, i.e. the most relevant enzyme in 
xenobiotic human biotransformation. The SOS-CYPtest systems were developed to 
address a specific limitation of current in vitro HTS-genotoxicity tests, namely the lack 
of human biotransformation. The novel SOS-CYPtest systems are also suitable for HTS 
screening formats. Thus, the test strains described in this thesis, constitute a new 
generation of human biotransformation competent tester bacteria effective for testing 
genotoxic compounds for risk assessment, but also for mechanistic studies, e.g. on the 
molecular mechanisms underlying the functioning of CYP enzymes and their 
polymorphic forms. In this thesis CYP1A2 has been used to provide a proof of concept.  
 
In terms of future perspectives, the currently developed SOS-CYPtest systems, 
are prototypes that can be optimized and further specialized. Subsequent efforts should 
preferably be dedicated to the validation of assay(s) including genotoxins with different 
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mechanisms, but also including non-genotoxic compounds. This in order to challenge the 
test systems as much as possible, and also to proceed with optimizations for commercial 
purposes. Other human CYP isoforms could also be applied or even other 
biotransformation enzymes such as NQOs, SULTs and GSTs, all leading to bioactivation 
to and/or protection against CRMs. Several of these enzymes have already been expressed 
in bacteria [28-31]. The expression of other CYPs (and their polymorphic forms) 
especially the most relevant for pro-carcinogens bioactivation, namely CYPs 1A1, 1B1, 
2A6, 3A4 is of special interest [3].  
The integrated statistical multivariate methods are of great use for analysis of this 
type of data, and thus for improving the quality of interpretations and extrapolations both 
for risk assessment and/or functional/mechanistic studies. Extended design and 
engineering of the genotoxicity assays per se, e.g. by refining the reporter and cellular 
systems, may also be considered. In this context, the integration in the bacterial genome 
of two reporters (notably for cytotoxicity and genotoxicity) can be envisioned, ideally 
even considering placement of both reporters in the same target cell. Similarly, gene-
reporters could be applied to monitor other effects of xenobiotics, such as oxidative stress.  
Our test systems are representing only CYP1A2-mediated metabolism, however, one 
might also envision simultaneous co-expression of different CYP isoforms and/or other 
biotransformation enzymes (phase I, II and III) trying to get closer to the in vivo situation. 
The use of different promotors for each enzyme might even be considered, e.g. to vary 
levels of expression for mechanistic purposes or to better represent inter-individual 
differences. Alternatively, one could use mixtures of different reporter bacteria, each 
containing different CYP isoforms and/or other biotransformation enzymes (phase I, II 
and III). Such reporter bacteria could be mixed in relative quantities mimicking specific 
metabolism in tissues (e.g. liver, lung, cardiac tissues, etc.). Such approaches might also 
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represent CYP- and/or other enzymes, (such as GSTs) mediating detoxification routes of 
parent compounds and/or metabolites. The use of other bacterial backgrounds and/or the 
use of other indicative reporter bacteria together with a bioreactor could also be explored. 
The current bacterial genotoxicity strains could be the point of departure for these further 
developments. 
 
In xenobiotic risk assessment, the potency to induce carcinogenesis is usually 
provided by genotoxicity or mutagenicity testing. The major handicap of current in vitro 
HTS-systems to detect relevant DNA-reactive metabolites is mostly due to inadequate 
representation and/or failure of human biotransformation. The studies in this thesis 
demonstrate possibilities to overcome this issue. Mechanistic information regarding 
human biotransformation enzymes is also generated. Application and further engineering 
of the current in vitro HTS-methods to study genotoxicity can contribute to improved 
selection of safer drug candidates in pharmaceutical R&D, but also for the identification 
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Humans are continuously exposed to a variety of xenobiotics, such as, 
pharmaceuticals, cosmetics, dietary, occupational or environmental chemicals.  Most 
genotoxic carcinogens are chemically inert, requiring metabolic bioactivation by 
biotransformation enzymes to form chemically reactive metabolites (CRMs), which may 
subsequently covalently bind to DNA, RNA and proteins. A diversity of metabolic 
pathways has been recognized in the bioactivation of carcinogens, with a key role of 
Cytochrome P540 (CYP) enzymes. In this context, the CYP1A family is of special 
interest in the bioactivation of specific classes of chemical carcinogens and in the 
development of cancer. 
Ever since the introduction of the revolutionary S. typhimurium mutagenicity 
assay, the “Ames test” over four decades ago, continuous efforts have been made on the 
improvement and application of additional bacterial-based genotoxicity assays. However, 
the majority of the available bacterial cell systems used for genotoxicity assessment still 
lack xenobiotic biotransformation, since they do not contain appropriate metabolic 
competences.  
The primary aim of the research described in this thesis was to develop new 
bacterial genotoxicity test systems, being: i) competent in terms of human CYP-mediated 
biotransformation and ii) suitable for HTS applications. The bacterial test systems should 
be suitable for genotoxicity and mechanistic studies, and for co-expression of different 
CYP enzymes and related polymorphic variants.  The secondary aim of the research was 
to investigate the relevance of different CYP alleles of non-synonymous polymorphic 
forms. For these purposes, their activity towards a diverse group of genotoxic and non-




Cytochrome b5 (b5). Human CYP1A2 and several polymorphic CYP1A2 variants were 
chosen as model enzymes for proof of concept.  
 
Part I. Introduction 
In Chapter 1, the pathways of xenobiotic biotransformation and the role of CRMs 
in genotoxicity and adverse drug reactions (ADRs) are discussed. An overview of the 
biotransformation enzymes involved in the bioactivation/bioinactivation of foreign 
compounds and the association between CRMs and toxicity in general, and genotoxicity 
in particular, is presented. Inter-individual differences in drug metabolism resulting from 
genetic polymorphisms of drug metabolizing enzymes, and their implications for ADRs 
and susceptibility to cancer is highlighted. The importance of the CYP superfamily, 
including the electron donor accessory enzymes b5 and NADPH cytochrome P450 
oxidoreductase (CYPOR), is explained with a special focus on CYP1A2. Chemical 
carcinogenesis and mutagenesis, and the role of bioactivation of xenobiotics are 
introduced as well. In this context, HTS-suitability of in vitro assays for genotoxicity 
detection, with emphasis on bacterial systems, is discussed as well.  
 
Part II. Characterization of Human Cytochrome P450 1A2 Polymorphic Variants 
Part II of this thesis deals with a comprehensive characterization of WT plus 8 
non-synonymous polymorphic variants of human CYP1A2, namely T83M, S212C, 
S298R, G299S, I314V, I386F, C406Y and R456H; and the role of the accessory redox 
partner cytochrome b5. 
In Chapter 2, a thorough characterization of the WT CYP1A2 plus 8 non-
synonymous polymorphic variants (indicated above) is described for their metabolic 
capacities. Each of the eight CYP1A2 variants plus WT was co-expressed with human 




similar levels of apoprotein and holoprotein expression, except for I386F and R456H, 
which showed only apoprotein. However, both were functionally inactive. The 
CYPOR/CYP ratios for the different variants were found to be in the range of those 
observed in human liver microsomes, except for I386F and R456H, due to lack of 
CYP1A2 holoenzyme (vide supra). Activities of the CYP1A2 variants were determined, 
using 8 different substrates. The resulting data set, consisting of 16 different activity 
parameters for each variant, was extensively analyzed using multivariate analysis 
methods. These results were subsequently interpreted using the human CYP1A2 crystal 
structure. It was concluded that among all analyzed human CYP1A2 variants,  G299S is 
the most deviating enzyme in comparison to WT, whereas variant T83M is only slightly 
but significantly different from the WT. Furthermore, bioactivation of NNK 
(mutagenicity) was shown to be the most discriminative activity among the CYP1A2 
variants. In addition, R456 could be identified as a critical residue for heme anchoring 
and stabilization. 
In Chapter 3, the effect of the b5 protein on the activities of WT CYP1A2 plus 
the same 8 non-synonymous polymorphic forms is described. A similar approach, as 
reported in Chapter 2 was applied. CYPOR contents and b5 (holo- and apo-protein) 
expression levels were determined and comparable among the strains. CYP1A2 variant 
levels, were comparable amongst variants (except for I386F and R456H) and similar to 
the ones described in Chapter 2, indicating that b5 co-expression had minor effects on 
CYP expression, in this model.  The CYP1A2 variants were screened using the same 
methods and substrates as described in Chapter 2. The results obtained were merged with 
the ones reported in Chapter 2. The combined data set was then analyzed through 
multivariate analysis and the structural knowledge derived from the human CYP1A2 




variants T83M and C406Y are the most divergent enzymes in catalytic properties when 
compared to WT in b5’s presence. Collectively, data indicate that b5 likely exerts a 
compensatory effect on the perturbed functional capacities of the polymorphic variants, 
leading to a more WT-like behavior. Furthermore, the data seems to implicate CYP1A2 
residue G299 is in interaction with CYPOR and/or b5.  
 
Part III. Development of Bacterial HTS-Systems for Detection of Genotoxic 
Electrophilic Reactive Metabolites 
Part III of this thesis describes the engineering of bacterial systems to efficiently 
detect DNA-damaging CRMs generated by human CYP1A2. 
In Chapter 4, the development of genotoxicity test systems, metabolically 
competent in human CYP1A2 and suitable for HTS purposes is presented. The principle 
of detection was based on a reporter fusion with the promotor sequence of sulA (one of 
the highest inducible bacterial genes upon DNA damage) with GFPmut3.1, a selected 
GFP reporter. An additional strain containing a constitutive promoter to correct for 
possible cytotoxic effects of test compounds was included, using the same GFP reporter. 
The reporter systems were initially used in four different bacterial backgrounds, namely 
TA1535 and TA100: two S. typhimurium strains of the Ames test, and FP401 and PD301, 
two E. coli strains developed in our laboratory in Lisbon. After optimization of assay 
conditions, all 4 reporter strains were tested with three direct-acting mutagens (4NQO, 
MNNG and CHP), to determine the sensitivity in genotoxicity detection. Subsequently, 
the two most effective bacterial systems, namely the ones based on strains TA1535 and 
PD301, were adapted to co-express human CYP1A2 and CYPOR, using the bi-plasmid 
system described previously, along with the GFP reporters. All strains demonstrated 
equivalent CYP and CYPOR levels and CYPOR/CYP ratios were within the range 




mutagens, namely, 2AA, IQ and 1AP, known to form DNA-reactive metabolites through 
CYP1A2-mediated metabolism.   
The application of the newly developed bacterial genotoxicity assay (described in 
Chapter 4) for HTS application is reported in Chapter 5. This concerns the study of WT 
CYP1A2 plus the same 8 polymorphic forms, studied in Chapters 2 and 3, and using the 
S. typhimurium TA1535 based HTS system. CYP and CYPOR levels were comparable 
among all strains and CYPOR/CYP ratios were within the range observed in human liver 
microsomes, except for the strains containing variants I386F and R456H, with the 
expression issues described in Chapter 2 and 3. Still, the bioactivation of two pro-
mutagens by the I386F variant could be detected. The CYP1A2-dependent genotoxicity 
of the pro-mutagens 2AA, IQ and 1AP could be detected and the results were analyzed 
through multivariate analysis. Variant T83M demonstrated again to be the most divergent 
isoform from WT among all variants, while variants G299S and I386F were slightly but 
significantly different from WT. These results were comparable with those obtained in in 
Chapter 2, in which for each CYP1A2 variant 8 different substrates (namely NNK, IQ, 
2AA MR, ER, CEC, phenacetine and clozapine) were used and 16 different activity 
parameters were measured. This particular outcome indicated the effectiveness of the 
newly developed bacterial HTS system for genotoxicity testing, not only for investigation 
of the effect of CYP1A2 polymorphisms on pro-mutagens bioactivation, but also for 
providing insights in the molecular mechanism of CYP1A2 functioning. 
 
Conclusions and perspectives 
We designed and engineered the novel SOS-CYPtest system. This system is using 
several E. coli and S. typhimurium tester strains, which are competent in human CYP 
metabolism and are appropriate for in vitro HTS genotoxicity testing of chemicals, which 




compounds, the newly developed SOS-CYPtest system seems to have the appropriate 
characteristics for the detection of DNA damaging CRMs in a HTS manner. HTS 
characteristics include a short assay time (max 120-180 min), the need of only small 
amounts of test compound (less than a few micrograms), the adaptability to a microplate 
reader format and real-time measurement.  
The secondary aim of this thesis was to investigate specific CYP alleles, focusing 
on non-synonymous polymorphic forms, and the role of the accessory enzyme b5.  
CYP1A2 was chosen as a model enzyme. Due to the huge amount of data produced, and 
to be able to scrutinize appropriately all results, multivariate analysis methods were 
applied and appeared to be a powerful and very useful tool regarding data analysis. All-
together, it is concluded that 5 of the 8 different CYP1A2 variants analyzed, namely 
variants T83M, G299S, I386F, C406Y and R456H, were of relevance in terms of altered 
metabolism. Consistently, R456H was inactive. T83M and C406Y were the most 
different enzymes when compared to WT CYP1A2, while variant I386F is a very unstable 
enzyme in which b5 plays a key role in its stability/activity. The results obtained clearly 
implicated G299 in CYP1A2 to interact with CYPOR/b5. Collectively, b5 seems to 
compensate for structural deviations of the CYP1A2 variants, most likely through 
extensive allosteric effects.  Not only the proximal zones of the active center (I386F) and 
the b5/CYPOR/CYP1A2 interface (G299S) are affected, but also more distal zones such 
as the substrate entrance/product exit channel (T83M and C406Y). 
In xenobiotic risk assessment, the potency to induce carcinogenesis is usually 
provided by genotoxicity or mutagenicity testing. The major handicap of current in vitro 
HTS-systems is mostly due to inadequate representation and/or failure of human 
biotransformation. The studies in this thesis demonstrate possibilities to overcome this 




of the current in vitro HTS-methods to study genotoxicity can contribute to improved 
selection of safer drug candidates in pharmaceutical R&D, but also for the identification 



























Os seres humanos são continuamente expostos a uma variedade de xenobióticos 
tais como, produtos farmacêuticos, cosméticos, compostos presentes nos alimentos, 
agentes químicos ocupacionais ou ambientais. A maioria dos carcinogéneos genotóxicos 
são quimicamente inertes, requerendo bioativação metabólica pelos enzimas de 
biotransformação para formar metabolitos quimicamente reativos (CRMs), que 
posteriormente se podem ligar covalentemente a DNA, RNA e proteínas. Na bioactivação 
de carcinogéneos, foram reconhecidas diversas vias metabólicas, tendo os enzimas do 
Citocromo P540 (CYP) um papel fundamental. Neste contexto, a família CYP1A tem 
especial interesse na bioactivação de classes específicas de agentes químicos 
cancerígenos e no desenvolvimento de cancro. 
Desde a introdução há mais de quatro décadas do "teste de Ames", um ensaio 
revolucionário de mutagenicidade em S. typhimurium, têm sido realizados esforços 
contínuos para a melhoria e aplicação de novos ensaios de genotoxicidade baseados em 
bactérias. No entanto, a maioria dos sistemas celulares bacterianos atualmente disponíveis 
para a avaliação da genotoxicidade ainda não possuem sistemas de biotransformação de 
xenobióticos, uma vez que não contêm as competências metabólicas apropriadas. 
O objetivo principal da investigação descrita nesta tese foi o desenvolvimento de 
novos sistemas bacterianos para testar genotoxicidade, sendo estes: i) competentes em 
termos de biotransformação mediada por CYP humano e ii) adequados para aplicações 
em high-throughput screening (HTS). Os sistemas de teste bacterianos devem ser 
adequados para estudos de genotoxicidade, estudos mecanísticos, e para co-expressão de 
diferentes enzimas CYP e das suas variantes polimórficas. O objetivo secundário foi 
investigar a relevância de diferentes alelos polimórficos não-sinónimos de CYP. Para tal, 




genotóxicos e não genotóxicos, incluindo o papel do Citocromo b5 (b5), um parceiro redox 
acessório. Para prova de conceito, CYP1A2 humano e várias variantes de CYP1A2 
polimórficas foram escolhidos como enzimas modelo. 
 
Parte I. Introdução 
No Capítulo 1, são discutidas vias de biotransformação xenobiótica e o papel dos 
CRMs na genotoxicidade e nas reações adversas a medicamentos (ADRs). É apresentada 
uma visão geral dos enzimas de biotransformação envolvidos na 
bioativação/bioinativação de xenobióticos, e a associação entre CRMs e toxicidade em 
geral e genotoxicidade em particular. São destacadas as diferenças inter-individuais no 
metabolismo de fármacos resultantes de polimorfismos genéticos nos enzimas de 
metabolização, e suas implicações para ADRs e susceptibilidade ao cancro. A 
importância da superfamília de CYP, incluindo os enzimas acessórios dadores de 
electrões, b5 e NADPH citocromo P450 oxidoredutase (CYPOR), é explicada, com foco 
especial em CYP1A2. É também discutido o papel da bioactivação de xenobioticos na 
carcinogénese e mutagénese. Neste contexto, a adequabilidade de ensaios de 
genotoxicidade para uso em contexto de HTS é discutida, com enfase em sistemas 
bacterianos. 
 
Parte II. Caracterização de Variantes Polimórficas do Citocromo P450 1A2 
Humano 
A Parte II desta tese aborda a caracterização aprofundada de CYP1A2 humano 
WT e de 8 variantes polimórficas não-sinónimas, nomeadamente: T83M, S212C, S298R, 





No Capítulo 2, é descrita uma caracterização abrangente das capacidades 
metabólicas de CYP1A2 WT e das 8 variantes polimórficas não-sinónimas (indicadas 
acima). Cada uma das oito variantes de CYP1A2 mais WT foi co-expressa em conjunto 
com CYPOR humano em estirpes de E. coli, utilizando um sistema bi-plasmídico de co-
expressão. Todas as variantes apresentaram níveis semelhantes de expressão de 
apoproteína e holoproteína, com excepção de I386F e R456H, onde se observou apenas 
a presença de apoproteína. Desta forma, ambas as variantes são funcionalmente inativas. 
Os rácios CYPOR/CYP encontrados para as diferentes variantes foram equivalentes aos 
observados em microssomas hepáticos humanos, exceto para I386F e R456H, devido à 
falta de holoenzima CYP1A2 (vide supra). As actividades das variantes de CYP1A2 
foram determinadas, utilizando 8 substratos diferentes. O conjunto de resultados obtido, 
composto por 16 parâmetros de actividade diferentes para cada variante, foi extensamente 
analisado com recurso a métodos de análise multivariada. Estes resultados foram 
posteriormente interpretados usando a estrutura cristalina de CYP1A2 humano. Concluiu-
se que, entre todas as variantes de CYP1A2 humana analisadas, a variante G299S é o 
enzima mais divergente em relação ao WT, enquanto a variante T83M é apenas 
ligeiramente, mas significativamente diferente da variante WT. Adicionalmente, a 
bioactivação do composto NNK (mutagenicidade) demonstrou ser a actividade mais 
discriminativa entre as variantes de CYP1A2 analisadas. Além disso, o R456 pôde ser 
identificado como um resíduo crítico para a ancoragem e estabilização do heme.  
No Capítulo 3, é descrito o efeito do b5 nas actividades de CYP1A2 WT e das 
mesmas 8 formas polimórficas não-sinónimas. Foi aplicada uma abordagem semelhante 
à relatada no Capítulo 2. Os teores de CYPOR e os níveis de expressão de b5 (holo- e 
apo-proteína) foram determinados, sendo comparáveis entre estirpes. Os níveis de 




I386F e R456H) e semelhantes aos descritos no Capítulo 2, indicando que a co-expressão 
de b5 não tem grande impacto na expressão de CYP. As variantes CYP1A2 foram testadas 
com os mesmos métodos e substratos descritos no Capítulo 2. Os resultados obtidos 
foram fundidos com os relatados no Capítulo 2. Este conjunto de dados combinados foi 
então avaliado através de análise multivariada, tendo em conta o conhecimento estrutural 
derivado da estrutura cristalina de CYP1A2 humano. Concluiu-se que, na presença de b5, 
de entre todas as variantes humanas de CYP1A2 analisadas, as variantes T83M e C406Y 
são os enzimas mais desviantes em propriedades catalíticas quando comparadas à WT. 
Colectivamente, os dados indicam que provavelmente b5 exerce um efeito compensatório 
sobre as capacidades funcionais alteradas das variantes polimórficas, levando a um 
comportamento mais próximo da variante WT. Adicionalmente, os dados parecem 
implicar o resíduo G299 de CYP1A2 na sua interacção com CYPOR e/ou b5. 
 
Parte III. Desenvolvimento de Sistemas HTS Bacterianos para Detecção de 
Metabolitos Reactivos Electrofílicos Genotóxicos 
A Parte III desta tese descreve a engenharia de sistemas bacterianos para 
detecção eficiente de CRMs DNA-reactivos gerados pelo CYP1A2 humano.  
No Capítulo 4, é apresentado o desenvolvimento de sistemas de teste de 
genotoxicidade, metabolicamente competentes em CYP1A2 humano e adequados para 
HTS. O princípio da detecção baseou-se na fusão de um repórter com a sequência do 
promotor de sulA (um dos genes bacterianos mais induzíveis após dano de DNA), com 
GFPmut3.1, um repórter GFP. Foi incluída uma estirpe adicional contendo um promotor 
constitutivo para corrigir possíveis efeitos citotóxicos dos compostos de teste, utilizando 
o mesmo repórter GFP. Os sistemas repórteres foram inicialmente utilizados em quatro 




typhimurium do teste de Ames, e FP401 e PD301, duas estirpes de E. coli desenvolvidas 
no nosso laboratório em Lisboa. Após a optimização das condições de ensaio, as quatro 
estirpes foram testadas com três mutagénios de acção directa (4NQO, MNNG e CHP), 
para determinar a sensibilidade do ensaio na detecção de genotoxicidade. Posteriormente, 
os dois sistemas bacterianos mais eficazes, nomeadamente os baseados nas estirpes 
TA1535 e PD301, foram adaptados para co-expressar CYP1A2 humano e CYPOR, 
utilizando o sistema bi-plasmídico descrito anteriormente, conjuntamente com os 
repórteres GFP. Todas as estirpes demonstraram níveis equivalentes de CYP e CYPOR, 
estando os rácios CYPOR/CYP dentro do intervalo observado em microssomas hepáticos 
humanos. Os dois sistemas foram testados com três pró-mutagénios, nomeadamente, 
2AA, IQ e 1AP, conhecidos por formar metabolitos DNA-reactivos através de 
metabolismo mediado por CYP1A2. 
No Capítulo 5 é relatada a aplicação HTS do ensaio de genotoxicidade bacteriana 
recém-desenvolvido (descrito no Capítulo 4). Foram utilizados CYP1A2 WT mais as 8 
formas polimórficas (estudadas nos Capítulos 2 e 3), aplicando o sistema de HTS 
baseado em S. typhimurium TA1535. Os níveis de CYP e CYPOR foram comparáveis 
entre todas as estirpes e os rácios CYPOR/CYP estavam dentro do intervalo observado 
nos microssomas hepáticos humanos, com excepção das estirpes contendo as variantes 
I386F e R456H, que apresentaram os mesmos problemas de expressão descritos nos 
Capítulos 2 e 3. Ainda assim, pôde ser detectada a bioactivação de dois pro-mutagénios 
pela variante I386F. A genotoxicidade dos pró-mutagénios 2AA, IQ e 1AP dependente 
de CYP1A2 pôde ser detectada, tendo os resultados obtidos sido analisados através de 
análise multivariada. A variante T83M demonstrou novamente ser a isoforma mais 
divergente da WT entre todas as variantes, enquanto as variantes G299S e I386F foram 




aos obtidos no Capítulo 2, no qual, para cada variante CYP1A2, foram utilizados 8 
substratos diferentes (NNK, IQ, 2AA MR, ER, CEC, fenacetina e clozapina) medindo 16 
parâmetros de actividade. Este resultado demonstrou a eficácia do sistema HTS 
bacteriano recém-desenvolvido para testes de genotoxicidade, não apenas para investigar 
o efeito de polimorfismos de CYP1A2 na bioactivação pró-mutagénica, mas também para 
fornecer informações sobre o mecanismo molecular do funcionamento de CYP1A2. 
 
Conclusões e Perspectivas 
Com a realização desta tese desenhámos e desenvolvemos o novo sistema SOS-
CYPtest. Este sistema utiliza várias estirpes de teste de E. coli e S. typhimurium, tornadas 
metabolicamente competentes em CYP humano e apropriadas para testar in vitro a 
genotoxicidade de químicos em HTS, sendo este o principal objectivo deste estudo. 
Embora tenha sido testado com apenas um número restrito de compostos, o novo sistema 
SOS-CYPtest parece ter as características apropriadas para a detecção de CRMs DNA-
reactivos, no formato HTS. Estas características HTS incluem um tempo de execução 
curto (120-180 min max.), a necessidade de pequenas quantidades de composto de teste 
(menos de alguns microgramas), a capacidade de adaptação ao formato de um leitor de 
microplacas e a medição em tempo real. 
O objectivo secundário desta tese foi investigar alelos específicos de CYP, com 
foco em formas polimórficas não-sinónimas e no papel do enzima acessório b5. CYP1A2 
foi escolhido como um enzima modelo. Devido à enorme quantidade de dados gerados, 
e de forma a poder analisar todos os resultados adequadamente, foram aplicados métodos 
de análise multivariada, que demonstraram ser uma ferramenta poderosa e muito útil na 
análise de dados. No conjunto, conclui-se que 5 das 8 variantes diferentes de CYP1A2 




mais relevantes em termos de alteração no metabolismo. A variante R456H foi 
consistentemente inactiva. T83M e C406Y foram os enzimas mais divergentes em 
comparação com WT, enquanto a variante I386F é um enzima muito instável na qual b5 
desempenha um papel fundamental na estabilidade/actividade. Os resultados obtidos 
implicaram claramente o resíduo G299 de CYP1A2 na interacção com CYPOR/b5. 
Colectivamente, b5 parece compensar os desvios estruturais das variantes de CYP1A2, 
muito provavelmente através de efeitos alostéricos. Não apenas as zonas proximais do 
centro activo (I386F) e a interface b5/CYPOR/CYP1A2 (G299S) são afectadas, mas 
também outras zonas distais, como o canal de entrada do substrato/saída do produto 
(T83M e C406Y). 
Na avaliação de risco de xenobióticos, a capacidade para induzir a carcinogénese 
é geralmente averiguada com recuso a testes de genotoxicidade ou mutagenicidade. A 
principal desvantagem dos atuais sistemas HTS in vitro deve-se à representação 
inadequada e/ou falha da biotransformação humana. Os estudos nesta tese descrevem 
possibilidades para superar essa questão. Informações mecanísticas foram também 
geradas. A aplicação e o aperfeiçoamento do actual sistema in vitro para estudar 
genotoxicidade, pode contribuir para melhorar a investigação e desenvolvimento 
farmacêuticos na selecção de candidatos a medicamentos mais seguros, bem como para 
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